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Abstract 
 
Clinical translation of MSCs-based therapies remains challenging, and one of the key cause 
for this failure is the lack of tools to determine the fate of these transplanted cells non-
invasively and longitudinally. Whatever the strategy, namely using either MSCs as direct 
effector cells or using genetically manipulated MSCs, it is imperative that the fate of these 
transplanted cells is understood to ascertain homing efficiency, dosing regimens, optimal 
timing and effective route of delivery to the diseased tissue. Hence, in vivo cell tracking is 
potentially a powerful tool to monitor non-invasively the distribution and accumulation of 
therapeutic cells such as MSCs. Development of accurate imaging modalities to track MSCs 
would allow clinicians to determine whether cell delivery has occurred at the appropriate site 
and if cells have reached their targeted location. Consequently, non-invasive real-time 
imaging techniques need to be developed to optimise and allow success of cell-based 
therapies. The absence of a confounding background signal and consequent unequivocal 
assignment makes 19F MRI one of the most attractive modalities for the tracking of injected 
cells in vivo. In Chapter 2, we evaluated the feasibility of poly(OEGMA-co-TFEA) as a 
potential 19F MR tracer for MSCs. Whilst these monomers contain a relatively low weight-
fraction of fluorine, unique monomers with a higher fluorine content should be explored to 
achieve higher imaging sensitivity. In this chapter, we also describe the synthesis of novel 
partly-fluorinated polymeric nanoparticles with small size and high fluorine content as MRI 
agents. The polymers, constructed from perfluoropolyether methacrylate (PFPEMA) and 
oligo(ethylene glycol) methacrylate (OEGMA) have favourable cell uptake profiles and 
excellent MRI performance. To facilitate cell studies the polymer was further conjugated with 
a fluorescent dye creating a dual-modal imaging agent. The efficacy of labelling of MSCs 
was assessed using 19F NMR, flow cytometry and confocal microscopy. The labelling 
efficiency of 2.6 ± 0.1 x 1012 19F atoms per cell, and viability of >90 % demonstrates high 
uptake and good tolerance by the cells. This loading translates to a minimum 19F MRI 
detection sensitivity of ~ 7.4 x 103 cells/voxel. Additionally, in Chapter 3, our results 
demonstrate that PMSCs can be efficiently labelled with this new fluorinated copolymer, 
without the use of transfection agents, and with negligible deleterious effects on the viability, 
mitochondrial and phenotypic function of the cells. Chapter 3 also describes in vivo 
longitudinal detection and bio-distribution of labelled PMSCs in animal models using 19F MRI 
and optical imaging.  In Chapter 4, we report a comprehensive evaluation to ascertain 
uptake mechanism involved in the internalisation in MSCs of our copolymer that was also 
effectively employed as a 19F MR tracer. Commonly used chemical inhibitors, which block 
specific pathways and endocytic markers, are utilized to ascertain the route of uptake in the 
cells.  Furthermore, studies were conducted to identify co-localisation of copolymers with 
specific organelles, and endocytic markers used to validate mechanism of uptake adopted 
by these copolymers. 
Overall, these copolymer show outstanding potential for 19F MRI cellular tracking and for 
quantification of non-phagocytic and therapeutically relevant cells in vivo. 
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Chapter 1 Introduction 
Chapter 1  
Introduction 
1.1 Stem cells  
Stem cells are proving to be of great interest as potential therapeutic tools with the promise 
to revolutionize the treatment of a variety of human diseases by restoring tissue and organ 
function. [1, 2] On their discovery in 1963, E.A. McCulloch & J.E. Till described these cells to 
be an undifferentiated, self-renewing, progenitor cell population, and were termed as stem 
cells. [3]  Stem cells can be classified into two broad categories, namely, embryonic and adult 
stem cells. 
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Figure 1. 1. Derivation of a human embryonic stem cell line, and differentiation strategies.  
ESCs are pluripotent cells (ESCs) that are able to differentiate into ectodermal, mesodermal 
and endodermal lineage. [4] 
1.1.1 Embryonic stem cells 
Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocyst formed 
after in vitro fertilization of the egg. [5] These pluripotent cells are capable of differentiating 
into all three germ layers, and capable of indefinite proliferation (Figure 1.1). [6, 7]  However, 
ESCs are capable of forming teratomas after implantation, hence tumourigenicity is a major 
safety concern. Formation of teratomas is most probably due to the presence of oncogenes 
and trisomies causing unregulated differentiation of ESCs. [8] Additionally, the harvesting of 
ESCs by the destruction of the blastocyst has raised numerous ethical issues; hence, 
limiting their current clinical value. [9] 
 
1.1.2 Adult stem cells (Mesenchymal stem cells) 
Alternatively, adult stem cells provide clinical relevance, and are devoid of ethical concerns 
and teratoma development. These cells can be found in many tissues in the body including 
brain, muscle, bone marrow, skin, liver, dental pulp and adipose tissues. [10-12] However, 
MSCs from these sources are difficult to access for isolation of cells. Mesenchymal stem 
cells (MSCs), a type of adult stem cell have recently generated increased interest for 
combating a broad range of diseases, with over 200 clinical trials involving naïve MSCs 
(listed in the clinical trials database; Figure 1.2). [13] MSCs were first discovered by 
Friedenstein in the stromal compartment of bone marrow and subsequently there have been 
many reports describing the presence of MSCs in various adult tissues niches  
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(adipose, peripheral blood, dermis and dental pulp), extraembryonic tissues (umbilical cord, 
placenta) and foetal tissues. [14, 15] Nonetheless, bone marrow derived MSCs (BM-MSCS) 
are the most characterized and extensively studied source of MSCs. [2] 
 
 
 
 
Figure 1. 2. Registered clinical trials of MSC. [13]  
A) Trials categorised by phase. B) Trials categorised by disease. 
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MSCs have no unique phenotypic marker. Nevertheless, for better characterization, the 
definitions of MSCs by the minimal criteria established by the International Society of 
Cellular Therapy (ISCT) are:  
(1) Plastic-adherent in culture. 
(2) Positive expression (> 98%) of CD73, CD90 and CD105. 
(3) Lacks expression of haematopoietic markers (CD34, CD45, CD11a, CD19 and Major 
Histocompatibility Complex (MHC) II molecules. 
(4) Able to differentiate into osteoblasts, adipocytes and chondroblasts under standard in 
vitro conditions. [10, 16] 
 
1.2 MSC characteristics and properties associated with therapeutic potential  
MSC-based therapies have attracted much interest as a highly promising strategy to combat 
many diseases including cancer.  This utility of MSCs is due to a number of characteristics, 
which include (Figure 1.3); 1) differentiation capabilities, [17]  2) immunomodulatory and 
immunosuppressive  properties, [18] 3) inherent tropism to injured tissue/tumour 
microenvironments, [19] and 4) inhibitory effects on several tumours. [20]  
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Figure 1.3. A schematic diagram depicting the biological properties of MSCs that are 
associated with their therapeutic effects. [17] 
1.2.1 Differentiation potential of MSCs 
 
MSCs have the ability to differentiate into cells of the mesenchymal lineage including 
adipocytes, chondroblasts and osteoblasts. [21, 22] Moreover, some studies have 
demonstrated that MSCs can also differentiate into cells of endodermal (hepatocytes) [23]  
and ectodermal lineages (neurons). [24]  MSCs have also been shown to differentiate into 
cardiomyocytes and other tissue specific cells after in vivo systemic injection for the 
treatment of myocardial infarction and osteogenesis imperfecta (OI), respectively. [25, 26] 
Moreover, MSCs revealed potential for wound healing via differentiation into multiple skin  
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types. [27] However, replacement of damaged cells by MSCs through tissue-specific 
differentiation may only be a minor component of the multifaceted mechanisms underlying 
the therapeutic effect of MSCs. [17] 
 
1.2.2 Immunomodulatory and immunosuppressive properties 
 
The ability of MSCs to modulate the immune response allows autologous or allogeneic 
transplants of these cells with an attenuated immune response by the host. Allogeneic MSC 
transplants survive longer than other allogeneic cells. MSCs lack expression of major 
histocompatibility complex-II (MHC class II) molecules, hence are capable of evading 
recognition by alloreactive T cells and escape immune surveillance. [15, 28] In addition, MSCs 
lack expression of co-stimulatory molecules such as CD40, CD80 or CD86, and this may 
contribute to the observed immune tolerance. [21, 29] MSCs express low levels of MHC Class 
I molecules, making them less susceptible to cell mediated cytotoxicity by natural killer (NK) 
cells. [15, 30]  MHC-identical, MHC-haploidentical, and MHC-unmatched MSC have been 
utilised effectively and successfully in clinical setting. [31-33] This distinctive immune privileged 
feature of MSCs provides the flexibility of utilizing both autologous and allogeneic MSCs in 
the clinical scenario.  
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1.2.3 Ability to migrate and home to injured tissues 
 
MSCs have a distinctive and inherent ability to migrate and home to sites of injured tissues, 
which includes the tumour microenvironment. MSCs have also been shown to migrate 
towards glioma both in vitro and in vivo. [20] In addition to targeting the main tumour mass, 
MSCs have been shown to track small tumour microsatellites from different tumour types. 
[34-36] This pathotropic capability makes MSCs an ideal candidate as a delivery vehicle of 
anticancer agents for targeted therapy in brain tumours. [37, 38] The most plausible 
mechanism for this specific migration may be the release of chemotactic gradients from the 
tumours, which enable MSCs to home and modulate the tumour microenvironment. 
Furthermore, tumours produce an array of cytokines and chemokines that may function as 
ligands for MSC receptors. [39] Another rationale for MSCs migration could be the hypoxic 
conditions produced by tumours, which may augment MSCs expression of migratory 
signals. [40] However, the exact mechanism for migration and homing has not been 
completely elucidated. Nonetheless, a number of extensive studies have shown that the 
migratory ability of MSCs is associated with different cytokine/receptor pairings, such as 
SDF-1/CXCR4, SCF-c-Kit, HGF/c-Met, VEGF/VEGFR, PDGF/PDGFr, MCP-1/CCR2 and 
HMGB1/RAGE. [19] The most prominent and widely studied cytokine/receptor pair is SDF-1 
and its receptor CXCR4. It has been shown to play a key role in the migration of various 
stem cell-types including adult SCs, ESCs and induced pluripotent SCs (iPSCs). [41]  
Different sources of MSCs may have variable degrees of migratory potential in different 
tumour microenvironments. Therefore, further investigations are essential in order to better 
understand the mechanisms underlying the migratory and homing abilities of the MSCs from 
various niches. 
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1.2.4 Inhibitory effects on tumours 
 
There is accumulative evidence that suggests that MSCs can be exploited as therapeutic 
tools for treatment/management of various diseases, including cancer. [42-44] Naïve MSCs 
have been demonstrated to exhibit the inherent ability of attenuating growth of various 
tumours. [45-47] Khakoo et al. have demonstrated that intravenous (i.v.) injection of human 
bone marrow derived MSCs in a mouse model of Kaposi’s sarcoma, migrated to sites of 
tumourigenesis and potently inhibited tumour growth. [36] Rat umbilical cord MSCs 
administered (i.v.) or intra tumourally (i.t.) in a rat model of mammary adenocarcinoma 
completely eradicated the tumour with no evidence of recurrence. [47] MSCs also exhibited 
anti-angiogenic effects, in both in vitro and in vivo mouse models of melanoma. MSCs 
implanted (i.t.) in subcutaneous mice melanoma model inhibited tumour growth via 
apoptosis. [19, 48] Although the mechanism underlying the intrinsic inhibition of various 
tumours has not been completely elucidated, their actions can nevertheless be ascribed to 
factors that are secreted by MSCs via paracrine signalling, and via physical communication 
between MSCs and tumour cells. [41, 49]  MSCs secrete many cytokines, chemokines and 
growth factor, which play a critical role in local cellular functions.  These molecules have 
established anti-apoptotic and regenerative capabilities. [11, 17]  
Several studies have established that hMSCs inhibited growth of cancer cells (MCF-7, K562 
and C6) via secretion of Dickkopf-1 (DKK-1), which induced suppression of Wnt signalling. 
[50-52]  HMSCs have also been shown to exert inhibitory effects on tumours primarily through 
direct contact by hindering Akt phosphorylation. [36] Consequently, there are a myriad of 
factors that work synergistically to bring about this inhibitory effects on tumours.  
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1.3 Limitations of bone marrow-derived MSCs (BM-MSCs) in clinical settings 
 
The main source of MSCs used in preclinical and clinical studies are the bone marrow and 
adipose tissue.  The preference towards the use of BM-MSCs in present clinical trials is 
probably a result of the bone marrow being the initial source for MSCs. [13] However, the use 
of autologous BM-MSCs has several impediments, which may limit their large-scale clinical 
applications. Harvesting of BM-MSCs is invasive and painful, with decreasing quality and 
yield of stem cells with age. [7]   Additionally, utilization of the patient’s MSCs may not be 
practical as these may possibly be affected by disease. [13] Hence, an alternative source of 
allogeneic MSCs is required for successful and sustainable clinical applications. [53] 
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1.3.1 The Placenta - A rich and accessible source of MSCs 
 
 
Figure 1. 4. Schematic representation of a human term placenta. 
 
The human placenta plays a vital role in foetal development, nutrition and maintaining foetal 
tolerance. [54] However more recently, the placenta has gained additional interest because 
it contains a variety of stem cells, including MSCs. [55]  The most important factor is the 
availability of placentae, which are discarded post-partum. It has an abundant supply of 
MSCs, involves non-invasive donor procurement and does not elicit ethical controversy.   A 
human placenta comprises tissues of both foetal and maternal origin. The amnion and 
chorion are of foetal origin and specific regions of the decidua are of maternal origin (Figure 
1.4). [56] 
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MSCs derived from extra-embryonic tissues, such as the placenta and umbilical cord share 
basic properties with BM-MSCs, including adherence to plastic, expression of specific 
markers and capacity for tri-lineage differentiation as demarcated by ISCT. [13] Additionally, 
they express ESCs markers such as Oct-4, Nanog, Tra-1-60, Tra-1-81 SSEA3 and SSEA4, 
a characteristic lacking in most adult derived MSCs.  These pluripotency markers are critical 
transcriptions factors expressed that sustain its undifferentiated state or “stemness”. [8, 55] 
This implies that these are very primitive cells, hence MSCs obtained from early ontological 
sources may have more desirable properties compared to adult BM-MSCs. [7]  Placental 
MSCs (PMSCs) exhibit greater proliferation capacity (doubling times), with broader 
differentiation abilities, in comparison to adult BM-MSCs (Table 1.1). [7, 57, 58] This is probably 
due to the fact that the placenta plays a critical role in the growth of the developing foetus. 
[56] PMSCs also demonstrate faster growth kinetics, higher engraftment properties and 
greater colony-forming unit-fibroblast (CFU-F) developing ability. [55, 58] Additionally, PMSCs 
have superior immunomodulatory and immunosuppressive properties. PMSCs lack or 
express lower levels of human leukocyte antigen (HLA) class I, and hence display lower 
immunogenicity than adult BM-MSCs. [9] 
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Table 1. 1. Frequency and proliferative characteristics of HMSCs obtained from different 
sources. [13] 
a Expressed as percentage of plated mononuclear cells that form CFU-F (colony-forming 
unit – fibroblast) unless otherwise stated. 
b Cumulative PD (population doublings) counted from first passage to senescence. 
 
 
 
There are also inherent differences between feotal PMSCs (F-PMSCSs) and maternal 
PMSCs (M-PMSCs). Zhu et al. demonstrated that feotal PMSCS express significantly higher 
levels of hepatocyte growth factor (HGF) than maternal PMSCs. HGF is a growth factor that 
promotes tissue repair, angiogenesis and is involved in regulatory function by inducing 
dendritic and regulatory T-cells. This possibly suggests that it might have a superior 
advantage in terms of therapeutic applications in comparison to M-PMSCs. [53]  F-PMSCs 
have been validated to show stronger immune modulatory function. They expresses higher 
levels of CD 200, which is a cell surface glycoprotein that facilitates  
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immunosuppressive signal that has been demonstrated to modulate immune responses in 
macrophages and dendritic cells. [59, 60] F-PMSCs also displayed higher osteogenic 
differential potential in comparison to M-PMSCs. [53]  
 
1.3.1.1 Placenta derived MSCs (PMSCs) - Preclinical studies in animal models 
 
PMSCs were first described in 2004, creating much interest in the field of cellular therapy 
as a readily available, alternative and superior source of MSCs for the treatment of a variety 
of diseases (Table 1.2). [55] This has motivated many researchers to investigate their 
potential therapeutic effects in a variety of animal models, including ischaemic stroke, 
myocardial infarction, Parkinson’s, Duchenne muscular dystrophy, diabetes mellitus and 
osteogenesis imperfecta (OI). The outcome of these studies show promising and optimistic 
results. [9, 55] Conversely, to date, the potential therapeutic effects of these cells have yet to 
be explored in any oncology models. In contrast, the inhibitory effects of BM-MSCs and 
embryonic stem cells (ESCs) on a variety of cancer models has been demonstrated in 
numerous studies.[36] 
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Table 1. 2. Summary of animal models treated with placental MSCs of diverse origins. [55] 
MSCs Origin Animal 
model 
Disease 
treated 
Outcome References 
PMSCs Human Rat Ischaemic 
stroke 
Simulation and migration of SCs 
and progenitor cells in the host 
[61, 62] 
PMSCs Human Rat Hypoxia-
ischaemia 
and 
inflammatio
n 
Survival of the graft after 4 weeks, 
possible autologous cell graft 
[63] 
PMSCs 
from 
chorionic 
villi 
Human Mouse  Diabetes 
mellitus 
Reduction of hyperglycemia, 
restoration of normoglycemia, 
increase in body weight, 
indicating signs of diabetes 
reversal. No teratoma in vivo after 
transplantation 
[64] 
PMSCs 
from 
chorionic 
villi 
Human N.A Engineered 
heart valve 
Postnatal applications [65] 
PMSCs 
from 
chorionic 
villi 
Human Nude 
rat 
Cartilage 
defects-
articular 
osteochondr
al defects 
Hyaline cartilage appearance [66] 
PMSCs Human Mouse Duchenne 
muscular 
dystrophy 
Expression of muscle specific 
genes during differentiation in 
vitro. Expression of dystrophin 
and laminin in vivo 
[67] 
AMSCs Human 
& Rat 
Rat Normal & 
infarcted 
cardiac 
tissue 
Ameliorate ventricular function, 
capillary density and scar tissue 
[68] 
  
MSCs isolated from extra-embryonic tissues have been positioned as a possible 
intermediary between ESCs and BM-MSCs. [9]  Hence, PMSCs have properties that may 
obviate the adverse concerns associated with the clinical use of ESCs, such as a lack of 
tumourogenicity and reduced ethical concerns. [69] Furthermore, their more primitive 
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characteristics in comparison to BM-MSCs, which includes higher expansion capabilities, 
phenotypic plasticity, enhanced immunomodulation, lower immunogenicity and ready  
 
availability, makes PMSCs more suitable for clinical translation. In addition, a study by 
Barlow and co-workers compared both human BMSCs with PMSCs and concluded that 
human placenta is a suitable alternative source for human MSC and their use is being 
investigated in clinical trials.[57] Hence, PMSCs have been chosen as the specific cell type 
for the studies conducted in this thesis. 
 
1.4 Labelling MSCs for longitudinal and non-invasive monitoring using MRI. 
 
Stem cell therapy provides an extremely innovative and promising strategy for the treatment 
of many diseases. [70]  However, translation of SCs based therapies from bench to the clinic 
remains challenging with only a single clinical trial in progress. [70] One of the main reasons 
for this failure is the lack of non-invasive and longitudinal tools to determine the fate of these 
transplanted cells. Presently, an array of imaging modalities including magnetic resonance 
imaging (MRI), positron emission tomography (PET), computed tomography (CT), single-
photon emission computed tomography (SPECT), ultrasound (US), fluorescence and 
bioluminescence imaging (BLI) have become available for in vivo cell tracking, with each 
technique having its advantages and disadvantages (Table 1.3). [71]    
 
 
 
 
 
Chapter 1 Introduction 
 
Table 1. 3. Comparison of non-invasive imaging modalities for in vivo cell tracking. [71] 
2PLSM: two-photon laser scanning microscopy 
*Strengths and weaknesses are given using a relative scale in which + = poor, ++ = 
moderate and +++ = excellent 
 
Unfortunately, conventional stem cell tracking modalities such as fluorescence and 
bioluminescence used in the laboratory have limited clinical application. [13, 72, 73] Whatever 
the approach, either using SCs as direct effector cells or using genetically engineered SCs, 
cell tracking is vital to monitor the fate of the transplanted cells. To allow optimization of 
cellular therapy, it is imperative that non-invasive real-time imaging techniques be developed 
to ascertain homing efficiency, dosing requirements, optimal timing and route of delivery and 
many other critical factors. In vivo cell tracking is potentially a powerful tool and its capability 
to non-invasively monitor distribution and accumulation of therapeutic cells such as MSCs 
would allow clinicians to determine whether cell delivery has occurred at the appropriate 
location and if cells have reached their targeted location for each  
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patient. [74] This project will focus on tracking of cells with MR imaging agents such as 19F 
MR imaging tracers. 
1.4.1 Cellular Magnetic Resonance Imaging (MRI) 
  
Cellular imaging is defined as non-invasive and repetitive imaging of targeted cells or cellular 
processes in living organisms. [75] MRI is a promising imaging modality for sequential 
tracking of SCs. [76]  MRI does not utilise ionizing radiation and is deemed safe for deep 
tissue imaging at high resolution. [71] It is achieved by pre-labelling SCs prior to implantation 
with an agent which is visible in an MRI scan. [77] MRI signal can be generated/controlled in 
several ways including with positive contrast agents containing paramagnetic metals 
(gadolinium), negative contrast agents comprising of superparamagnetic iron oxides (SPIO) 
or with 19F containing probes (Table 1.4 & 1.5). 
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Table 1. 4. Overview of available in vivo MRI-based cell tracking techniques. [71] 
CEST, chemical exchange saturation transfer; MRI, magnetic resonance imaging; PFC, 
perfluorocarbon; SPIO, superparamagnetic iron oxide. *T1 is the nuclear spin–lattice 
relaxation time. 
‡
T2 is the spin–spin relaxation time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 Introduction 
 
 
Table 1. 5. MRI signal can be generated/controlled by four different approaches [71].  
1) Positive contrast agents containing paramagnetic metals. 2) Negative contrast agents 
containing superparamagnetic iron oxides. 3) Molecular probes that induce chemical 
exchange saturation transfer. 4) Molecular probes containing 19F. 
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1.4.1.1 Negative contrast agents containing superparamagnetic iron oxides (SPIO) 
 
In the early 90s, Weissleder et al. observed that SPIOs and USPIOs associate in 
endosomes after endocytosis causing an amplification in susceptibility effects. [78] 
Consequently, T2/T2* contrast is probably the most broadly utilised technique for SC tracking 
studies using MRI. [79]  These agents are comprised of a monocrystalline iron oxide core 
with a polysaccharide coating such as dextran. [80] Iron oxide particles in SPIO contrast 
agents have a strong magnetic moment which principally affects T2 (spin-spin relaxation 
time).  These particles strongly disturb the magnetic field of their surrounding which affects 
proximate water protons, hence effecting a local signal loss (negative contrast) of SPIO (50-
100 nm)/USPIO (smaller than 50 nm) labelled cells on T2-weighted MR images. Regions 
containing SPIO particles appears hypointense/dark in the images (Figure 1.5 & 1.6). [71] 
USPIO particles are possibly more appropriate than SPIO particles for tracking of non-
phagocytic cells such as SCs, due to their higher cellular uptake and longer plasmatic half-
life which will then allow extended cell tracking period. [81, 82] Hence, it can be inferred that 
smaller particles are internalized more efficiently in SCs. 
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Figure 1. 5. Cell tracking using MRI with contrast agents (SPIO & Gd) and 19F tracers. [77] 
Typical anatomical MRI utilizes the 1H from water in tissues. Gd and SPIO labels typically 
require ‘before’ and ‘after’ images for localization (white arrows), resulting in a final hyper 
intense or hypo intense spot signal, respectively. With a 19F label, imaging can be carried 
out in a longitudinal manner for 19F (specifically the labelled cells) and 1H (anatomy) 
without a ‘before’ image. 
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Figure 1. 6. Diagram depicting ex vivo and in situ labelling of cells with MR contrast 
agents (SPIO & PFC emulsion). [71] 
 
 
 
 
 
Chapter 1 Introduction 
 
1.4.1.2 Advantages of SPIO/USPIO contrast agents 
SPIO/USPIO contrast agents for cell labelling are attractive predominantly because of the 
following properties: [75, 83] 
1) They provide most contrast in signal (hyper/hypo intensity) specifically in T1/T2* 
weighted MR images. The sensitivity for detecting SPIO labelled cells is very high. 
Moreover, single labelled cells can be visualized in vivo under certain conditions. [84] 
 
2) Iron oxide is non-toxic. These particles are biodegradable and are taken up by 
Kupffer cells in liver. The iron is reused/recycled by cells via biochemical pathways 
for iron metabolism. 
 
3) Dextran, being the most common surface coating used, permits direct chemical 
linkage of functional groups and ligands. Hence, allows greater flexibility in 
experimental design. 
 
4) Easily detected by light and electron microscopy. 
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1.4.1.3 Limitations of SPIO/USPIO contrast agents 
The approach of labelling cells with SPIO/USPIONs for cell tracking has its limitations 
which include: 
1) Although it has been demonstrated that single cells can be distinguished, [85] 
contrast produced by SPIO labelled cells can be confounded with other sources 
such as bleeding or blood vessels. [86] Other causes of signal loss (hypo intense 
regions) appears in MR images that are sensitive to iron, including blood, bone and 
air. Therefore, tracking of labelled cells in instances of traumatic injury with existing 
haemorrhage, makes it challenging to unequivocally identify regions containing 
labelled cells. [83]  
 
2) It is impossible to distinguish between live and dead cells. When labelled cells die, 
SPIO particles remain within or around the cells till phagocytosed by macrophages. 
[87]  
 
3) Death of labelled cells can result in the potential transfer of imaging agent to 
resident macrophages hence causing false positive contrast. This was observed in 
a few studies, but the majority of animal studies have shown the opposite, in which 
the labelled cells in MRI are not macrophages.[88-90] Hence, concern about 
phagocytic engulfment of labelled cells appears exaggerated and should not 
hamper future research in this field. 
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4) Cell division dilutes intracellular label and can diminish image of contrast of cells 
through time. [71]  Consequently, limiting the potential of long term visualization of 
labelled cells. Nevertheless, limitations detailed in points (2-4) are applicable to all 
types of contrast agents or tracers for cell tracking. 
 
5) Iron-labelled cell quantification is extremely challenging as a consequence of 
susceptibility artefacts.   Indirect quantification of labelled cells involves the 
measure of “signal void volume” or the “number of black pixels” and it is determined 
by the change relative to the preimplantation imaging time point. [91] Moreover, 
contrast generated by SPIO-labelled cells is attained indirectly, hence making 
quantification of the number of cells in vivo questionable. [76] 
 
Two clinically approved SPIO agents are ferumoxides (Feridex; USA, Endorem; Europe) 
with a particle size of 120-180 nm and ferucarbotran (Resovist) with a particle size of 
approximately 60 nm. [92, 93] These SPIO agents are approved exclusively for liver imaging. 
However, SPIO stem cell labelling is not a FDA approved indication since the effect on the 
phenotype and function of stem cells have not been completely elucidated. [94]  
 
 
 
 
 
Chapter 1 Introduction 
1.4.1.4 19F MRI 
It has been established that MRI is a promising modality for tracking of SC based therapy. 
As mentioned earlier in this chapter, contrast produced from SPIO labelled cells may not be 
specific to the cells nor directly quantitative.  Another approach to overcome these limitations 
is through 19F MRI, whereby cells are labelled with fluorinated tracers to distinguish them 
from the background (Figure 1.7). [76]   The 19F nucleus has 100% natural abundance, and 
is appropriate for labelling as its MR sensitivity is just 17% less than that of 1H [77] and it has 
a resonant frequency that is 94% of that of 1H. [95]   
 
Figure 1. 7. Main steps involved in cell labelling for 19F MRI [96]. Appropriate selection of 
label and labelling protocol is vital for success of the experiment (Step 1). Cell labelling 
(Step 2), may require enhancement with coatings or transfection agents. After suitable 
preparation (Step 3) the cells can be imaged. Post-processing leads to quantification (Step  
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4). Finally, various ex vivo analysis can be carried out. (Step 5) to corroborate the in vivo 
data. 
 
The absence of a 19F MRI signal from the body provides 19F MRI with a potentially high 
specificity and contrast-to-noise ratio after a fluorinated compound is introduced as a tracer. 
[95] The MR effect of 19F adds a “hot spot” to the conventional anatomical 1H image. [97] 19F 
MR images of labelled cells are overlaid on the 1H MRI image performed in the same 
imaging session with the same scanner to avoid image registration issues. Hot spot imaging 
is comparable to other imaging techniques such as PET or SPECT, which utilizes 
radionuclides, but without accompanying ionizing radiation. Hence, MRI has distinct 
advantages over other nuclear and optical imaging techniques. [95] 
 
Recently, intense effort has been committed to the development of 19F MRI agents, including 
perfluorocarbon (PFC) emulsions, 19F-containing small molecules and 19F-containing 
macromolecules.[98-109] The richness of the chemistry of fluorinated organic compounds from 
small molecules to macromolecules provides tremendous possibilities for the development 
of 19F MRI agents.  
 
 
 
1.4.1.5 Advantages of 19F MR imaging 
19F MRI agents could provide an ability to label therapeutic cells such as MSCs with 
minimal effect on its phenotype and characteristics due to the: 
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1) High specificity- Immobilized fluorine that is present in bone and teeth displays a 
very short T2 (spin-spin relaxation time) that is not observable using conventional 
MRI techniques. Hence, 19F MRI provides an extremely high contrast-to-noise ratio 
and specificity due to the absence of background signal when a 19F agent is 
introduced as a tracer. Therefore, signal obtained is specific to labelled cells unlike 
metal ion-based cell labelling methodologies where false positive cell detection is 
possible. 
  
2) Capacity for cell quantification - The signal established is directly proportional to the 
amount of 19F present. Therefore, from the in vivo images, this provides 
quantification of cell numbers when the average 19F content per cell is known. [96]  
Consequently, as 19F MRI enables quantification of cell numbers it may be 
beneficial for optimizing efficacy of stem cell therapy. [76] 
 
Overall, 19F MRI provides a highly specific, unambiguous and quantitative approach of 
tracking of labelled SCs.  
 
1.4.1.6 Limitations of 19F imaging 
1) Low sensitivity 
In comparison to SPIO agents, the sensitivity of 19F labelling to detect small cell 
numbers is potentially lower. Although the (SNR) of the 19F images will be considerably 
lower in comparison to 1H MRI, it does not require a high 19F (SNR) since this atom is 
mainly absent from the body. [74] Nonetheless, this disadvantage is compensated by  
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the lack of background signal in 19F images allowing cell detection to be unequivocal 
hence no occurrence of false positives. [110] 
 
As described earlier in Section 1.4.1.4, common limitations of essentially all nanoparticle 
based imaging agents includes inability to discriminate between live and dead cells, 
dilution of intracellular labels as a result of cell division and transfer of labels to resident 
macrophages resulting in a false positive signal. [87, 111, 112] 
 
 
1.4.1.7 Requirements of 19F tracers 
To achieve 19F MRI-based cell tracking, cells need to be loaded with adequate fluorine for 
imaging within a practical time frame.  This entails the preparation of suitable labels to load 
the applicable cells ex vivo. [96] The ideal tracer should have characteristics that includes 
[96, 97] 
 1) Adequate fluorine content for detection,  
2) Scalable synthesis and formulation,  
3) Defined chemical properties, 
4) Simple 19F NMR spectrum, possibly with a single, sharp, and intense peak, 
 
5) Negligible in vitro and in vivo toxicity,  
6) Biological and chemical stability permitting a long shelf life, 
 7) Short T1 and long T2 relaxation times for optimal imaging performance 
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It is also extremely critical that the tracer or cell labelling protocol does not significantly 
alter the phenotype and function of cells as this could reduce the therapeutic efficacy of 
these cells. [71] 
 
1.4.1.8 PFCs as 19F imaging tracers 
Perfluorocarbons (PFC) are C-F polymers and one of the most common tracers used in 19F 
imaging.  PFCs have distinctive characteristics such as high hydrophobicity, significant 
lipophobicity, extremely low intermolecular cohesion, low surface tension and biologically 
inert [74].  PFCs are generally stable compounds that are excreted by the typical clearance 
mechanisms and ultimately eliminated via exhalation and bowel excretion. [113] Most 
fluorocarbons revealed no significant toxicological hazards, carcinogenicity or mutagenicity 
hence making it clinically attractive as a cell tracer. [74] 
Consequently, PFCs have been widely used in a range of biomedical applications including 
formulation of artificial blood substitutes. [114, 115] Thus, a great amount of data are available 
on the toxicity and clearance mechanisms of these polymers. The employment of PFCs as 
MRI agents are reliant on its chemical structure. PFCs utilised for MRI can be categorised 
into five groups which includes (Figure 1.8). [74]  
a) Aromatic and unsaturated PFCs  
b) Saturated linear PFCs (PFOB, PFOA) 
c) Saturated ring systems PFCs [perfluorodecalin (PDC)] 
d) Perfluoroamines (FC-43) 
e) Perfluoroethers and polyethers [PTBD, perfluoro-15-crown-5-ether (PCE), linear 
perfluoropolyether polymer (PFPE), FBPA]. 
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Figure 1. 8. PFCs for potential MRI application. [74] 
Out of the list above, only (PFPE, PCE, perfluorodecalin, PFOB) have been used for MRI 
cell tracking. In recent years, particles containing perfluoropolyethers (PFPE) have been 
presented as an attractive 19F imaging agent due to their simple 19F NMR spectrum and 
relative ease of synthesis. [116, 117] PFPEs, in particular linear perfluorinated polymers, are 
not soluble in water and require incorporation within hydrophilic segments or within an 
emulsion.  
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1.4.1.9 In vivo19F MRI and cell tracking 
 
Cell tracking by 19F MRI has the ability to optimise cell based therapies in various diseased 
models due to its high specificity and capability for quantitative tracking of labelled cells in 
vivo. [117] Cell tracking applications involve a ‘tracer’ agent and 19F MR detects the 
concentration of 19F nuclei internalised in cells of interest. The majority of 19F MRI cell 
labeling studies have employed the commercial product Celsense, which are PFC 
emulsions (typical sizes from 100 to 300 nm) based on linear PFPE polymer mixtures.[76, 118] 
A small number of studies have demonstrated MR detection of 19F labeled stem cells in vivo, 
and four studies have reported longitudinal imaging of the fate of these cells post 
transplantation (Table 1.6).[76, 83, 119, 120] These involved labeling of neural stem cells (NSCs) 
with PFC nanoemulsions apart from a single study, which utilized labeled bone marrow 
derived MSCs in a healthy mouse model. In particular, Bible et al. utilised 19F imaging to 
detect Celsense-labeled neural stem cells (NSCs) suspended in a bioscaffold implanted into 
the lesion cavity of a rat stroke model.  The group also observed a significant decrease in 
19F signal between days 1 and 7 post implantation of labelled NSCs. Conversely, Boehm-
Sturm et al. validated the detection of 150,000 labelled NSCs implanted in the striatum of 
healthy mice and established that the fluorine signal changes slightly between days 2 and 
6. These studies demonstrated that 19F signal was still detectable and quantifiable up to 2 
weeks post implantation of MSCs with minimal adverse effects on the properties of the SCs 
[76, 119]. Ribot et al. demonstrated in vivo detection of 1.5 x 106 IM injected MSCs in a nude 
mouse model. They reported a substantial decrease in 19F MR signal between days 3 and 
12 post implantation and a steady decrease in signal was observed for up to 26 days post 
implantation. [83] However, it is also critical to explore  
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labelling of SCs in a diseased and immunocompetent model as the rate of cell death is 
probably greater than in a healthy animal model.  
Table 1. 6. Summary of longitudinal studies of in vivo tracking of 19F labelled SCs. 
19F 
tracer 
Type 
of 
cells 
MRI 
streng
th 
19F 
sequence 
Acqui-
sition 
time 
Days imaged 
post 
implantation 
Length 
of time 
19F 
signal 
detecte
d 
Anim
-al 
mod
el 
 
Ref 
Celsen
se 
hBM-
MSCs 
9.4 T 3D bSSFP 1 hr 0,3,12,17,26 26 days Healt
hy 
nude 
mice 
[83] 
PFCE Mouse 
NSCs 
9.4 T Fast Spin 
Echo 
- 3,7,14 2 weeks Healt
hy 
nude 
mice 
[119] 
Celsen
se 
hNSCs 11.7 T Turbo Spin 
echo 
1.5 hrs 2,6 6 days Healt
hy 
nude 
mice 
[76] 
Celsen
se 
hNSCs 7 T Fast Spin 
Echo 
45 mins 0,1,7 7 days Strok
e 
Model 
(Rat) 
[120] 
Celsen
se 
MSCs 9.4 T 3D bSSFP 90 mins 0,3,9,16 16 days Immu
noco
mpete
nt & 
health
y 
nude 
mice 
[121] 
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However, a concern with nanoemulsions is the inevitable process of Ostwald ripening which 
results in growth of larger particles at the detriment of the smaller particles.[122] Additionally, 
the chemical inertness of nanoemulsions limits their potential broader application due to lack 
of available sites for chemical modification. Finally, the large size of nanoemulsions can 
cause the agents to be retained within the organs for an extended period of time. [74] 
 
1.4.1.10 Partially-fluorinated polymers (PFPs) as 19F MRI tracers 
 
In order to address these drawbacks, partially-fluorinated polymers (PFPs) have been 
proposed as alternative 19F MRI agents.[98] Fluorine-containing polymers are readily 
prepared for example via copolymerization of fluorinated monomers. A large range of 
structures of PFPs can be envisaged, allowing the ability to attach functional groups which 
provide a combination of different imaging modalities, therapeutic agents and targeting 
moieties for more specific and directed imaging in the body.[123] This versatility allows the 
researcher greater control in the optimization of the experimental design involving the 
imaging agents. Furthermore, PFPs are highly stable and the generally smaller sizes lead 
to shorter, but controllable retention times in the body. 
 
Several groups have introduced unique PFPs as 19F MRI CAs via incorporation of fluorinated 
monomers with hydrophilic or functional segments through chemical polymerizations.[98] In 
a study from our group, Thurecht et al. described the preparation of  
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hyperbranched polymers (HBPs) with a fluorine content of ~ 2.5 wt. %, with 2,2,2-
trifluoroethyl acrylate (TFEA) as the fluorine monomer, ethylene glycol dimethacrylate 
(EGDMA) as the crosslinking monomer and oligo(ethylene glycol) methyl ether methacrylate 
(OEGMA) as the hydrophilic monomer. These HPB molecules have been imaged 
successfully in a mouse model following systemic injection, in a scan period of less than 10 
minutes.[99] Despite considerable advances, the use of PFPs as MRI contrast agents is often 
limited by low fluorine content (often below 5 wt. %) leading to lower imaging sensitivity. The 
monomers 2,2,2-trifluoroethyl acrylate (TFEA) or 2,2,2-trifluoroethyl methacrylate (TFEMA) 
are commonly used as the fluorine-containing monomer for the synthesis of PFP contrast 
agents, but these monomers possess a relatively low weight-fraction of fluorine. Therefore, 
to achieve higher imaging sensitivity, novel monomers with a higher fluorine content should 
be investigated.  
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1.5 Nanomaterials 
Nanomaterials can be characterised as objects ranging between a few nanometres to less 
than 100 nanometres, possessing varying properties that are based on their size, structure 
and morphology. [124]  The nanoscale size allows increased accessibility of nanoparticles 
(NP) to cellular machineries and hence may cause novel and effective biological impacts. 
Additionally, NP surfaces can be modified with targeting moieties to attain efficient affinity to 
disease locations. Therefore, nanomaterials have been widely investigated in numerous 
biomedical applications including bio-imaging, targeted drug delivery and bio-sensing 
(Figure 1.9).   [125-129]  
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Figure 1.9. Examples of nanomaterials and their functional groups for biological 
applications. [125] 
The mechanism by which NPs enter the cell has significant implications on their fate and 
also impacts the biological systems in terms of efficacy and/or toxicity. The route of entry 
into the cell is very important for determining the final intracellular location of the particle and 
its resultant intended efficacy and toxicity.  Despite staggering literature available on the 
development and application of novel NP, clinical translation of many of these NPs is difficult 
due to this lack of knowledge and emphasis on NP-cell interactions. Therefore, it is crucial 
to understand NP interactions with cellular systems, such as endocytic mechanisms utilised 
by NP to enter cells for future clinical applications. [130-132] This data allows development of 
various methodologies to escape degradation in the lysosomes and further optimisation of 
NP for efficient clinical translation. Additionally, understanding of exocytosis mechanisms of 
nanoparticles is also essential for safe and efficient therapeutic application since exocytosis 
plays a fundamental role in the removal of nanoparticles with drugs or contrast agents from 
the body. [131, 133] 
Endocytosis is a fundamental cellular process that is activated by cells to internalise various 
macromolecules. Endocytic pathways that govern the shipping of a specific cargo involve a 
range of mechanisms at the cell surface. Several entry pathways have been recognised, 
which differ in terms of the cargoes transported and protein machinery that aids the process. 
[134] Endocytosis is a process that cells employ to take up NPs into the cells. Typically after 
internalisation, NPs undergo different journeys by migrating to different compartments: to 
recycling endosomes for reprocessing back to plasma membrane to late endosomes and 
lysosomes for degradation, to the Golgi network or to other locations in the cell. [135] 
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It has been previously reported that a range of NP characteristics including size, shape, 
charge, cell type, cellular environment affects efficiency of NP uptake.  [136, 137] These factors 
will be discussed further on in this chapter. 
1.5.1 Cellular entry pathways for NPs 
Cell uptake of NP may occur via different types of endocytic pathways and is broadly 
classified into phagocytosis (cell eating) and pinocytosis (cell drinking). [138] Phagocytosis is 
restricted to specialised cells (e.g. macrophages and dendritic cells) and involves 
engulfment of large particles resulting in the formation of intracellular phagosomes. [139] 
Typically, larger particles as large as 10 µm in diameter adopt this pathway to enter cells.  
Conversely, pinocytosis occurs in all cell types and the mechanisms underlying the pinocytic 
pathways and the functions of some proteins involved have not been completely elucidated. 
Currently, pinocytosis can be generally categorized into macropinocytosis, clathrin-
dependent (CDE), and clathrin-independent (CIE) endocytosis based on the proteins 
involved in the pathways (Figure 1.10). [136, 140] These pathways vary in the size of the 
detached vesicles, structure of the coat protein and fate of the internalized NP. [141] 
Generally, type of pinocytic pathway adopted is based on the interaction of NP and cells. 
Correspondingly, these pathways can be cell specific, as not all cell types are furnished with 
the essential tools to accomplish the complete range of pathways. [142] 
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Figure 1.10. Multiple portals of entry into cells. Endocytic pathways are distinct based on 
size of endocytic vesicle, the nature of cargo and the mechanisms of vesicle formation. [131] 
 
1.5.1.1 Phagocytosis 
Phagocytosis is performed by specialised cells including macrophages, monocytes, 
dendritic cells and neutrophils that are proficient in clearing foreign materials, pathogens 
such as bacteria or yeasts, and cellular debris. It is a highly regulated process involving 
specific signalling cascades that initiates assembly of actin and development of cell surface 
protrusions that consumes the foreign materials (Figure 1.11). [143, 144] 
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Phagocytic cells can engulf particles as large as 10 μm in diameter, hence this can be a 
major hurdle that impedes effective delivery of NP to its intended site of action. [136] For 
instance, i.v. injected NP can be easily identified by the body’s immune surveillance and 
cleared from circulation by the macrophages of the reticuloendothelial system (RES) before 
reaching the designated site. [145] Normally, particles that have hydrophobic properties are 
easily detected by the immune system and undergo opsonisation whereby NPs are 
chemically adjusted to have stronger interactions with surface receptors on phagocytes. [146, 
147] Hence, it is crucial to design NPs through surface modification with hydrophilic polymers 
such as PEG as it has been well documented to repel opsonins resulting in an increased 
circulation half-life. [148] 
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Figure 1.11. An overview of phagocytic pathway. The foreign NPs are recognized by 
specific receptors, which targets surface-bound opsonins, are internalized to form endocytic 
vesicles called phagosomes. The fusion of phagosomes with the lysosomal compartment 
leads to the formation of phagolysosomes, where the foreign particles are enzymatically 
degraded. [149]  
 
1.5.1.2 Clathrin-dependent endocytosis (CDE) 
CDE is a well-established endocytic pathway and involves assembly of a coat protein, 
clathrin, on the cytosolic part of the plasma. Clathrin is a protein comprised of three clathrin 
heavy chains and three light chains that forms a triskelion structure (Figure 1.12). 
Internalisation of cargo occurs via interaction of NP with specific receptors present on the 
cytomembrane, which then induces assembly of clathrin coated pits on the cytosolic 
membrane in the presence of adaptor proteins. 
 Typical sizes of these pits are in the range of 60-200 nm in diameter.  Subsequently, these 
pits pinch off to develop endocytic vesicle via GTPase activity of dynamin resulting in clathrin 
coated vesicles (CCV). The protein coat that encapsulates the newly formed endocytic 
vesicle is promptly disassembled. Eventually, these vesicles will be transported to the 
lysosomes where the NP will be degraded. Besides clathrin, this pathway also requires 
several important adaptor and accessory proteins to operate. [139, 150, 151] 
CDE has been previously classified as ‘receptor mediated’ endocytosis, however it is evident 
that this term is ambiguous since most pinocytic pathways involves specific receptor-ligand 
interactions. CDE is a constitutive process that occurs in all mammalian  
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cells. Its main function is to continuously take up vital nutrients such as low-density 
lipoprotein particles (LDL) and iron loaded transferrin (Tfn). [152, 153] 
 
 
 
Figure 1. 12. Fundamental components of the machinery influencing CDE. [154] 
1.5.1.3 Clathrin-independent endocytosis (CIE) 
Although the mechanism of CIE has not been completely established, caveolae mediated 
uptake is probably the best characterised CIE pathway.  
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Figure 1.13. Endocytic trafficking of CTxB and S40. [155] 
 
1.5.1.3.1 Caveolae-mediated uptake 
This pathway can be categorised as clathrin independent, dynamin dependent and 
cholesterol sensitive endocytic route. Caveolae are small (50-80 nm), sphingolipid and 
cholesterol-rich invaginations of plasma membrane domains and can be identified by the 
presence of integral membrane protein caveolin. [130, 156, 157] Caveolin is a dimeric protein 
that binds cholesterol and sphingolipids in specific sites of the plasma membrane and results 
in the development of caveolae. Caveolin-1, caveolin-2 and caveolin-3 are the main 
structural proteins of caveolae, which are part of the caveolin gene family. Caveolin-1 (Cav1) 
is the most vital structural protein in caveolae and is located in small vesicles in the 
cytoplasm. Caveolin-null mice that lack the chief protein isoform caveolin-1 did not 
demonstrate detectable caveolae, hence affirming its structural importance. Caveolae can  
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internalise molecules such as Simian virus 40 (SV40) and cholera-toxin- binding subunit 
(CTxB) via interaction that is regulated by dynamin, protein kinase C and tyrosine kinases 
with receptors present on the plasma membrane (Figure 1.13). [158] This induces the 
development of flask-shaped vesicles, which detaches from the membrane and fuse with 
caveosome or with early endosome. Subsequently, SV40 is trafficked to the endoplasmic 
reticulum (ER) and caveolin is recycled back to the plasma membrane. While CTxB is most 
probably transported via early endosomes to the Golgi complex. [155] 
In comparison to CDE, this endocytic route takes a longer period of time and includes 
smaller vesicles in the process. [158] This route has also been shown to bypass lysosomes, 
reaching the endoplasmic reticulum and nucleus.  Hence, many pathogens such as bacteria 
and viruses opt for this route to escape lysosomal degradation. [159-161] Therefore, this 
pathway can be adopted for targeted macromolecule delivery. Conjugating particles with 
folic acid ligands has been proposed to promote the caveolae-mediated mechanism. [162-164] 
1.5.1.3.2 Clathrin- and caveolin-independent endocytosis 
Entry into a cell can also occur without the presence of clathrin and caveolin. Caveolae 
represents just one category of cholesterol rich microdomians. Others, generally termed as 
lipid rafts, diffuse freely on the cell surface. [165] These small rafts, 40-50 nm in diameter, can 
be internalised within any endocytic vesicle. Interleukin-2 (IL-2) receptors on lymphocytes 
which is also related to lipid microdomains have been demonstrated to be taken up by 
clathrin- and caveolin-independent pathways. [166]  The Hanes group revealed that small 
polystyrene particles (< 25 nm) were taken up by Hela cells via a clathrin, caveolae and 
cholesterol independent pathway and escaped typical endosomal lysosomal 
compartments.[167]  Hence, it has been postulated that very small NP may adopt a non  
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clathrin-, non-caveolae- mediated pathway. Recently, this area has attracted much attention 
but unfortunately, the mechanism is still poorly understood.  
1.5.1.4 Macropinocytosis 
 
 
Figure 1.14. Pathways of macropinocytosis. [168] 
Macropinocytosis can be defined as a non-receptor, non-selective, actin-driven, clathrin and 
caveolin-independent endocytic mechanism which involves internalisation of suspended 
macromolecules into macropinosomes (0.5-10 μm). Generally, macropinocytosis involves 
cell surface ruffling that is triggered in many cell types via stimulation by growth factors and 
specific signalling. In macrophages, macropinosomes travel into the cytosol and fuse with 
lysosomes (Figure 1.14). However, in human A431  
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cells, macropinosomes are transported back to the cell surface of membranes where the 
cargoes are released to the extracellular space. In summary, macropinosomes can be 
transported to lysosomes or recycled back the plasma membrane. [154, 169] Therefore, the 
final destination of macropinosomes is cell dependent. 
1.5.2 Factors affecting NP uptake & endocytosis pathway selection 
Physical and chemical properties of particles, including size, shape, surface charge, surface 
chemistry, cell type and cellular environment play important roles in the uptake of NP and 
determines the pathway of entry. 
1.5.2.1 Size 
Particle size plays a very crucial role in the internalisation of NP. Rejman et al. investigated 
the effect of particle size on the pathway of internalisation in non-phagocytic melanoma cells 
using a range of different sized (50-1000 nm) polystyrene beads. It was concluded that the 
uptake of NP smaller than 200 nm involved CDE. Authors also demonstrated that NP of 500 
nm in size is internalised via caveolae-mediated endocytosis and avoided accumulation in 
lysosomes. [157] This uptake via caveolae-mediated endocytosis of the NP negates the 
typical perception that caveolae-mediated endocytosis is associated with the internalisation 
of small NPs due to the size of caveolae (~50 – 60 nm). [156] 
The Hanes group also demonstrated that small polystyrene NPs (43 nm) entered Hela cells 
by CDE. [167] This data is consistent with previously reported study, which demonstrated that 
lipoplexes with an average size of 200 nm are taken up via CDE. [170]  A common trend 
observed was that small NPs had faster uptake kinetics compared to large NPs. 
Consequently, the mechanism of uptake adopted by NPs and its subsequent trafficking was 
clearly size-dependent.  
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1.5.2.2 Shape 
Additionally, physical shape of the NPs has an impact on cellular uptake. Zhao et al. reported 
that worm-like PFPs achieved the highest uptake in CHO cells, followed by spheres and 
vesicles. [171] Gratton et al. demonstrated that rodlike NPs attained the highest uptake in 
Hela cells, followed by spheres, cylinders and cubes. Also, authors established that a 
combination of CDE and caveolae mediated endocytosis were involved in internalisation of 
cylindrical shaped NPs. [172] Conversely, in several published studies with gold NPs smaller 
than 100 nm, it was revealed that spherical shaped NPs had significantly higher and faster 
rate of uptake compared to nanorods. [173, 174] Thus, no general consensus can be 
determined yet.  
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Figure 1.15. Nanoparticles which possess different charge and different hydrophobicity 
present different affinity with the cell membrane. [175] 
1.5.2.3 Surface charge 
The surface charge of nanoparticles can affect their efficacy and adopted uptake route 
because biological systems consist of various charged biomolecules. Generally, NPs with 
positively charge surfaces have efficient uptake in cells via strong electrostatic interactions 
with negatively charged plasma membrane (Figure 1.15). [176] DeSimone et al. reported that 
positively charged NPs with the same shape and size had higher levels of internalisation 
(84%)  in Hela cells as compared to negatively charged NPs equivalents (< 5%). [172]  
Additionally, several reports have indicated that cationic NPs enter cells via CDE. [177, 178] 
Nonetheless, several other studies have described the successful uptake of negatively 
charged NPs via caveolae mediated pathways and caveolae independent pathways. [179-184] 
It should be noted that positively charged NPs may bypass endosomes after internalisation 
and accumulate in the perinuclear region due to the ‘proton-sponge’ effect. NPs with no net 
charge may be taken up in cells by hydrophobic and hydrogen bonding interactions. [185] 
Neutral NPs showed no preference for a specific route of uptake and neutral PEGylated 
particles are reported to evade macrophage uptake.  
1.5.2.4 Surface Hydrophobicity 
The surface hydrophobicity of NPs is determined by the chemical structure at the surface. 
The degree of hydrophobicity can influence NPs interactions and uptake pathways selected 
in cells. Hydrophobic NPs have stronger interactions with the cell membrane compared to 
hydrophilic NPs. Commonly used hydrophilic polymers as PEG and dextran that are utilised 
for NP modification may reduce the affinity between NPs and lipid bilayers of cells. [186-188] 
Accordingly, these polymers can increase circulation half-life of NPs in the blood. 
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1.5.2.5 Cell type 
Not all cells are equipped with the necessary proteins involved in specific endocytic 
pathways. MSCs are non-phagocytic cells and are generally unable to internalise NPs via 
phagocytosis. Similarly, HepG2 cells lack endogenous caveolin, hence are incapable of NP 
uptake by caveolae mediated endocytosis. [189] Nonetheless, present studies lack emphasis 
on the association between cell type and endocytic pathways.  
Overall, the mechanism of uptake is dependent on not only size, shape, surface charge and 
surface chemistry, but several other factors. These include NP-cell interactions, incubation 
parameters, cell treatment, etc. Hence, the mechanism of uptake of a specific NP in a 
particular cell type depends on the combined effects of many parameters. 
 
1.5.3 Identification of endocytic pathways  
Earlier, researchers either utilised endocytic markers to determine intracellular location of 
NPs or used endocytic inhibitors to elucidate the pathways adopted for the uptake of the 
NPs. However, combining these two methods will provide more convincing evidence of the 
pathway of endocytosis. 
1.5.3.1 Use of specific endocytic markers 
Specific markers/probes are internalised via a specific endocytic pathway. Typical examples 
for CDE are uptake of iron loaded human transferrin (hTf) via transferrin receptors and 
cholesterol rich low-density lipoprotein (LDL) particles through the LDL  
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receptors. Despite the fact both LDL and Tf are internalised via CDE, their intracellular 
destinations are different. While Tf is recycled back to the cell surface, LDL is transported to 
the lysosomes and undergoes degradation. Hence, Tf is a robust and specific marker for 
CDE. [190, 191]  
 
Lactosylceramide (LacCer) is a glycosphingolipid that is located in lipid rafts and is 
internalised by CIE, dynamin and caveolin-1 dependent pathways. [192, 193] Hence, it has 
been reported to be employed as a marker for caveolae mediated endocytosis. Additionally, 
the cholera toxin beta subunit (CTxBs) and Shiga Toxin have been used as markers for 
caveolae dependent endocytosis. [194, 195] High molecular weight dextrans are specifically 
taken up into macropinosomes and hence utilised as a marker for macropinocytosis. [196] 
Several markers can be utilised to determine the destination of the NPs in cells via proteins 
present in the intracellular organelles (Table 1.7). These proteins are conjugated with 
fluorescent dyes and can indicate the precise location of NP in the cells via confocal 
microscopy. Several examples include caveolin-1 on caveolae, lysosome associated 
membrane protein 1(LAMP-1), Rab7 in the late endosome, etc. [197, 198] Furthermore, there 
are dyes for organelles such as LysoTracker and MitoTracker which can be employed to 
observe co-localisation of specific organelles with labelled NPs via confocal imaging. 
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Table 1. 7. Markers commonly used to identify cellular structures. 
Markers Compartment localised 
Transferrin Clathrin coated pits, early and 
recycling endosomes 
LDL Clathrin coated pits 
EEA1 Early endosomes 
LAMP-1 Lysosomes 
LysoTracker Lysosmes and late 
endosomes 
MitoTracker Mitochondria 
Rab 7 Late endosomes 
Rab 11 Recycling compartment 
 
1.5.3.2 Use of specific inhibitors 
Endocytic inhibitors can be employed to impede specific pathways to verify the pathways 
utilized by the NPs to enter the cells. Established markers can be used in parallel to 
corroborate the specific uptake pathways utilised by cells. There are many different inhibitors 
reported in the literature, but we will focus on the most frequently used drugs (Table 1.8) to 
study the uptake of PFPs in MSCs. This methodology is based on the assumption that these 
inhibitors have precise effects on a type of endocytic pathway.  
However, some studies have indicated that these inhibitors are not exclusively specific to a 
particular pathway and may influence other pathways. [199] Additionally, it has also been 
reported that these inhibitors may block different endocytic pathways in different cell types. 
[200] 
There are several advantages in the use of chemical inhibitors. Mainly, these inhibitors may 
be employed to affect all cells equally in a population and hence effects can be titrated. 
Additionally, cells only require a short incubation time with inhibitors to develop distinctive 
effects hence avoiding the development of delayed side effects. Lastly, strategies that use 
chemical inhibitors are cost, labour and time efficient. [135, 150] 
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Table 1. 8. Endocytic inhibitors and controls utilised for uptake mechanisms studies. 
Endocytic 
Pathway  
Inhibitor Comment Concentrat
ion Range 
Expos
ure 
Time 
Endocytic 
Control 
Ref 
Clathrin-
dependent 
endocytosis 
(CDE) 
Chlorpromaz
ine 
(CPZ) 
- Reversible 
- Distinguish 
between 
clathrin- and 
caveolae-
mediated 
endocytosis 
5-10 μg/ml 30 min 
to  
2 hours 
Transferrin 
from Human 
Serum 
(hTf) 
[150, 
151, 
200-
203] 
Lipid raft-
dependent 
endocytosis 
(Clathrin-
independent 
CIE) 
Methyl-β-
cyclodextrin 
(MβCD) 
- Reversible 
- Interferes with 
micropinocytosi
s and clathrin-
mediated 
endocytosis 
1-10 mM 30 min 
to  
2 hours 
Lactosyl-
ceramide 
(LacCer) 
[135, 
139, 
150, 
200, 
201, 
204] 
Caveolae-
dependent 
endocytosis 
(Clathrin-
independent 
CIE) 
Genistein 
(Gen) 
- Causes cell 
morphological 
changes 
200-400 μM 30 min 
to  
2 hours 
Lactosyl-
ceramide 
 (LacCer) 
[151, 
156, 
200, 
201, 
205] 
Macropinocytos
is 
Phagocytosis 
(N/A for MSCs) 
5-(N-Ethyl-N-
isopropyl) 
amiloride 
(EIPA) 
- Non-specific 
- Interferes with 
actin which 
affects other 
endocytic 
pathway 
25-150 μM 2 hours Dextran [150, 
201, 
206, 
207] 
* 
Endocytosis 4 °C - Non-specific - - - [151, 
208] 
 
There are many types of chemical inhibitors employed in uptake mechanism studies. [150] 
However, only the commonly used inhibitors are discussed below. 
1.5.3.2.1 CDE Inhibitors 
Chlorpromazine hydrochloride (CPZ) is a cationic amphiphilic drug which when employed in 
a micromolar range (50-100 µM) inhibits clathrin-mediated endocytosis. [209, 210] CPZ inhibits 
clathrin-coated pit formation by triggering a reversible loss of clathrin, adaptor protein  
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complex 2 (AP2) and its assembly from the cell surface. [150, 211]  Potassium depletion has 
been shown to suppress CDE via aggregation of clathrin in cytoplasm, which prevents it 
from functioning at the cell surface. [212] However, substantial reduction of potassium can 
affect DNA and protein synthesis. [213]  Treatment of cells with hypertonic sucrose also blocks 
CDE but may cause adverse effects on cells such as cell shrinkage and modifications to the 
actin cytoskeleton. [214] 
1.5.3.2.2 CIE inhibitors 
MβCD is a cyclic heptasaccharide and has a strong affinity with  cholesterol. MβCD develops 
soluble inclusion complexes with cholesterol when used in millimolar concentrations, 
causing a reduction of this lipid in the membrane. [150]  MβCD is commonly used as an 
inhibitor of CIE, to ascertain if endocytosis is dependent on the integrity of the lipid rafts. 
Since cholesterol is required for caveolae mediated uptake, it has also been reported to 
inhibit internalisation via caveolae. [215] Genistein, a tyrosine kinase inhibitor, has been 
reported to inhibit SV40 induced vesicle development from caveolae, hence used as a 
caveolae inhibitor. [130, 158] It has also been reported to prevent recruitment of dynamin II and 
cause local disruption of the actin network which are crucial events in the caveolae mediated 
pathway. [200] 
 
1.5.3.2.3 Macropinocytosis inhibitors 
Macropinocytois can be blocked by amiloride and its analogues which prevent Na+/H+ 
exchange in the plasma membrane. This will interfere with actin remodelling that is essential 
for membrane ruffling. [216, 217] Besides employing chemical inhibitors and endocytic markers, 
temporary or stable knock out mutants of proteins required for specific pathways can be 
utilized as biological inhibitors.  
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Knock out cell-lines can be generated by RNA interfering silencing mechanisms or by 
expressing dominant-negative proteins, which silences or inactivate specific genes or 
proteins correspondingly. Consequently, these events lead to inhibition of a particular 
pathway.[218-220] 
 
1.6 Aims of this project 
19F MRI has been an established imaging modality because of its high specificity due to the 
absence of endogenous fluorine signal in the body. Additionally, this modality allows cell 
quantification as signal intensity is directly proportional to the amount of 19F present. Overall, 
19F MRI provides a highly specific, unambiguous and quantitative approach to tracking of 
labelled MSCs. Despite the appealing advantages, 19F MRI has not been exploited in the 
clinic predominantly because of the lack of suitable and efficient tracers [71, 76]. Therefore, it 
is essential to develop robust fluorinated tracers to completely exploit MRI as a powerful 
imaging tool for the tracking of therapeutically relevant cells such as MSCs.  19F MRI based 
cell tracking has great potential especially in optimization of MSC therapy to attain clinical 
success and it is anticipated to be routinely utilised in the near future. Furthermore, besides 
emphasis on the development and application of novel MR tracers, much focus is also 
required to understand the interactions of NPs with cellular systems. This includes a 
thorough evaluation of endocytic mechanisms utilised by NPs to enter cells, exocytosis, 
retention and dilution of NPs in cells.  
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Thus, the aims of this project are as follow: 
1) Tracking of placenta derived MSCs labelled with novel fluorinated nanoparticles in 
animal models with MRI. 
 Synthesis and characterisation of fluorinated copolymers 
 Isolation and characterisation of human FBMSCs and PMSCs from term 
placentas 
 Comprehensive in vitro evaluation of novel fluorinated copolymers in 
FBMSCs and PMSCs 
 Cell detection by 19F MRI 
2) Longitudinal tracking of labelled cells in healthy and mice mouse models using MRI 
and fluorescence imaging. 
 
3) Ascertaining uptake mechanisms of copolymers in MSCs. 
 
With regards to these objectives, this thesis is divided into five chapters. Chapter 1 details 
a comprehensive literature review, which encompasses the utilisation of placental derived 
MSCs, tracking of MSCs using MRI and uptake mechanism pathways adopted by NPs to 
enter cells. Chapter 2 reports the proficiency of labelling FBMSCs with Poly(OEGMA-co-
TFEA) copolymers and its feasibility as an 19F MR cell tracer. Chapter 2 also describes the 
design and characterisation of a novel partially fluorinated polymer, poly(OEGMA-co-
PFPEMA), synthesised via RAFT polymerisation. This chapter also details the efficiency 
and feasibility of labeling well-characterized human PMSCs with poly(OEGMA-co- 
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PFPEMA). Cell uptake was assessed by 19F NMR, and corroborated by flow cytometry and 
confocal microscopy. Importantly, in vitro 19F MR imaging of labelled cells were acquired at 
a 9.4 T to demonstrate copolymers as a promising 19F MR tracer. Chapter 3 describes in 
vivo longitudinal detection and bio-distribution of labelled PMSCs in animal models using 
19F MRI and optical imaging. Additionally, PMSCs labelled with copolymers were carefully 
evaluated for any variations according to the criteria established for MSCs by the ISCT. 
Chapter 4 describes studies of specific endocytic mechanisms adopted by copolymers to 
enter PMSCs and to explore the fate of these NPs in cells. Commonly used chemical 
inhibitors, which block specific pathways and endocytic markers, are utilised to ascertain the 
route of internalisation in the cells.  Furthermore, studies were conducted to identify co-
localisation of copolymers with specific organelles, and endocytic markers used to validate 
mechanism of uptake adopted by these copolymers. Finally, Chapter 5 provides a summary 
of the findings reported in this thesis. 
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Chapter Two 
2.1 Introduction  
Mesenchymal stem/stromal cells (MSCs), a type of adult stem cell, have recently attracted 
enormous interest for the treatment of a broad range of diseases, with almost 600 clinical 
trials involving MSCs listed in the clinical trials database (http://clinicaltrials.gov/).[1] In these 
studies, MSCs have been exploited either as a therapeutic agent or as a delivery system.[2] 
This broad utility of MSCs is now recognized as being due to a range of properties in addition 
to their capacity for differentiation,[3] which includes immunomodulation and 
immunosuppression,[4] inherent tropism to injured tissue/tumour microenvironments [5] and 
inhibitory effects on several tumour types.[6] Despite this promise, translation of MSC-based 
therapies to the clinic remains challenging and results are often discouraging. [7] The full 
therapeutic potential of MSCs can only be attained if they migrate and home to the sites of 
lesion, survive and engraft post implantation. The lack of tools to understand the fate of 
transplanted cells, non-invasively and longitudinally, is in part responsible for conflicting 
clinical trial results. [8] Unfortunately, conventional imaging modalities for the tracking of stem 
cells in the laboratory such as fluorescence and bioluminescence imaging have limited 
potential for clinical translation. [1, 9] 
In vivo cell tracking is potentially a powerful tool to monitor non-invasively the distribution 
and accumulation of therapeutic cells such as MSCs. Development of accurate imaging 
modalities to track MSCs would allow clinicians to determine whether cell delivery has 
occurred at the appropriate site and if cells have reached their targeted location.[10] 
Consequently, non-invasive real-time imaging techniques need to be developed to ascertain 
homing efficiency, dosing requirements, optimal timing and route of delivery to allow success 
of cell-based therapies.[10] 
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MRI is a particularly promising imaging modality for longitudinal tracking of MSCs [11]  as it 
does not involve ionising radiation and is considered safe for deep tissue imaging at high 
resolution. [12] Tracking is attained by pre-labelling MSCs preceding implantation with an 
agent which provides a change in contrast on an MRI scan.[13] The MRI signal can be 
generated and influenced  in several ways including with positive contrast agents containing 
paramagnetic metals (e.g. gadolinium), negative contrast agents comprised of 
superparamagnetic iron oxides (SPIO) or partly-fluorinated molecules or particles for 19F 
MRI.[14] 
T2/T2* contrast agents have been the most commonly employed agents for tracking of stem 
cells using MRI.[15] A number of preclinical in vivo studies tracking MSCs using SPIOs has 
been reported in various animal models. [16, 17] Nonetheless, the approach of labelling cells 
with superparamagnetic iron oxide particles for cell tracking has several limitations, which 
have been discussed in Chapter One of this thesis.  
An alternative approach to cell quantification is through 19F MRI, where cells are labelled 
with fluorinated molecules or nanoparticles.[11] 19F MRI does not however provide anatomical 
information and hence 19F MR images are overlaid on a 1H MRI anatomical image acquired 
concurrently with the same scanner, in order to avoid image misregistration. [18] As indicated 
above, 19F MRI allows for quantification of injected cells as the signal intensity is, in principle, 
directly proportional to the number of 19F nuclei present. Therefore, the in vivo image can 
provide a quantitative measure of cell numbers when the average content of 19F spins per 
cell is known. [19] Consequently, as 19F MRI enables quantification of cell numbers it may be 
beneficial for optimising MSC-based therapies. Overall, 19F MRI provides a highly specific, 
unambiguous and quantitative approach of tracking of labelled MSCs. 
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Recently, much emphasis has been dedicated to the development of 19F MRI agents, 
including perfluorocarbon (PFC) emulsions, 19F-containing small molecules and 19F-
containing macromolecules (Table 2.1).[20-31] Currently, particles containing 
perfluoropolyethers (PFPE) have been presented as an attractive 19F imaging agent due to 
their simple 19F NMR spectrum and relative ease of synthesis.[32, 33] PFPEs, in particular 
linear perfluorinated oligomers, are not soluble in water and require incorporation within 
hydrophilic segments or within an emulsion. The majority of 19F MRI cell labelling studies 
have employed the commercial product Celsense, which are PFC emulsions (typical sizes 
from 100 to 300 nm) based on linear PFPE polymer mixtures.[11, 34] Only a small number of 
publications have demonstrated MR detection of 19F labeled stem cells in vivo, and four 
studies have reported longitudinal imaging of the fate of these cells post transplantation.[11, 
35-37] However, a concern with nanoemulsions is the inevitable process of Ostwald ripening, 
chemical inertness and the large size of these agents. [10, 38] Therefore,  partially-fluorinated 
polymers (PFPs) have been proposed as alternative 19F MRI agents.[20] The advantages of 
PFPs include high stability, small size, fast clearance from the body and capacity for facile 
chemical modifications. [20, 39] Several groups have introduced unique PFPs as 19F MRI CAs 
via incorporation of fluorinated monomers with hydrophilic or functional segments through 
chemical polymerizations. [20] Despite significant developments, the use of PFPs as MRI 
tracers is often restricted by low fluorine content (often below 5 wt. %) hence leading to lower 
imaging sensitivity. The monomers 2,2,2-trifluoroethyl acrylate (TFEA) or 2,2,2-trifluoroethyl 
methacrylate (TFEMA) are frequently used as the fluorine-containing monomer for the 
synthesis of PFP tracers. Hence, we evaluated the feasibility of poly(OEGMA-co-TFEA) as 
a potential 19F MR tracer for MSCs. However, these monomers contain a relatively low 
weight-fraction of fluorine.  
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Consequently, unique monomers with a higher fluorine content should be explored to 
achieve higher imaging sensitivity.  
 
Table 2. 1. Perfluorocarbon (PFC) emulsions, 19F-containing small molecules and 19F-
containing macromolecules for MRI application. 
Fluorine 
monomer 
Size 
(nm) 
T1 value 
(ms) 
T2 value 
(ms) 
MRI strength 
(Tesla) 
Ref 
TFEA 5 480 90 9.4 Thesis 
PFPE 12 410 60 9.4 [40] 
Thesis 
TFEA 10 480 88 16.4 [21] 
PFtb 12 500 100 4.7 [41] 
TFEA 20-45 500-600 249-331 7 [20] 
TFEA 8 420 54 16.4 [24] 
TFEA 60 537 176 9.4 [42] 
PFPE 
(Celsense) 
100-300 470 250 3 [43] 
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Therefore, in this chapter we also describe the design and synthesis of novel fluorinated 
copolymers using a novel perfluoropolyether methacrylate (PFPEMA) as the fluorinated 
monomer and OEGMA as a hydrophilic component necessary to impart solubility in aqueous 
media. The poly(OEGMA-co-PFPEMA) was modified by conjugation with a fluorescent dye 
to allow parallel validation studies (flow cytometry and microscopy), creating a dual-modal 
imaging agent. The polymers were characterized by 1H NMR, 19F NMR, size exclusion 
chromatography (SEC) and dynamic light scattering (DLS) and loaded into human MSCs 
derived from term placenta (PMSCs) as they are abundant, involve non-invasive donor 
procurement, do not elicit ethical concerns and hence, are a therapeutically-relevant source 
of MSCs. [44, 45] The efficacy of labelling of the PMSCs was assessed using 19F NMR and 
corroborated with flow cytometry and confocal fluorescence microscopy. In vitro 19F MR 
imaging of labelled PMSCs were conducted at 9.4 T and showed high sensitivity allowing 
the acquisition of high resolution images within short acquisition times. Our results suggest 
that this dual-modal 19F MRI probe is a particularly promising nanoparticle for tracking and 
quantification of non-phagocytic and therapeutically-relevant cells such as MSCs. 
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Experimental Section 
2.2.1 Materials 
All chemicals were reagent grade and used without further purification unless specified. 
Oligo(ethylene glycol) methyl ether methacrylate (OEGMA, MW = 475 g mol-1) was 
purchased from Sigma-Aldrich and passed through basic alumina columns to remove 
inhibitors prior to use. 2,2,2-trifluoroethyl acrylate (TFEA) was purchased from Aldrich and 
dried over CaH2 and then distilled under reduced pressure before use. Monohydroxy-
perfluoropolyether (PFPE-OH, ~1650 g mol-1) was supplied by Apollo Scientific Ltd, UK. The 
RAFT agent, 4-cyanopentanoic acid dithiobenzoate (CPADB), was synthesized according 
to a previously-reported method [46]. Deuterated solvents (CDCl3 and D2O) were purchased 
from Cambridge Isotope Laboratories. 
Dulbecco’s modified Eagle medium (DMEM) with high glucose, phosphate-buffered saline 
(PBS), Tryple Express, fetal bovine serum (FBS), antibiotic-antimycotic (AA), ActinRed™ 
555 reagent and membranes for dialysis (molecular weight cut-off of 3500 Da) were 
purchased from ThermoFisher Scientific. Gelatin was obtained from VWR Chemicals. 
Paraformaldehyde (PFA), trifluoroacetic acid (TFA), methacryloyl chloride, α,α,α-
trifluorotoluene (TFT), N-(5-fluoresceinyl) maleimide, n-hexyl amine, dimethylphenyl 
phosphine (DMPP), cell counting kit-8 (CCK-8) were obtained from Sigma Aldrich. Mounting 
media with DAPI was purchased from Vector Laboratories and MTS assay kit from 
Promega. 
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2.2.2 Characterization of copolymer  
1H NMR, 19F NMR and 19F T1 and T2 relaxation times of the poly(OEGMA-co-PFPEMA) 
copolymers were measured at 9.4 T using a Bruker Avance III 400 MHz spectrometer fitted 
with a broadband BBFO probe with 19F acquisition on the X channel. Cells in three T175 
flasks were cultured in a solution containing the poly(OEGMA-co-PFPEMA) at a 
concentration of 20 mg ml-1 for 24 h and then fixed with 4 % paraformaldehyde (PFA) for 30 
min. The samples were transferred into 3 mm NMR tubes and inserted into 5 mm NMR 
tubes filled with D2O. The volume of the cells was sufficient to fill the detector region of the 
NMR coil, typically ~ 4 cm in length from the bottom of the NMR tube. Acquisition of 19F 
NMR spectra and measurements of T1 and T2 relaxation times were carried out at 310 K. 
19F NMR spectra of labeled cells were obtained using a relaxation delay of 1 s, acquisition 
time of 1.26 s and the number of scans was 1024. The 19F spin-spin (T2) relaxation times 
were measured using the Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence at 310 K. The 
relaxation delay was 1 s, the acquisition time was 0.16 s and 64 scans were acquired. For 
each measurement, the echo times were varied from 2 to 770 ms and 16 points were 
collected. 19F spin-lattice (T1) relaxation times were measured using the standard inversion-
recovery pulse sequence. The relaxation delay was 2 s, the acquisition time was 0.16 s and 
the number of scans was 32. For each measurement, the recovery times were varied from 
2 ms to 3 s and 16 points were collected. 
DLS measurements were acquired using a Nanoseries Zetasizer (Malvern, UK) with a 2 mW 
He-Ne laser functioning at wavelength of 633 nm and a scattering angle of 173°. 
Hydrodynamic diameter was measured twice to obtain an average value. The concentration 
of the copolymer was 1 mg ml-1. 
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SEC was performed on a Waters Alliance 2690 separations module equipped with an RI 
detector. The polymer was dissolved in tetrahydrofuran (THF), passed through 0.45 μm 
filter, and eluted at 1 mg ml-1 in THF. 
2.2.3 Synthesis of perfluoropolyether methacrylate and poly(OEGMA-co-PFPEMA) 
Into a two-neck flask fitted with a dropping funnel, stirrer bar and purged with N2, 
monohydroxy-terminated perfluoropolyether (PFPE-ol) (1.65 kDa, 2.0 g, 1.21 mmol), 
triethylamine (211 µL, 0.153 g, 1.52 mmol), 2,6-di-t-butyl-4-methylphenol (20 mg) in α,α,α-
trifluorotoluene (2 mL) (TFT) were added. Methacryloyl chloride (142 µL, 0.152 g, 1.45 
mmol) was added dropwise at 0 °C, stirred for 1 h at this temperature, and then allowed to 
warm to room temperature overnight. The mixture was then diluted with TFT (20 mL) poured 
into water (50 mL) and the organic phase was washed with HCl (5%, 2 x 50 mL), NaOH (2 
x 50 mL) and water to neutrality followed by drying over MgSO4. The product was collected 
by filtration through a sintered glass funnel, before being reduced to dryness under high 
vacuum (0.1 mmHg). The perfluoropolyether methacrylate (PFPEMA), a colorless oil, was 
treated with another portion of 2,6-di-t-butyl-4-methylphenol (20 mg), sealed under N2 and 
stored below 5 °C. 
The copolymerization of OEGMA and PFPEMA was conducted as follows. In a typical 
experiment, OEGMA (1.2 g, 5 mmol), PFPEMA (1.73 g, 1 mmol), V40 (4.89 mg, 0.02 mmol), 
and CPADB (27.9 mg, 0.1 mmol) were dissolved in 5 ml TFT and sealed in a 25 mL flask 
fitted with a magnetic stirrer bar. The solution was then deoxygenated by purging thoroughly 
with nitrogen for 15 min, heated to 90 °C in an oil bath, and allowed to react for 24 h. The 
resulting solution was centrifuged for 5 min at 4000 rpm and the supernatant was 
precipitated into hexane and dissolved in THF three times. The precipitate was then 
dissolved in water and purified by dialysis, yielding a pink viscous solid after freeze drying. 
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2.2.3.1 Reduction of the polymer to free thiol 
Polymers with the terminal RAFT groups were reduced to the thiol by aminolysis in the 
presence of n-hexyl amine using a 4:1 molar ratio to the poly(OEGMA-co-PFPEMA) 
copolymer and catalytic amount of dimethylphenyl phosphine (DMPP) to prevent the 
formation of disulfides (1 mol %). 
 
2.2.3.2 Conjugation of poly(OEGMA-co-PFPEMA) with N-(5-fluoresceinyl)maleimide dye 
The procedure was as follows: an aqueous solution of poly(OEGMA-co-PFPEMA) (100 mg, 
0.005 mmol) was gradually titrated into a DMSO solution containing N-(5-
fluoresceinyl)maleimide (2.3 mg, 0.0054 mmol). The pH was adjusted to ~ 6 and the mixture 
was allowed to react at room temperature in the dark for 24 h. A yellow product was obtained 
after dialysis against water and freeze drying. The wavelengths of the maxima in excitation 
and emission of the dye were 492 nm and 518 nm, respectively. The same procedure was 
adopted for conjugation with another dye, Cy 5.5 (red). The wavelengths of the maxima in 
excitation and emission of the dye were 685 nm and 710 nm, respectively 
 
2.2.4 Human mesenchymal stem cells 
Third trimester placentas were acquired from healthy mothers with uncomplicated 
pregnancies at term during elective caesarean section (CS) and termination of pregnancy 
samples, as approved by The Human Research Ethics Committee of the Royal Brisbane 
and Women’s Hospital. MSCs were isolated from the maternal side of the placenta  
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(decidua). Patients gave written informed consent for the use of tissue for research purposes 
in compliance with national research guidelines. 
 
2.2.4.1 Isolation of fetal bone marrow mesenchymal stem cells (FBMSCs) 
FBMSCs were obtained as described for termination of pregnancy (TOP) by Campagnoli et 
al. In brief, the femur were dissected from other tissues and ends cut off. Bones were flushed 
with MSC media (AAN) and transferred to a flask with medium. Cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM, Invitrogen), supplemented with 10% fetal 
bovine serum (FBS), 1% antibiotic/antimycotic (AA), at 37 °C in a humidified atmosphere, 
with 5% CO2. [47]  
2.2.4.2 Isolation of decidua derived MSCs 
M-PMSCs were isolated from the maternal side of the placenta (decidua) (Figure 2.1). 
Decidua derived m-PMSCs were obtained from 0.5 cm deep villi tissue furthest from the 
umbilical cord containing the decidua. This tissue was collected, (~10 ml mark of a 50 ml 
tube), washed with PBS and finely minced. Tissue were treated with 100U/mL Collagenase 
type I (Invitrogen), 5 μg/mL, DNase I (Sigma-Aldrich) and 2.4 U/ml dispase (Invitrogen) in 
serum free DMEM-HG (4.5 g/L glucose, Invitrogen) for 1-2 hours at 37°C with gentle rocking 
and occasional manual shaking. The solution, termed digest media, was freshly prepared 
prior to use and was incubated in at least a 1:1 ratio with the tissue (e.g. 10 ml of tissue plus 
10 ml of digest media). Standard MSC media was added to inactivate the enzymes and the 
samples were pulse spun for about 30 sec to collect the large debris at the bottom of the 
tube. The supernatant was collected, and fresh media was added to the debris to recover 
more cells, briefly centrifuged and this step was repeated for a third time. All of the 
supernatants were pooled, centrifuged for 5 min at 340 g. This supernatant was carefully 
decanted, leaving some solution over the cell pellet. The  
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cells were resuspended in 35 ml of MSC media and filtered through 100 μm mesh. Cell 
suspensions were transferred to a T175 flask per 10ml of tissue.  
 
Figure 2.1. Third trimester placenta acquired from healthy mothers with uncomplicated 
pregnancies at term during elective caesarean section (CS). 
 
2.2.4.3 Cell culture of MSCs 
Decidua-derived MSCs were cultured in Dulbecco’s modified Eagle medium (DMEM, 
Invitrogen), supplemented with 10% fetal bovine serum (FBS), 1% antibiotic-antimycotic 
(AA), at 37 °C in a humidified atmosphere, with 5% CO2. Cells were passaged at 90% 
confluency at a ratio of 1:2 or 1:3. [48]  
2.2.4.4 Characterization of MSCs 
The MSCs were characterized and fulfilled the minimal criteria established by the 
International Society of Cellular Therapy (ISCT). [49] 
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2.2.4.4.1 Tri-lineage differentiation assay 
MSC growth media and complete differentiation media used for the investigations of tri-
lineage differentiation of PMSCs were prepared as per the manufacturer’s information. Cells 
grown to not more than 80% confluency with at least 90% viable cells (assessed with Trypan 
Blue Exclusion Assay) were seeded according to manufacturer’s instructions (Thermofisher 
StemProR differentiation kit) with the MSC growth media. MSC growth media was replaced 
with the appropriate pre-warmed complete differentiation media to initiate osteogenesis, 
adipogenesis or chondrogenesis differentiation. Cultures were refreshed with the 
appropriate pre-warmed complete differentiation media every 3-4 days.   
 
After 21 days, cells were fixed with 4% PFA and stained with the appropriate dyes according 
to the manufacturer’s recommendations. The cells were either stained with Alizarin Red, Oil 
Red O or Toluidine Blue to evaluate the differentiation of PMSCs into osteogenic, adipogenic 
and chondrogenic lineages respectively. All the staining solutions were filtered before use 
to remove any impurities and precipitation. The stained samples were imaged on a Nikon 
Inverted Microscope equipped with Phantom V9 high speed color camera with the 
appropriate magnifications. The images were post processed in ImageJ.   
 
2.2.4.4.2 Expression of MSC markers 
To determine PMSCs phenotypical characteristics, MSCs were cultured in a flask till 
confluency. Cells grown to 80% confluency with more than 90% cell viability (assessed with 
Trypan Blue Exclusion Assay) were detached and re-suspended at a cell density of 1 x 106 
cells/ml in the 1X washing/staining solution (1X PBS, 1% FBS). Nine tubes with each  
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consisted of 100 µL cell suspension were labelled with the appropriate colour compensation 
controls, MSC marker antibodies (BD Human MSC Analysis Kit) and isotype control 
cocktails (Table 2.2) in dark for 30 minutes on ice. The stained cells were washed twice with 
1X washing/staining solution and re-suspended in 500 µL staining solution. The stained cells 
were kept on ice throughout the experiment and analyzed on a flow cytometer. The data 
obtained were post processed in FlowJo V10 software. 
 
Table 2. 2. MSC marker antibodies and isotype controls cocktails (BD Human MSC Analysis 
Kit). 
Tube Antibody Volume 
(µl) 
Comment 
1 FITC Mouse Anti-Human CD90 1 FL1 Compensation 
Control 
2 PE Mouse Anti-Human CD44 1 FL2 Compensation 
Control 
3 PerCP-Cy™5.5 Mouse Anti-Human 
CD105 
1 FL3 Compensation 
Control 
4 APC Mouse Anti-Human CD73 1 FL4 Compensation 
Control 
5 Nothing Nothing Cell Control 
6 hMSC Positive Isotype Control Cocktail 4 Isotype Control 
PE hMSC Negative Isotype Control 
Cocktail 
4 
7 hMSC Positive Cocktail 4 Sample of Interest 
PE hMSC Negative Cocktail 4 
8 hMSC Positive Isotype Control Cocktail 4 Isotype Control for 
Drop In Marker Drop in isotype control (i.e. PE Mouse 
IgG2b, κ) 
1 
9 hMSC Positive Cocktail 4 Positive Marker 
Cocktail with 
Additional Drop In 
Marker 
PE Drop in (i.e. PE Mouse Anti-Human 
CD44) 
1 
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2.2.5 19F NMR analysis of cellular uptake 
The extent of internalization of the polymers by MSCs was quantified using 19F NMR. Cells 
were grown to 90% confluency in T175 flasks, and then incubated with media containing 
polymer at different concentrations (1, 3, 5, 10, 15 and 20 mg ml-1) for 24 hours to determine 
the optimal labeling concentration. The total cell number was determined using a 
hemocytometer with Trypan blue exclusion. An average of 2 x 106 cells was required per 
condition. Labeled cells were assayed for 19F content by NMR as previously described.[10, 
37] A known number of cells was placed in lysis buffer and mixed with D2O and trifluoroacetic 
acid (TFA) as the internal 19F standard compound. 19F NMR spectra of the cell pellets were 
acquired with a delay time of 10 s and 128 scans. The mean number of 19F nuclei per cell 
(Fc) was calculated using Equation (1). 
Fc=
3.Is.Mr.Na
IrNc
      (1) 
Where (Is/Ir) is the ratio of the integrated intensities of the PFPE peak in the cell pellet divided 
by that of the trifluoroacetic acid (TFA) reference peak, Nc is the number of cells in the pellet, 
Mr is the number of moles of the TFA reference, Na is Avogadro’s number. 
2.2.5.1 Confocal microscopy 
Imaging was conducted to ascertain if the copolymers were internalized by the cells. Cells 
were seeded onto coverslips and 3 mg ml-1 of poly(OEGMA-co-PFPEMA) conjugated with 
N-(5-fluoresceinyl)maleimide was added and incubated for several hours. 
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2.2.5.1.1 Preparation for imaging fixed cells  
The cells were fixed for 15 min in 4% paraformaldehyde (PFA), before being rinsed 3×5 
mins in phosphate-buffered saline (PBS). Subsequently, ActinRed™ 555 reagent 
(ThermoFisher) which selectively labels F-actin was added to the fixed cells, incubated for 
30 minutes, before being rinsed 3×5 min in (PBS), and mounted with DAPI in Vectashield. 
ActinRed™ 555 dye is excited at wavelength of 540 nm and has an emission maximum at 
565 nm. Images were acquired using a Zeiss LSM 710 inverted confocal microscope and 
were analyzed using ZEN software (Zeiss).  
2.2.5.1.2 Preparation for imaging live cells  
Cells were rinsed 3x5 mins in phosphate-buffered saline (PBS). Hoechst stain was added 
and cells were incubated for 30 minutes. Cells were washed 3x5 mins in phosphate-buffered 
saline (PBS). Images were acquired using a Zeiss LSM 710 inverted confocal microscope 
with cells were kept in a constant environment at 37°C and 5% CO2. Images were analyzed 
using ZEN software (Zeiss).  
 
2.2.5.2 Quantifying cell labeling using flow cytometry 
Cells labeled with polymer were seeded at a density of 100,000 cells/well in a 24 well plate. 
Different concentrations (0, 1, 3, 5, 10, 15 mg ml-1) of the copolymer were added to the 
media. After incubation for 24 hours, cells were trypsinized and suspended in (PBS) for 
analysis using a BD LSR II Flow Cytometer. The relative fluorescence intensity per condition 
was obtained. 
 
Chapter 2 Characterisation and In Vitro Evaluation of Copolymer 
 
 
2.2.6 Cytotoxicity and viability assay 
To measure the effect of the polymer on cell viability, the Trypan Blue exclusion test 
(Invitrogen) was conducted immediately after labeling with varying concentrations of 
polymer. To quantify a potential impact of the polymer on the cells mitochondrial function, 
the CCK-8 assay compared 19F-labeled to control cells, as described previously.[50] The 
CCK-8 assay measures the amount of formazan dye that is reduced by intracellular 
dehydrogenase. The number of living cells is proportional to the concentration of the 
formazan dye. Briefly, the CCK-8 solution (10 μl) was added to cells seeded in a 96-well 
plate and incubated for four hours. Absorbance was read on a Tecan plate reader at a 
wavelength of 450 nm. MTS assay is another colorimetric kit for determining the number of 
viable and proliferating cells. Absorbance was read on a Tecan plate reader at a wavelength 
of 490 nm. Similar to CCK-8 assay, the quantity of formazan product as measured by the 
amount of 490nm absorbance is directly proportional to the number of living cells in culture. 
CCK-8 assay involves most of the dehydrogenase in a cell. Alternatively, MTS only involves 
mitochondrial dehydrogenase. 
 
 
2.2.7 Standard Protocol for labeling MSCs with poly(OEGMA-co-PFPEMA) 
Based on the results obtained for measurement of cellular uptake and viability, a 
concentration of polymer solution of 10 mg ml-1 and incubation time of 24 hours were 
determined to be optimal conditions for uptake of the polymer by human derived PMSCs. 
Cells were seeded into a T75 culture flask and grown to 90% confluency prior to labeling  
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with the polymer using the conditions immediately above. PBS was added to the flask and 
decanted (washing step) to remove excess copolymers and Tryple Express was added to 
dissociate the cells from the flask. Cell suspensions with PBS were centrifuged at 400 g for 
5 minutes (three times) and the cell pellet was resuspended in PBS to remove excess 
copolymers. Cells were resuspended for all subsequent experiments. 
 
2.2.8 Preparation of cell phantoms 
19F MRI phantoms consisting of 0.4x106, 0.8x106, 1.6x106, and 3.2x106 cells labeled with 10 
mg ml-1 of copolymers were suspended in a (50 μl) volume of 6% gelatin in Eppendorf tubes. 
A control consisting of unlabeled PMSCs in a (50 μl) volume of 6% gelatin in a tube was 
imaged together with the 19F phantoms. Samples were loaded with increasing cell numbers 
in order to determine the threshold for cell detection. This procedure yields an estimate of 
the concentration of cells that can be detected upon transplantation given the particular 
hardware configuration, imaging methods employed, and the time constraints of in vivo 
imaging.[37] 
 
 2.2.9 19F MRI and measurement of relaxation times: In vitro MRI  
All MR images were acquired on a 9.4 T Bruker system using a 1H/19F dual resonator 40 
mm volume coil. Co-localization and positioning of slices for the 19F scan were achieved 
using an 1H MR scan that was acquired using a rapid acquisition with relaxation 
enhancement (RARE) sequence (RARE factor = 16, TE = 88 ms, TR = 1500 ms, FOV = 80 
× 80 mm, matrix = 128 × 128), 4 slices at 2 mm thickness. The 19F images were  
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acquired using a RARE sequence (TR = 1500 ms, TE = 44 ms, RARE factor = 8, averages 
= 256, FOV = 80 × 80 mm, matrix size = 64 × 64, single slice at 20 mm thickness, 51 mins 
scan time). 1H/19F images were analyzed using Image J software. 
2.2.10 Quantification of MRI 
 The intensity of the signal in a particular voxel of a 19F MR image is proportional to the total 
number of 19F nuclei within that volume. To calculate the signal-to-noise ratio (SNR) in the 
19F MR images, the average signal was obtained in a region of interest (ROI) consisting of 
49 voxels for each phantom (0, 0.4, 0.8, 1.6, and 3.2 x 106 PMSCs). The SNR was 
determined based on Equation (2): 
SNR=
Mean Signal (labeled cells) - Mean Background Signal
Standard deviation of background
   (2) 
 
 
The measured phantom SNR was plotted as a function of its cell number. The minimum cell 
per voxel detection threshold was established by extrapolating the SNR to a value of 1.5. 
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2.3 Results and Discussion 
Our group has previously reported the synthesis of a series of novel thermoresponsive 
copolymers, including poly(poly(ethylene glycol) methyl ether methacrylate-co-2,2,2- 
trifluoroethyl acrylate) (poly(OEGMA-co-TFEA)). Poly(OEGMA-co-TFEA) copolymers, 
containing OEGMA as hydrophilic units and TFEA as hydrophobic units, were synthesized 
through RAFT polymerization (Scheme 2.1). [26] 
The 19F NMR T1 and T2 relaxation times of the copolymers, of central importance for MRI 
applications, were measured by dissolving the polymer in PBS/D2O (90/10, v/v) at a 
concentration of 20 mg ml-1 at 310 K. The values of 19F NMR T1 and T2 of copolymers are 
480 ms and 90 ms, respectively. The 19F NMR T1 and T2 relaxation times in labelled cells, 
i.e. of the polymer within FBMSCs, were 490 ms and 92 ms, respectively. It can be inferred 
from these values that the copolymer after uptake by fetal bone marrow mesenchymal stem 
cells (FBMSCs), is adequate for MR imaging with an adequate signal-to-noise ratio in vitro.  
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Scheme 2.1. Schematic diagram illustrating the synthesis of poly(OEGMA‐co‐TFEA) 
copolymers via RAFT polymerization. [26] 
2.3.1 Efficiency of labelling human FBMSCs with poly(OEGMA-co-TFEA) 
To evaluate the efficiency of labelling human FBMSCs with the 5 nm diameter copolymers, 
the cells were incubated with cell culture media containing polymer at increasing 
concentrations. Cell uptake was assessed by 19F NMR and corroborated by flow cytometry. 
2.3.1.1 19F NMR analysis to quantify fluorine content per cell 
Uptake of Poly(OEGMA-co-TFEA) was measured by 19F NMR (9.4 T). A quantitative 
measure of the intracellular fluorine content was obtained by comparison of the intensity in 
the 19F NMR spectrum to that of a reference standard (trifluoroacetic acid, TFA). Distinct 
peaks were observed at −76 ppm for TFA and a peak at -73 ppm for the poly(OEGMA-co-
TFEA) labelled cells (Figure 2.2) . The peak from the labelled cells was very small in  
 
comparison to the reference peak. Cell uptake was found to increase in proportion to the 
concentration of the copolymer in incubation media, with an average uptake of 10.33 X 109 
19F atoms/cell at 10 mg/ml of poly(OEGMA-co-TFEA) (Figure 2.3) 
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Figure 2.2. Representative NMR spectra of 5mg/ml poly(OEGMA-co-TFEA) labelled 
PMSCs corresponding to a 19F atoms/cell labelling efficiency. The integrated value of the 
TFA peak was normalized to 1 and the integrated value of the poly(OEGMA-co-TFEA) peak 
was taken at (-72 to -73 ppm) with a value of  407.4.  
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Figure 2.3. Plot of 19F/cell against concentration of poly(OEGMA-co-TFEA) mg/ml. FBMSCs 
were incubated at different concentrations for 24 hours. The number of 19F/cell was 
determined based on a formula discussed in Section 2.2.5, which takes into account the 
integrated area of both TFA and labelled cells from the NMR spectra.  
2.3.1.2 Quantifying cell labelling using fluorescence by flow cytometry  
Flow cytometry of FBMSCs incubated with poly(OEGMA-co-TFEA) with attached N-(5-
fluoresceinyl)maleimide in solutions of varying concentrations confirms that the extent of  
 
cell uptake is directly proportional to polymer concentration in solution (Figure 2.4a and b). 
 
Figure 2.4. Results of flow cytometry of FBMSCs incubated with increasing concentrations 
of poly(OEGMA-co-TFEAMA) with N-(5-fluoresceinyl)maleimide a) Fluorescence 
histograms. b) Relative fluorescence intensity (measure of efficiency of cell labelling) 
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measured by flow cytometry as a function of concentration of copolymer in solution. Output 
provides values for 10 000 cells for each condition.  
 
2.3.1.3 Microscope fluorescence imaging  
  
FBMSCs were labelled with different concentrations of poly(OEGMA-co-TFEA) with N-
(5fluoresceinyl)maleimide at 1, 3, and 5 and 10 mg/ml for 24 hours incubation.  Fluorescence 
images had to be taken at 20 X magnification, as fluorescence intensity at  
 
40 X was too strong to get a clear image. FBMSCs specifically attached to the cells as 
visualized by fluorescence microscopy. However, as mentioned earlier it is necessary to 
determine if the polymer is internalized in the cell or simply attached to the cell membrane 
via confocal microscopy. Results indicated that higher polymer concentration in culture 
media effects in greater uptake in cells as depicted by the increased fluorescence intensity 
(Figure 2.5). However, this approach only provides a qualitative measure of the uptake of 
the polymer in the cells.   
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Figure 2.5. Fluorescence microscopy of FBMSCs labelled with (1, 3, 5 and 10 mg/ml) of 
Poly(OEGMA-co-TFEA) with N-(5-Fluoresceinyl)maleimide for 24hours. Overlay of images. 
20X magnification. Size bar = 26 µm. A) 1 mg/ml B) 3 mg/ml C) 5 mg/ml D) 10 mg/ml                                                                                                             
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Cell uptake was found to increase in proportion to the concentration of the copolymer in 
incubation media, with an average uptake of 10.33 X 109 19F atoms/cell at 10 mg/ml of 
poly(OEGMA-co-TFEA) (Figure 2.3). Nonetheless, this fluorine content per cell attained is 
much lower than values previously reported for MSCs and other cell types labelled with 
PFPE nanoemulsions, which is within the range of 1010 to 1013 19F atoms/cell. [11, 34, 51] 
 
Overall, MSCs labelled with poly(OEGMA-co-TFEA) had a considerably lower fluorine 
content/cell  in comparison to results previously reported for MSCs labelled with fluorinated 
nanoemulsions. Therefore, further studies focused on a unique polymer using a novel 
perfluoropolyether methacrylate (PFPEMA) as the fluorinated monomer and OEGMA as the 
hydrophilic component required to effect solubility in aqueous media. The polymer was 
synthesized using RAFT polymerization. To the best of our knowledge, there is no previous 
report of the chemical preparation of water-soluble PFPE based polymers as 19F MR tracers, 
and we consider this an attractive and promising direction in the field of MRI. 
2.3.2 Characterization of poly(OEGMA-co-PFPEMA) copolymer 
The synthetic approach for the synthesis of functionalized PFPE-based polymers is 
illustrated in Scheme 2.2. First, a polymerizable methacrylate of PFPE (PFPEMA) was 
prepared by a standard elimination reaction between methacryloyl chloride and the 
monohydroxy-terminated PFPE. Typical 1H NMR spectra in CDCl3 and the assignments to 
the spectra of the PFPE and PFPEMA are shown in Figure 2.6. The peak located at ~4.7 
ppm in the NMR spectrum of PFPEMA can be assigned to the methylene protons of PFPE 
segments adjacent to the ester, confirming the successful attachment of the PFPE to the 
polymerizable methacrylate. 
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Scheme 2.2. Schematic diagram illustrating the synthesis of poly(OEGMA-co-PFPEMA) 
copolymers via RAFT polymerization and the attachment with green fluorescence dye 
MalNFlu. 
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Figure 2.6. 1H NMR spectra of the monohydroxy terminated PFPE and PFPE methacrylate 
in CDCl3. 
 
Figure 2.7. 1H NMR spectra of the crude sample of the RAFT polymerization of OEGMA 
and PFPE methacrylates in CDCl3.  
 
Statistical copolymers of PFPEMA and OEGMA were synthesized through RAFT 
polymerization. As shown in Figure 2.7, the conversion of OEGMA and PFPEMA to polymer 
during the polymerization could be determined from the integrated intensities in the 1H NMR 
spectrum of the crude sample (85 % and 78 %, respectively). Typical 1H and 19F NMR 
spectra of the poly(OEGMA-co-PFPEMA) copolymer after purification and the  
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corresponding assignments are shown in Figure 2.8. The molecular weight and composition 
of the copolymer can be calculated from the integrals of the peaks arising from protons H3, 
H4 and the RAFT agent proton H7 as shown in (Figure 2.8a). It can be concluded that the 
molecular weight of the poly(OEGMA-co-PFPEMA) copolymer is ~75000 g mol-1 and the 
ratio of OEGMA to PFPEMA repeat units is ~7. The observation of a value of Mn,NMR larger 
than the theoretical value (Mn,th) may indicate the loss of RAFT end groups during 
polymerization. The fluorine content was calculated to be 21.4 wt %, which is significantly 
higher than previously reported fluorinated polymers for MRI (normally below 5 wt %).[21, 24-
27] The peaks in the 19F NMR spectrum (Figure 2.8b) were assigned successfully based on 
previous reports and the integrated intensities of each peak correspond to the number of 
fluorine atoms in the chemical structure (Figure 2.8c). [52, 53] It should be noted that the most 
intense peak, due to the fluorinated methyl and methylene groups (~-80 ppm, F1 in the 
spectrum), dominates the spectrum and will predominantly contribute to the subsequent 19F 
MRI signal. The hydrodynamic diameter of the copolymer was approximately 12 nm as 
measured using DLS, indicating the molecules were present as unimers in solution. To 
achieve conjugation with a fluorescent dye, the RAFT end group of the copolymer was 
reduced to free thiol in the presence of n-hexyl amine. N-(5-fluoresceinyl)maleimide, a green 
fluorescent dye, was directly conjugated to the copolymer, creating a dual modality imaging 
agent. The properties of the polymers deduced from the detailed characterization are 
summarized in Table 2.3. 
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Figure 2.8. (a) and (b) The 1H and 19F NMR spectra in CDCl3 and assignments to the spectra 
of the poly(OEGMA-co-PFPEMA). (c) The chemical structure of the poly(OEGMA-co-
PFPEMA) synthesized through RAFT polymerization. 
 
The 19F NMR T1 and T2 relaxation times of the copolymers, important for MRI applications, 
were measured by dissolving the polymer in PBS/D2O (90/10, v/v) at a concentration of 20 
mg ml-1 at 310 K. The values of 19F NMR T1 and T2 of the high fluorine-containing copolymers 
are 410 ms and 60 ms, respectively. The 19F NMR T1 and T2 relaxation times in labelled 
cells, i.e. of the polymer within PMSCs, were 420 ms and 62 ms, respectively. It can be 
concluded from these values that the copolymer after uptake by PMSCs is suitable for MR 
imaging with a high signal-to-noise ratio in vitro.  
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Table 2. 3. Details of the chemical structure of the copolymer of OEGMA and PFPE. 
 
Polymer 
 
Conversion [%] 
OEGMA   PFPE 
 
19F 
[wt %] 
Mn, NMR 
[g mol-1] 
Mn, SEC 
[g mol1] 
Mn, th 
[g mo-1] 
ÐM 
 
Dh 
[nm] 
Poly(OEGMA-co-PFPE) 
copolymer 
   85.1      77.9 21.4 75 000 11 870 33 500 1.13 12 
 
2.3.3 Characterization of PMSCs 
PMSCs and FBMSCs (data not shown) were carefully characterized according to the 
criteria’s established for MSCs by the International Society for Cellular Therapy (ISCT) for 
the i) plastic adherence ii) expression of specific MSCs markers and lack of HSC markers,  
and iii) tri-lineage differentiation potential. Figure 2.9 demonstrates that more than 98% of 
cell populations expressed MSC markers (CD44, CD73, CD90 and CD105) with negligible 
(1.35%) expression of HSC markers (CD11b, CD19, CD34, CD45 and HLA-DR). MSCs 
between passages four to seven were utilised for all experiments in this thesis. 
Characterization of MSCs were performed at all early passages (4-7) to ensure only optimal 
quality cells were used for all experiments. 
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Figure 2.9. Results of flow cytometry experiments confirming expression of MSC markers 
(CD44, CD73, CD90 and CD105) and lack of specific markers (CD34, CD11b, CD45 and 
HLA-DR) in PMSCs. 
Additionally, after 21 days of treatment with osteogenic differentiation cocktail medium, 
osteoblasts were observed after being stained with Alizarin Red, which binds to calcium 
matrix deposits (Figure 2.10). PMSCs were also able to differentiate into adipocytes, 
demonstrated by the presence of lipid droplets. Additionally, labelled PMSCs displayed 
chondrogenic capability, exhibited by the toluidine blue stained chondrogenic pellet. 
Moreover, MSCs labelled with copolymers maintained plastic adherence in standard cell 
culture conditions. 
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Figure 2.10. Bright field microscopy images of osteogenic, adipogenic and chondrogenic 
differentiation of PMSCs. Scale bars: 200 µm (adipogenic and chondrogenic) 50 µm 
(adipogenic). All experiments were performed at least three times and representative 
images are shown. 
2.3.4 Efficiency of labeling of human PMSCs with poly(OEGMA-co-PFPEMA) 
To assess the efficiency of labelling human PMSCs with poly(OEGMA-co-PFPEMA), the 
cells were incubated with cell culture media containing polymer at a range of concentrations. 
Cell uptake was assessed by 19F NMR, and corroborated by flow cytometry and confocal 
microscopy.  
2.3.4.1. 19F NMR analysis to quantify fluorine content per cell 
A quantitative measure of the intracellular fluorine content was obtained by comparison of 
the intensity in the 19F NMR spectrum to that of a reference standard (trifluoroacetic acid, 
TFA). Well-defined peaks in the 19F NMR spectra are observed at −76 ppm for TFA and 
major peaks between −80 to -85 ppm for the labelled cells Figure 2.11a. Integration of the 
peaks allowed the extent of cell uptake to be calculated, and this was found to increase in 
proportion to the concentration of the copolymer in the incubation media (Figure 2.11b). 
The content of observable fluorine nuclei is comparable or superior to results reported for  
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MSCs [11, 35, 37, 54] and other therapeutically relevant cells [43, 55, 56] labelled with PFPE 
nanoemulsions. Hence, cell uptake achieved with our copolymers, without addition of 
transfection agent, is within suitable limits and comparable with other published reports. 
 
Figure 2.11. a) 19F NMR spectrum of 2 x 106 cells labelled with 20 mg ml-1 of copolymers. 
Peak F1 of the copolymer, see Figure 2.8 b), is centered at ~82 ppm. TFA was used as a 
reference and gives a peak at -75.5 ppm. b) Plot of number of 19F nuclei per cell against 
concentration of poly(OEGMA-co-PFPEMA) in the incubation medium. MSCs were 
incubated at different concentrations for 24 hours. All values are presented as mean ± 
standard deviation. 
 
Recently, a number of researchers have studied the effects of size, shape and surface 
chemistry (for e.g. surface hydrophobic/hydrophilic balance, surface charge, zeta potential) 
on cellular uptake and toxicity of nanoparticles. In brief, smaller sized and more hydrophobic 
molecules are internalized and leave cells more rapidly. [57, 58] The high level  
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of uptake of poly(OEGMA-co-PFPEMA) by the PMSCs, without the assistance of 
transfection agents or electroporation, is likely a consequence of the small size of the 
copolymer (hydrodynamic diameter of ~12 nm) and partial hydrophobic nature resulting from 
its high fluorine content (21.4 wt %). We suggest that the conformational flexibility inherent 
in the polymeric structure allows the hydrophobic groups to be presented to the cell 
membrane, thus facilitating passage across the membrane. 
The ability to load the cells without the use of transfection agents is a major advantage as 
transfection agents are usually not suitable for clinical use. Transfection techniques can be 
utilized to potentially increase the uptake of agents in cells but these may adversely affect 
cellular functions, for instance inducing a down-regulation of surface marker expression. [33] 
Furthermore, comprehensive studies of the effects of transfection techniques on the 
function, phenotype and proliferation in different cell types have not been reported. [59] 
Hence, it is highly attractive that non-phagocytic cells such as MSCs be labelled efficiently 
with MR tracers by simple co-incubation in culture media.  
2.3.4.2 Quantifying cell labelling using flow cytometry  
Flow cytometry of PMSCs incubated with poly(OEGMA-co-PFPEMA) with attached N-(5-
fluoresceinyl)maleimide in solutions of varying concentrations confirms that the extent of cell 
uptake is directly proportional to polymer concentration in solution (Figure 2.12a and b). 
These results are in line with measurements of fluorine content by 19F NMR (Figure 2.11b). 
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Figure 2.12. Results of flow cytometry of PMSCs incubated with increasing concentrations 
of Poly(OEGMA-co-PFPEMA) with N-(5-fluoresceinyl)maleimide a)Fluorescence 
histograms. b) Relative fluorescence intensity (measure of efficiency of cell labelling) 
measured by flow cytometry as a function of concentration of copolymer in solution. Output 
provides values for 10 000 cells for each condition.  
 
2.3.4.3 Confocal microscopic study of cellular uptake 
Cell labelling studies were carried out using poly(OEGMA-co-PFPEMA) conjugated with N-
(5-fluoresceinyl)maleimide dye to act as a fluorescent reporter. Figure 2.13a shows confocal 
fluorescence microscopy images of the PMSCs incubated with 3 mg ml-1 of poly(OEGMA-
co-PFPEMA)-DYE for three hours. Note that the boundaries of the PMSCs are labelled with 
ActinRed™ 555 reagent. The ortho projection of the 3D image indicates  
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that the copolymers have been taken up and reside within the cells (Figure 2.13b & Video 
2.1). Therefore, the confocal fluorescence images confirm internalization of copolymers 
within the cytoplasm and more precisely into vesicles of the cells (Figure 2.13a-b). 
Importantly no differences in morphology between labelled and unlabelled PMSCs were 
observable. 
 
Figure 2.13. Confocal fluorescence images of MSCs labeled with 3 mg ml-1of poly(OEGMA-
co-PFPEMA) with N-(5-fluoresceinyl)maleimide for 3 hours. The nuclei were stained with 
DAPI (blue), copolymer (green) and actin was stained red a) 40x magnification, size bar = 
20 µm. b) Ortho projection of 3D image. 20x magnification. Excitation wavelengths were 358 
nm, 492 nm and 540 nm, respectively. 
 
MSCs with copolymer PFPE.avi
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Video 2.1. Z-stack analysis of PMSCs labeled with 3 mg ml-1 of poly(OEGMA-co-PFPEMA) 
with N-(5-fluoresceinyl)maleimide. The nuclei were stained with DAPI (blue), copolymer 
(green) and actin was stained red. 
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Figure 2.14. Confocal fluorescence images of MSCs labelled with different concentrations 
(a-f; 1, 3, 5, 10, 15 and 20 mg ml-1) of poly(OEGMA-co-PFPEMA) conjugated with Cy5.5  
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dye for 4 hours. The nuclei were stained with DAPI (blue), copolymer (red). 20x 
magnification, size bar = 50 µm.  
 
Confocal images of PMSCs incubated with poly(OEGMA-co-PFPEMA) with attached Cy5.5 
dye in solutions of varying concentrations confirms that the extent of cell uptake is directly 
proportional to polymer concentration in solution (Figure 2.14a and b). These results are 
consistent with measurements of fluorine content by 19F NMR (Figure 2.11b) and 
fluorescence intensity via flow cytometry (Figure 2.12a-b). 
 
2.3.5 Cytotoxicity and proliferation of PMSCs 
Successful translation of materials to clinical applications depends on favorable 
cytocompatibility. Hence, CCK-8 assays were performed on PMSCs incubated with 
solutions of copolymers longitudinally from 24 hours to 7 days post incubation to examine 
cytotoxicity and proliferation of the cells (Figure 2.15a). The principle of the CCK-8 kit is that 
WST-8 can be reduced by dehydrogenase in mitochondria in the presence of an electron-
coupling reagent, producing highly water-soluble orange formazan. The depth of color is 
proportional to the cell proliferation, while it is inversely proportional to the cell toxicity. 
Therefore, the OD value was measured by a microplate reader at a wavelength of 450 nm, 
which could indirectly reflect the number of living cells. The results in Figure 2.15b indicate 
that there was a slight increase (~13%) in viability and mitochondrial activity of PMSCs 
exposed to solutions of poly(OEGMA-co-PFPEMA) at 20 mg ml-1 for 24 hours. Nonetheless, 
cell viability at all time points and concentrations was more than 80% except for at the 
highest concentration of 20 mg ml-1, 7 days after copolymers exposure (~78% cell viability).   
Viability of the cells was also confirmed by MTS assay (Figure 2.15c) and  
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the Trypan blue exclusion assay (Figure 2.15d). The assays indicate that the copolymers 
did not have a significant effect on the viability and mitochondrial function of the PMSCs. 
Based on the measurements of labelling efficiency and viability, a protocol of labelling of 
PMSCs with 10 mg ml-1 of poly(OEGMA-co-PFPEMA) for 24 hours was adopted as the 
standard procedure. 
 
 
Figure 2.15. Viability of PMSCs evaluated by CCK-assay (a & b), MTS-assay (c) and Trypan 
blue exclusion assay (d) as a function of concentration of poly(OEGMA-co-PFPEMA) 
solution. All values are presented as mean ± standard deviation based on triplicated 
samples. 
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2.3.6 Establishing a threshold for cell detection by 19F MRI 
For any MRI application, it is important to establish the detection limit for labelled cells. To 
achieve this, 19F MRI scans of a set of phantoms containing 0.4 x 106 to 3.2 x 106 PMSCs 
labelled with 10 mg ml-1 of poly(OEGMA-co-PFPEMA) for 24 hours were prepared and 19F 
MRI images were acquired. This allowed determination of the signal threshold for cell 
detection. T2-weighted images were acquired, using a scan time of 50 minutes, for both 
labelled and control unlabelled cells (2 x 106 cells). Signals from all phantoms containing 
cells were readily detected in this time period, and significantly the phantom with the smallest 
number of cells (0.4 x 106) also had a detectable 19F signal (Figure 2.16a). As anticipated, 
the 19F MR signal intensity (and hence signal-to-noise ratio, SNR) increased linearly with 
the number of cells (Figure 2.16b). If we propose a target SNR of 1.5 for unequivocal 
detection of labelled cells, a minimum of 3.6 x 105 cells labelled with copolymer in this 
manner is required for cell detection. Considering the cell pellet and voxel size, these results 
in a detection limit of ~ 7.4 × 103 cells/voxel. The detection limit of any MR tracer is 
dependent on the accumulation of labelled cells at the target site. Hence, detection limit 
attained here is based on the assumption that labelled cells will migrate and accumulate at 
targeted region upon injection in animal model. Thus, the population of cell number to track 
must be above a certain threshold for detection and this might differ based on cell type, 
migratory potential of cells, route of injection and disease models. 
To put this into perspective, a typical MSC based clinical therapy requires multiple 
intravenous infusion of cell numbers in the range of millions.[60, 61] It is very clear therefore 
that the cell detection limit of less than 104 cells/voxel attained with PMSCs labelled with 
poly(OEGMA-co-PFPEMA) is within the required range for tracking of stem cells. Previous 
studies involving tracking of PFPE labelled cells using MRI have reported minimum cell 
Chapter 2 Characterisation and In Vitro Evaluation of Copolymer 
 
detection sensitivity in the order of 104 to 105 cells/voxel with clinical MRI scanners and 103 
to 104 for high field animal scanners. Therefore, the cell detection limit achieved here with 
PMSCs labelled with these unique copolymers is comparable to data reported with high field 
animal scanners. [14, 33, 36, 62]Therefore, MSCs labelled with these copolymers may assist to 
optimize efficacy of stem cell therapy in specific parameters such as injection sites, routes 
of migration and accumulation cell numbers at engraftment site. It should be noted that 
experimental parameters, such as the image acquisition methodologies, magnetic field 
strength and detector coil configuration, are all important for determining the sensitivity in a 
specific experiment. 
 
 
Figure 2.16. a) 1H and 19F MRI of phantoms containing 0 = Unlabelled control, 0.4 x 106, 
0.8 x 106, 1.6 x 106 and 3.2 x 106 labelled pMSCs suspended in 6% gelatin. Images are 
shown using different colourimetric scales to allow clear visualization. b) SNR plotted against 
the number of cells labelled with copolymer. Error bars are over n=3 technical replicates. 
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2.4 Conclusions 
Fluorine containing polymers synthesized using RAFT polymerization were introduced as 
MR tracers. Labelling of MSCs with both poly(OEGMA-co-PFPE) and poly(OEGMA-co-
TFEA) resulted in high uptake in cells.  The newly introduced polymer, poly(OEGMA-co-
PFPE) labelled cells had a significantly higher content of observable fluorine nuclei in 
comparison to poly(OEGMA-co-TFEA) labelled cells, which is a prerequisite for the design 
of efficient 19F MR tracers. 
In summary, we have reported the successful and robust synthesis of a unique partially-
fluorinated polymer (poly(OEGMA-co-PFPE)) as a dual MR/fluorescence imaging agent. 
The copolymer, at a diameter of 12 nm has a high fluorine content of >20 wt. %, substantially 
higher than previously reported PFPs (< 5 wt. %) for MRI applications. Our results 
demonstrate that PMSCs can be efficiently labelled with these novel fluorinated copolymers, 
without the use of transfection agents, and with negligible effects on the viability and 
mitochondrial function of the cells. Additionally, we were able to measure 19F MR images of 
labelled cell phantoms at high field, and show that the imaging performance is comparable 
or superior to previously published results. We conclude that the copolymers reported here 
show outstanding potential to be utilized as imaging agents for 19F MRI-based tracking and 
quantification of non-phagocytic and therapeutically relevant cells such as MSCs. 
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Chapter Three 
3.1 Introduction 
In vivo cell tracking is potentially a powerful tool to monitor longitudinally and non-invasively 
the distribution and accumulation of therapeutic cells such as MSCs. MSCs have been 
described as a promising tool for the treatment of a variety of diseases based on results 
from preclinical and clinical studies. [1-5] Development of accurate imaging modalities to track 
MSCs would allow clinicians to establish if cell delivery has occurred at the appropriate site 
and if cells have reached their intended location.[6] Consequently, non-invasive real-time 
imaging techniques need to be developed to ascertain several parameters including homing 
efficiency, dosing requirements, optimal timing and route of delivery to allow success of cell-
based therapies.[6] As described in length in Chapters 1 and 2, 19F MRI provides a highly 
specific, unambiguous and quantitative approach to tracking labelled MSCs. In this chapter, 
longitudinal tracking of subcutaneously injected labelled cells in healthy, 
immunocompromised mice was conducted to assess feasibility of the copolymer as a 19F 
MR tracer. 
Labelling of MSCs with NPs may have an impact on the defining characteristics of MSCs 
such as phenotypical and functional properties, which might affect their intended therapeutic 
efficacy. Chang and co-workers demonstrated reduced in vitro chondrogenic and 
osteogenic differentiation of MSCs labelled with amine-surface-modified superparamagnetic 
iron oxide nanoparticles.[7] Therefore, to allow comparison between studies of MSCs, 
minimal criteria were established by the International Society of Cellular Therapy (ISCT). 
These include plastic adherence, ability to differentiate into mesenchymal lineage (bone, 
adipose tissue and cartilage) and expression of CD73, CD90 and CD105 on the cell surface 
while lacking expression of hematopoietic markers CD11b, CD19,  
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CD34, CD45 and HLA-DR and CD45.[8] Hence, differentiation potential, CD marker 
expression profiles and morphology of MSCs labelled with copolymer were evaluated to 
ascertain if the tracer had an effect on these defining MSC characteristics. In addition, this 
chapter include studies of exocytosis, retention and dilution of copolymer in cells.  
 
Despite an increasing number of studies on the utilisation of MSCs, there is a lack of 
knowledge on the optimisation, administration and in vivo trafficking of MSCs. [9] The delivery 
method of MSCs may affect the route they are trafficked to reach target sites. Systemic 
administration of cells include intravenous (I.V.), intraperitoneal (I.P.), intraarterial (I.A.) or 
intracardiac (I.C.) injections. [10]  
  
Several groups have reported that large quantities of I.V. injected MSCs become localised 
in the lungs. This accumulation of cells in lungs may reduce therapeutic efficacy at the 
intended target sites.[11-13] Subsequent to lung accumulation, MSCs are re-distributed to the 
liver, spleen, inflammatory or injured sites. In contrast, several studies of I.A. injections have 
reported decreased localisation of MSCs within the lungs, liver or spleen compared with I.V. 
delivery. [11, 14, 15] However, amongst the cell delivery methods, I.V. delivery is the most 
common and least invasive technique.[10] Additionally, it is crucial to demonstrate that MSCs 
do not have unwanted homing in specific organs. Hence, biodistribution and 
pharmacodynamic studies of MSCs are important aspects for clinical translation. In this 
chapter, the biodistribution of cells labelled with copolymer conjugated with Cy5.5 dye 
evaluated longitudinally using optical fluorescence imaging and 19F MRI is described. 
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3.2 Experimental Section 
3.2.1 Tri-lineage differentiation assay 
To assess the effect of uptake of the copolymers on PMSC tri-lineage differentiation, MSCs 
were grown in twelve well plates for adipogenic, osteogenic and chondrogenic assays. 
Three wells were incubated with the copolymers for 24 hours and another three wells were 
utilized for the unlabelled PMSCs (control). After 24 hours, the wells were washed with PBS 
and adipogenic/osteogenic/chondrogenic medium (Thermofisher StemProR differentiation 
kit) were added according to manufacturer’s instructions. The medium was replaced every 
3-4 days. After 21 days, the cells were fixed with 4% PFA and stained with Alizarin Red S 
to detect calcification, Oil Red O for identification of lipid vesicles and Toluidine Blue for 
staining the chondrogenic pellet. Images were captured on a Nikon inverted microscope 
equipped with a Phantom V9 high speed color camera. The images were processed using 
ImageJ software. 
3.2.2 Expression of MSC markers 
To determine the potential effect of labelling with the copolymers on the phenotypical 
characteristics, MSCs were cultured in a flask till confluency. PMSCs were incubated with 
copolymers for 24 hours and the flask was washed with PBS before detachment and 
suspension according to the manufacturer’s guidelines (BD Human MSC Analysis Kit) in 
staining solution as detailed in Section 2.2.4.4.2. Cells were incubated with antibodies as 
per instructions and analyzed on a flow cytometer, Accuri C6. Flow Jo Software was used 
for data processing.  
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3.2.3 Retention of copolymers in PMSCs 
Cells were stained with Trypan Blue and counted using a haemocytometer to measure cell 
proliferation at specific time points. Dilution and retention of copolymers were assessed by 
seeding cells at a density of 100,000 cells/well in a 24 well plate. Cells were incubated with 
copolymer for 24 hours and any copolymer that was not internalized was washed off with 
PBS. Subsequently, cells were trypsinized and suspended in PBS at specific time points for 
analysis whereby the fluorescence intensity was measured using flow cytometry. Exocytosis 
of copolymer was evaluated by seeding cells at a very low density/well in a 24 well plate. 
Cells were incubated with copolymer for 24 hours and any copolymer that was not 
internalized was washed off with PBS. Fluorescence intensity of cell culture medium 
(exocytosis of copolymer) was measured at specific time points using a plate reader. To 
establish if there is a transfer of the copolymer from labelled to resident cells, 2 ×104 cells 
labelled with the bimodal copolymer were co-cultured with 2 ×104 cells labelled with the 
green fluorescent Cell Tracker (10 μM for 20 minutes at 37°C). Images were acquired 1, 3 
and 7 days using a Zeiss LSM 710 inverted confocal microscope and were analyzed using 
ZEN software (Zeiss). The number of red, green and yellow cells were counted to determine 
transfer of the copolymer (red) into “unlabelled” (green) cells. 
3.2.4 Optimisation of different routes of injection in mice 
3.2.4.1 Preparation of labelled cells 
Cells were seeded into a T175 culture flask and grown to 90% confluency. Cells were 
labelled with copolymer for 24 hours incubation, at 37°C in a humidified atmosphere, with 
5% CO2).  After copolymer removal, PBS was added to the flask and decanted (washing 
step) to remove excess copolymer and Tryple Express was added to dissociate the cells 
from the flask. Cell suspensions with PBS were centrifuged at 400 g for 5 minutes (three  
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times) and the cell pellet was resuspended in PBS to remove excess copolymer. Cells were 
passed through a 40 µm cell strainer to obtain single cells in suspension. Cells were 
suspended in 0.1 mg of DNase I/L-15 medium and transported on ice prior to injections. 
3.2.4.2 Injection of labelled cells 
Cells were vortexed prior to injections. Mice were anaesthetized with an I.P. injection of half 
dose of ketamine/xylazine. 25 gauge (G) needles were primed with DNase I/L-15 medium 
before taking up cells suspension. Mice were inspected twice daily based on the assessment 
report described in Table 3.1. and Figure 3.1. 
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Table 3. 1. Assessment of pain and distress in mice. [16]  
 
Chapter 3 In Vivo Tracking of MSCs Labelled with Copolymer 
 
 
Figure 3. 1 Body Condition Scoring (BCS) is a quick, easy and reliable method for assessing 
mouse health. It utilizes a scoring system of 1 to 5 with 3 being the optimal condition, 1 being 
emaciated and 5 being obese. [16] 
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3.2.5 In vivo 19F MRI  
In vivo MRI - Experiments were carried out in accordance with the national guidelines 
provided and approved by the institutional animal care and ethics committees of the 
University of Queensland. Labelled human PMSCs (~ 1 x 106) were injected subcutaneously 
into the flank of a 12-week old female non-obese diabetic/severe combined immunodeficient 
(NOD SCID) mouse and 9-week-old athymic nudes mice. Mice were anesthetized with an 
intraperitoneal (IP) injection of ketamine/xylazine in water and placed in the scanner. 
Respiratory rates and temperature were monitored throughout imaging. Animals were kept 
warm until recovery. Images were acquired at several time points (1, 24, 48 hours and 7 
days post injection).  
 1H images were acquired using a RARE sequence (TR = 1500 ms, TE = 10 ms, RARE 
factor = 4, FOV = 58 × 58 mm, matrix = 128 × 128, 12 slices at 2 mm thickness). The 19F 
images were acquired using a RARE sequence (TR = 1500 ms, TE = 10 ms, slice thickness 
= 2 mm, RARE factor = 4, Matrix = 64 x 64, in-plane resolution = 0.9 mm). 1H/19F images 
were analyzed using Osirix software.  
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3.2.6 Biodistribution of labelled cells in animal models 
In vivo fluorescence imaging 
Mice were sedated via I.P. injections of ketamine/xylazine. Mice were injected with labelled 
cells via tail vein as described in section 3.2.4.2 with established optimized parameters. 
Imaging were performed at specific time points with an In Vivo MS FX Pro instrument, 
Bruker. Cy5.5 images were collected with a spectral unmixing protocol utilising excitation 
filters ranging from 540 nm to 630±10 nm, with collection through a 700 nm±17.5 nm 
emission filter set (f- stop 2.80, 2×2 binning,190 mm FOV, 10 s exposure time). To provide 
anatomical context, fluorescence images were co-registered with an X-ray image (f-stop 
2.80, 0.2 mm aluminium filter, 190 mm FOV, 30 s acquisition time). All images were batch 
exported as 16-bit TIFF images and image processing was completed initially by spectral 
unmixing with Bruker Multispectral software, followed by Image-J, Fiji software (National 
Institutes of Health). Fluorescence images were false coloured and overlaid onto X-ray 
images. 
 
Ex vivo fluorescence imaging 
Mice were e. uthanized at 48 hours and 7 days post injection of labelled cells. Organs were 
carefully removed and rinsed with PBS prior to optical imaging. Imaging was performed 
following the same protocol as above. All images were processed with Fiji software. 
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Recovery and health of mice- Mice were monitored until maintaining upright posture and 
walking normally about the cage before being returned to the animal housing room. Mice 
were monitored closely for the first few hours after cell administration, and then twice each 
day for 7 days. A mouse health score sheet was used to assess animals during this 
experiment: One point was given if animals showed ≥15% weight loss, hunched posture at 
rest, decreased activity or ruffled fur. Mice were sacrificed if they were in severe pain or 
distress. A detailed score sheet is included in section 3.5 Appendix. 
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3.3 Results and discussion 
3.3.1 Effects of copolymer uptake on typical PMSC characteristics 
 
Figure 3. 2 a) Expression of MSC markers (CD44, CD73, CD90 and CD105) and lack of 
specific markers (CD34, CD11b, CD45 and HLA-DR) in PMSCs after labelling with 
copolymers  b) Bright field microscopy images of osteogenic, adipogenic and chondrogenic 
differentiation of PMSCs after labelling with copolymers (bottom panel), PMSCs with no 
copolymers (upper panel). Scale bars: 200 µm (adipogenic and chondrogenic) 50 µm 
(adipogenic). No differences between labelled and unlabelled cells were observed for tri-
lineage differentiation. All experiments were performed at least three times and 
representative images are shown. 
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It is important that MRI cell trackers do not affect the phenotype, differentiation potential and 
function of the MSCs as any alterations after labelling could impact upon the efficacy of the 
MSC therapy. Therefore, the PMSCs labelled with copolymer were comprehensively 
assessed according to the criteria established for MSCs by the International Society for 
Cellular Therapy (ISCT) for i) plastic adherence ii) expression of specific MSCs markers 
(>98%) and lack of HSC markers (<2%),  and iii) tri-lineage differentiation potential. The 
results presented in Figure 3.2a demonstrate that more than 98% of the cell populations 
expressed MSC markers (CD44, CD73, CD90 and CD105) with negligible (0.32%) 
expression of HSC markers (CD11b, CD19, CD34, CD45 and HLA-DR). Additionally, after 
21 days of treatment with osteogenic differentiation medium, osteoblasts were observed by 
staining with Alizarin Red, which binds to calcium matrix deposits (Figure 3.2b bottom left 
panel). PMSCs labelled with the copolymers were also able to differentiate into adipocytes, 
demonstrated by the presence of lipid droplets (Figure 3.2b bottom panel). Additionally, 
labelled MSCs displayed chondrogenic capability, exhibited by the toluidine blue stained 
chondrogenic pellet (Figure 3.2b bottom right panel). Finally, MSCs labelled with the 
copolymers maintained plastic adherence under standard cell culture conditions. 
 
 
3.3.2 Retention of copolymers in PMSCs 
Proliferation of the PMSCs resulted in a steady reduction in the amount of copolymers 
present in the cells (Figure 3.3a-c). Nonetheless, a significant fluorescence signal was 
observed via flow cytometry even after 7 days following incubation with the copolymer 
(Figure 3.3b, black bars).  The confocal microscopy z-stack images (Figures 3.4 and 3.5) 
also confirm retention of the copolymers until the endpoint of the experiment. A decrease  
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in signal intensity was also observed in the in vivo 19F MR longitudinal imaging studies, and 
is most likely due to the dilution of the copolymers resulting from proliferation of cells or cell 
death. Cell division and consequent dilution of intracellular trackers are a challenge in long 
term in vivo cell tracking, for all approaches to cell tracking.[17] In addition, cell death can 
result in dispersion of tracer and loss of detectable MRI signal.  
 
Exocytosis (leakage) of copolymers can also contribute to the reduction in fluorescence 
intensity, and was assessed by measuring the fluorescence of the cell culture medium at 
specific time points using a microplate reader. Fluorescence of the cell culture medium 
increased gradually over time, indicating that a small fraction of the copolymers was 
released across this period (Figure 3.3b, red bars). The cells were confirmed to be viable 
(Trypan blue exclusion, data not shown) and therefore the fluorescence in the medium does 
not arise from copolymers released by dead cells. Nonetheless, the intensity of fluorescence 
arising from exocytosis is relatively low in comparison to the significant fluorescence 
retained within the MSCs (Figure 3.3b). It is also possible that copolymer may be 
exocytosed by cells and internalized by bystander cells such as resident macrophages. This 
may produce false positive signals if a large number of macrophages accumulates in an 
area of interest.[18] To assess this possibility, cells labelled with copolymer (red fluorescence) 
were co-cultured with cells labelled green (Cell Tracker, Figure 3.3c). DAPI-positive cells 
with both red and green signals were observed as yellow via confocal imaging. At day one 
post co-culture, approximately 25% of the cells were yellow indicating that some exocytosis 
and transfer of copolymer to neighboring cells had occurred. As pointed out by Bible et al.,[19] 
some of this fluorescence may arise from dead cells or from residual unwashed copolymer. 
Those authors observed similar levels of  
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fluorescence in cells labelled with Celsense. After three and seven days of co-culture, 27% 
and 21% of the DAPI positive cells were yellow, respectively, demonstrating that exocytosis 
and transfer of the copolymer to the bystander cells remains constant up to seven days after 
in vitro labelling. Hence, the presence of transplanted cells needs to be critically assessed 
to ascertain the degree this also occurs in vivo. The consistency of label transfer observed 
up to seven days allows subtraction of this value for in vivo quantification of “true” labelled 
cells. In addition, the degree of label transfer observed is only clinically significant if a large 
number of these cells accumulates in a region of interest. As mentioned above, death of 
labelled cells can result in potential transfer of any types of cell tracers to resident 
macrophages causing false positive signal. Nonetheless, this was observed in cells labelled 
with SPIOs in only a few studies [20, 21] but the majority of animal studies have demonstrated 
the opposite, in which MR signal is from labelled cells and not macrophages. [22-26] Hence, 
concern about phagocytic engulfment of labelled cells appears exaggerated and should not 
hamper future research in this field. 
 
As anticipated, the number of cells retaining copolymers (red cells) visualized by confocal 
microscopy decreased by approximately half at day seven. This decrease is predominantly 
due to dilution of the copolymers on proliferation of the cells. In conclusion, despite the ready 
uptake of the copolymers by the PMSCs, leakage of copolymer is minimal and there is 
sufficient retention to allow excellent in vivo imaging. 
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Figure 3. 3. a) Proliferation of PMSCs at specific time points b) Fluorescence intensity 
(measure of retention of copolymers in PMSCs) measured by flow cytometry as a function 
of time after incubation with copolymers (black bars). The fluorescence is for 10,000 cells at 
each time point. The fluorescence intensity of cell culture medium due to exocytosed 
copolymer (red bars). c) Co-culturing of cells labelled either with the bimodal copolymers 
(red fluorescence) or with bystander cells (labelled with green cell tracker). Yellow cells 
indicates that some exocytosis and transfer of copolymer to neighboring cells had occurred. 
All values are the mean ± standard deviation based on measurements in triplicates. 
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3.3.3 In vivo 19F MRI tracking 
 
Figure 3. 4 In vivo detection of labelled human PMSCs injected subcutaneously in a NOD-
SCID mouse. Images shown are 1, 24 hours and 7 days post injection and anatomical 
overlay of 19F/1H images, whereby the 19F is rendered in false color and 1H is in grayscale. 
MSCs are visible as a “hot spot” in the flank of mouse. a) Images acquired from 1 and 24 
hours post injection, 51 minutes scan. Slice thickness = 20 mm b) Images acquired from 7  
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days post injection, 12 minutes scan. Slice thickness = 2 mm. The arrow denotes slices 
containing 19F signal. 
 
The feasibility of detecting cells in vivo was demonstrated by subcutaneous injection of cells 
into a murine model. 19F MRI was performed at 1 hour, 24, 48 hours and 7 days post injection 
of ~ 1 x 106 labelled human PMSCs into the subcutaneous flank of a NOD SCID mouse and 
athymic nudes. Strong and unequivocal signals from labelled cells in all mice were clearly 
detected in 19F MR images acquired at 9.4 T, 1, 24 and 48 hours post injection (Figure 3.4-
3.6). Moreover, distinct signals from labelled cells at the site of injection were observed 7 
days post injection within a short acquisition time of 12 minutes (Figure 3.4b). However, we 
noticed a slight reduction in 19F MR signal intensity between days 1 and 7 post injection of 
the labelled MSCs in all three mice. Previously Bible et al. used 19F MRI to measure neural 
stem cells (NSCs) labelled with Celsense and suspended in a bioscaffold implanted into the 
lesion cavity of a rat stroke model. As in the current study, they observed a decrease in 19F 
MRI signal between days 1 and 7 post implantation.[19] Our results with labelled MSCs are 
therefore in accordance with other longitudinal imaging studies, which established a 
decrease in signal from the tracker over time.[27-29] The decline in 19F MR signal is expected 
and is probably due to cell proliferation or cell death which results in dilution of the copolymer 
as demonstrated in the in vitro study (Figure 3.3).  We also did not observe any significant 
difference in 19F MR signal intensity of labelled cells between the different strains of mice. 
Mice were observed twice daily throughout the 7 days following injection of labelled cells. 
Comprehensive examination (Table 3.1 and Figure 3.1) such as an assessment of  
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noticeable abnormalities, hydration levels, body condition, and the presence of deformities 
in the bones, genitals and abdomen were conducted. [16] 
 
Isoflurane is a fluorinated gaseous anaesthesia that is commonly utilised in in vivo 
experiments. However, it is not suitable for the tracking of fluorinated labelled cells because 
it accumulates within adipose tissues and lungs.[30]  Therefore, to strictly avoid false positive 
19F MR signals from isoflurane, IP injection of ketamine/xylazine was utilized for anesthesia 
for in vivo imaging.  
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Figure 3. 5. In vivo detection of labelled human PMSCs injected subcutaneously in an 
athymic nude mouse. Images shown are 1, 24, 48 hours and 7 days post injection and 
anatomical overlay of 19F/1H images, whereby the 19F is rendered in false color and 1H is in  
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grayscale. MSCs are visible as a “hot spot” in the flank of mouse. Images acquired are from 
51 minutes scan. Slice thickness = 2 mm. 
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Figure 3. 6. In vivo detection of labelled human PMSCs injected subcutaneously in an 
athymic nude mouse. Images shown are 1, 24, 48 hours and 7 days post injection and 
anatomical overlay of 19F/1H images, whereby the 19F is rendered in false color and 1H is in 
grayscale. MSCs are visible as a “hot spot” in the flank of mouse. Images acquired are from 
51 minutes scan. Slice thickness = 2 mm. 
3.3.4 Optimisation of labelled cell injections in vivo 
In this we study, we attempted several routes of cell injection through the tail vein, retro 
orbital, femoral artery and femoral vein. Mice were anaesthetised with ketamine/xylazine 
prior to injection of the cells. Initially, 3 x 106 labelled cells in a volume of 200 µl PBS were 
injected through the tail vein, as it is the most common injection method to access the 
circulatory system. It was observed that all mice began gasping heavily for air and died 
within a minute of injection. The cell number was finalised based on several reported studies 
of tail vein injection of MSCs in murine model (Table 3.2). However, most of these studies 
did not include clear details and instructions on cell preparation and injection parameters of 
cells in mice. 
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Table 3. 2. MSCs injection in murine models. 
Type of 
MSCs 
Route of 
injection 
Number 
of cells 
x (106) 
Volume of 
injection 
(µl) 
Medium Ref 
BMSC I.V. 1 200 PBS [31] 
BMSC I.V. vs I.A. 1 Not stated Not stated [32] 
BMSC I.P. vs I.V. 1 200 PBS [33] 
MSC Carotid artery in 
glioma model 
Not 
stated 
Not stated Not stated [34] 
BMSC I.V. 0.75 200 PBS [35] 
hMSCs  I.V. 4 Not stated Not stated [36] 
hMSC I.V. 1 200 PBS [37] 
hMSC I.V. 2 Not stated Not stated [38] 
 
 
Next, 3 x 106 labelled cells in a volume of 200 µl PBS were injected retro orbitally.  Similarly, 
all mice were gasping for air and died within minutes of injection. A 100 % mortality rate was 
attained with both routes of cell injection. Subsequently, a reduced cell number of 1 X 106 
cells in a volume of 200 µl PBS were injected via tail vein and retro orbitally. Again, 100% 
mortality was observed with both methods of cell administration. Several reported studies 
found that most mice would undergo increased mortality upon I.V. injection of MSCs due to 
potential pulmonary cell embolism. [33, 39] 
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Figure 3. 7. Ex vivo optical imaging. a) two mice (controls) b) Labelled cells were injected 
via three different routes in nude mice. Fluorescence intensity is rendered in false color as 
depicted in calibration colour chart. X-ray images overlaid on fluorescence images. Organs 
labelled above. 
 
Cell injections (1 X 106 cells, 200 µl PBS) through the femoral artery and femoral vein were 
attempted. 100 % mortality was observed despite adopting different routes of cell injections, 
reduced cell number, and in different strains of mice (athymic nudes and C57BL/6). 
Fluorescence intensity was only observed in the lungs for all three methods of injection. 
Mice were gasping most likely because of entrapment of cells in the lungs due to  
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clumping of cells. (Figure 3.7) MSCs are typically very large cells with an estimated size of 
30 μm (between 16- 53 μm) in suspension. The size of MSCs may vary based on the cell 
culture conditions used, osmolarity of culture medium, passage number or cell density 
during seeding. [40]  Hence, MSCs are most likely accumulated in the pulmonary capillary 
bed after intravenous injection due to their large size. In addition, the release of “sticky” DNA 
molecules from unhealthy cells can clump neighbouring cells together. Therefore, it is crucial 
to ensure that MSCs remain healthy, in single cells with no clumping in suspension prior to 
injection. Cells were passed through a 40 µm mesh cell strainer to obtain single cells in 
suspension. After which, Deoxyribonuclease I (DNase I) solution was added to the cell 
suspension at a final concentration of 0.1 mg/ml to avoid cell clumping and maintain single 
cells in suspension. Instead of PBS, L-15 medium was used in the final suspension prior to 
injection. L-15 is buffered by phosphates and free base amino acids instead of sodium 
bicarbonate. Hence, this medium is designed for supporting cell growth in environments 
without CO2 equilibration.  
Additionally, human clinical trials involving MSCs include injections in the range of 1-5 X 106 
cells/kg. [41, 42] To put this in perspective, a typical mouse (25 g) would only require a 
maximum dose of 7.5 X 104 cells. Hence, the number of cells injected in many published 
preclinical studies, utilised a dose of 10-100 times higher than has been utilised in clinical 
trials to date.[36, 37] Consequently, the number of cells injected in mouse models must be 
optimised to maintain therapy efficacy, avoid toxicity in mice while remaining clinically 
feasible. Finally, a minimum of 50% survival rate was attained in mice after cell injection with 
a set of optimised parameters. (Table 3.3). Details of cell preparation and cell injection 
parameters are included in Section 3.2.4. 
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Table 3. 3. Optimised parameters for I.V. cell injection in mouse model. 
Number 
of cells 
(X106) 
Volume 
of 
injection 
(µl) 
Medium Gauge of 
needle 
Cell suspension 
 
Anaesthesia dose 
0.5 100 L-15 25 G Cells sieved through 
40 µm strainer. 
0.1 mg/ml DNase 1 
in L-15 medium 
added to final cell 
suspension. 
Half dose of 
ketamine/xylazine was 
administered. 
Ketamine 50 mg/kg 
Xylazine 10 mg/kg 
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3.3.5 Biodistribution of labelled cells 
3.3.5.1 I.V. injected labelled cells 
 
 
Figure 3. 8. Longitudinal in vivo optical imaging in four athymic nude mice Mouse (M) 1, 2, 
3, 4. Biodistribution of labelled cells injected via tail vein of nude mice. Images shown are 
24, 48, 96 hours and 7 days post injection. Fluorescence intensity is rendered in false color 
as depicted in calibration colour chart.  
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Fluorescence optical imaging was utilized to track biodistribution of systemically injected 
labelled cells in vivo. Optical imaging was performed at 24, 48, 96 hours and 7 days post 
injection of ~ 0.5 x 106 labelled human PMSCs into the tail vein of athymic nudes. Distinct 
fluorescence signals from labelled cells were observed in all mice in optical images acquired 
at 24 and 48 hours post injection (Figure 3.8). Labelled cells appeared well distributed and 
did not accumulate in any specific region in mice. I.V. injection is the most common 
technique utilized for MSCs delivery. [32]  Nonetheless, the main concern with I.V. injection 
is the pulmonary first pass effects, which results in significant entrapment of cells in lungs. 
[13, 43] On the contrary, ex vivo images acquired at 48 hours and 7 days post injection of 
labelled cells corroborated that there was no accumulation of fluorescence signals in any 
specific organs (Figure 3.9). A reduction in fluorescence signal was detected at 96 hours 
and 7 days post injection of cells, possibly due to clearance of cells from the body. As 
anticipated, autofluorescence was observed in the stomach and intestines due to the diet of 
mice, which was composed of a standard and low fat formulation chows.  Standard rodent 
diets typically contain large amounts of alfalfa and, hence, chlorophyll which degrades to 
pheophorbide-a and pheophytin-a, which has excitation and emission wavelengths which 
overlaps with Cy5.5 dye. [44] 
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Figure 3. 9. Ex vivo optical imaging. a) Two mice (controls, no cells). Labelled cells were 
injected via tail vein of nude mice. Organs removed b) 48 hours post injection, c) 7 days post 
injection Fluorescence intensity is rendered in false color as depicted in calibration colour 
chart. X-ray images overlaid on fluorescence images. Organs labelled above. 
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3.3.5.2 I.P. injected cells 
 
Figure 3. 10. Longitudinal in vivo optical imaging in two athymic nude mice, Mouse (M1 & 
2). Biodistribution of labelled cells injected via intraperitoneal of nude mice. Images shown 
are 1, 24, 48, 96 hours and 7 days post injection. Fluorescence intensity is rendered in false 
color as depicted in calibration colour chart.  
 
Optical imaging was performed at 1, 24, 48, 96 hours and 7 days post injection of ~ 0.5 x 
106 labelled human PMSCs into the intraperitoneum of athymic nudes. Clear fluorescence 
signals from labelled cells were detected in all mice in optical images acquired at 1, 24 and 
48 hours post injection (Figure 3.10). Labelled cells are localized within intraperitoneum  
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cavity of mice at all time points. Ex vivo images acquired at 48 hours and 7 days post 
injection of labelled cells indicated that there was no accumulation of fluorescence signals 
in any specific organs (Figure 3.11). At 96 hours and 7 days post injection of cells, a 
decrease in fluorescence signal was observed, conceivably due to clearance of cells from 
the body.  
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Figure 3. 11. Ex vivo optical imaging. a) Two mice (controls, no cells). Labelled cells were 
injected through intraperitoneum of nude mice. Organs removed b) 48 hours post injection, 
c) 7 days post injection Fluorescence intensity is rendered in false color as depicted in 
calibration colour chart. X-ray images overlaid on fluorescence images. Organs labelled 
above. 
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3.4 Conclusions 
Our results demonstrate that the partly-fluorinated copolymer had no significant effect on 
typical MSC characteristics, which include expression of specific MSC markers and 
differentiation abilities of the MSCs. Leakage of copolymer from the cells after loading was 
minimal and there is sufficient retention to allow excellent in vivo imaging. Importantly, in 
vivo 19F MRI data showed that labelled PMSCs could be readily detected up to seven days 
post injection within a short MRI acquisition scan period (12 minutes).  In addition, ex vivo 
optical imaging showed that intravenous injection of labelled cells did not accumulate in any 
specific organs. 
We conclude that the copolymer reported here show outstanding potential to be employed 
as an imaging tracer for 19F MRI-based tracking and quantification of non-phagocytic and 
therapeutically-relevant cells such as MSCs. 
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3.5 Appendix 
 
 
SCORE SHEET FOR SCORING ENDPOINTS IN MICE 
(Scoring to commence at post natal day 100) 
 
Experimental/Treatment Group: 
 
Date:     
Time:      
AEC Number:     
Name of person scoring: 
Contact telephone Number: 
Name of Supervisor/Chief Investigator:   
      
Indicators Scoring of independent variables: 
Date  
General 
Health 
Eating 
 
0. Drinking and eating well 
1. Change in eating or drinking habit 
2. Inappetance 
3. Not eating/drinking, severely dehydrated 
Locomotion 0. Full extension of hind legs away from lateral midline when mouse is suspended by its tail.  
              The mouse is able to sustain extension for 2 seconds, suspended 3 times. 
1. Collapse of partial collapse of leg extension toward lateral midline or trembling of hindlegs 
during tail suspension. 
2. Rigid paralysis of hindlimbs at least one foot not being used for forward movement. 
3. Mouse is unable to right itself within 30 seconds after being place on its back. 
Behaviour 0. Normal 
1. Away from littermates 
2. Aggressive or huddled in corner 
3. Severe distress 
Appearance 0. Normal 
1. Ruffled fur 
2. Weeping eyes 
3. Weeping/closed eyes, urine staining, difficulty defecating 
Weight loss 
(scored 
every 2nd 
day) 
0. Normal 
1. 5-10% 
2.  10-15% 
3. >15% over 3 days 
TOTAL 
SCORE 
 
For total scores 
0 =  Normal:  No action 
1-4 =  Moderate changes: Should be monitored daily 
5-10 =  Significant changes: Monitor twice daily 
≥10 =   Euthanase 
 
Signature of person scoring: 
 
 
…………………………………………………………………… 
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Animal Ethics Approval Certificate 
 
 
 
 
 
 
 
 
 
 
***  Immediate euthanasia 
 1. A score of 3 in any one category 
 2. Loss of the righting reflex (unable to right within 30 seconds of being placed on their back). Any persistent 
signs of undue health (eye infections etc). Excessive weight loss (greater than 10% from the previous day). 
Complete paralysis of any hindlimb that renders the animal incapable of reaching food and water. 
Chapter 3 In Vivo Tracking of MSCs Labelled with Copolymer 
 
3.6 References 
[1] J.M. Hare, J.H. Traverse, T.D. Henry, N. Dib, R.K. Strumpf, S.P. Schulman, G. 
Gerstenblith, A.N. DeMaria, A.E. Denktas, R.S. Gammon, J.B. Hermiller, M.A. Reisman, 
G.L. Schaer, W. Sherman, Journal of the American College of Cardiology 2009, 54. 
[2] M.E.J. Reinders, J.W.d. Fijter, H. Roelofs, I.M. Bajema, D.K.d. Vries, A.F. Schaapherder, 
F.H.J. Claas, P.P.M.C.v. Miert, D.L. Roelen, C.v. Kooten, W.E. Fibbe, T.J. Rabelink, STEM 
CELLS Translational Medicine 2013, 2. 
[3] P.K. Gupta, A. Chullikana, R. Parakh, S. Desai, A. Das, S. Gottipamula, S. 
Krishnamurthy, N. Anthony, A. Pherwani, A.S. Majumdar, Journal of Translational Medicine 
2013, 11. 
[4] J.S. Lee, J.M. Hong, G.J. Moon, P.H. Lee, Y.H. Ahn, O.Y. Bang, STEM CELLS 2010, 
28. 
[5] H.J. Jin, Y.K. Bae, M. Kim, S.-J. Kwon, H.B. Jeon, S.J. Choi, S.W. Kim, Y.S. Yang, W. 
Oh, J.W. Chang, International Journal of Molecular Sciences 2013, 14. 
[6] J.M. Janjic, E.T. Ahrens, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2009, 1, 
492. 
[7] Y.K. Chang, Y.P. Liu, J.H. Ho, S.C. Hsu, O.K. Lee, Journal of Orthopaedic Research 
2012, 30. 
[8] M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, 
A. Keating, D. Prockop, E. Horwitz, Cytotherapy 2006, 8. 
[9] J.M. Karp, G.S. Leng Teo, Cell Stem Cell 2009, 4. 
[10] T. Mäkelä, R. Takalo, O. Arvola, H. Haapanen, F. Yannopoulos, R. Blanco, L. 
Ahvenjärvi, K. Kiviluoma, E. Kerkelä, J. Nystedt, T. Juvonen, P. Lehenkari, Cytotherapy 
2015, 17. 
[11] I.M. Barbash, P. Chouraqui, J. Baron, M.S. Feinberg, S. Etzion, A. Tessone, L. Miller, 
E. Guetta, D. Zipori, L.H. Kedes, R.A. Kloner, J. Leor, Feasibility, Cell Migration, and Body 
Distribution 2003, 108. 
[12] J. Nystedt, H. Anderson, J. Tikkanen, M. Pietilä, T. Hirvonen, R. Takalo, A. Heiskanen, 
T. Satomaa, S. Natunen, S. Lehtonen, T. Hakkarainen, M. Korhonen, S. Laitinen, L. Valmu, 
P. Lehenkari, STEM CELLS 2013, 31. 
[13] U.M. Fischer, M.T. Harting, F. Jimenez, W.O. Monzon-Posadas, H. Xue, S.I. Savitz, 
G.A. Laine, C.S. Cox, Stem Cells and Development 2009, 18. 
[14] D.L. Kraitchman, M. Tatsumi, W.D. Gilson, T. Ishimori, D. Kedziorek, P. Walczak, W. 
Paul Segars, H.H. Chen, D. Fritzges, I. Izbudak, R.G. Young, M. Marcelino, M.F. Pittenger, 
M. Solaiyappan, R.C. Boston, B.M.W. Tsui, R.L. Wahl, J.W.M. Bulte, Circulation 2005, 112. 
[15] R. Sackstein, J.S. Merzaban, D.W. Cain, N.M. Dagia, J.A. Spencer, C.P. Lin, R. 
Wohlgemuth, Nat. Med. (N. Y., NY, U. S.) 2008, 14. 
[16] T. Burkholder, C. Foltz, E. Karlsson, C.G. Linton, J.M. Smith, Current protocols in mouse 
biology 2012, 2. 
[17] E.T. Ahrens, J.W. Bulte, Nat. Rev. Immunol. 2013, 13, 755. 
[18] M. Srinivas, P.A. Morel, L.A. Ernst, D.H. Laidlaw, E.T. Ahrens, Magn. Reson. Med. 
2007, 58, 725. 
Chapter 3 In Vivo Tracking of MSCs Labelled with Copolymer 
 
[19] E. Bible, F. Dell'Acqua, B. Solanky, A. Balducci, P.M. Crapo, S.F. Badylak, E.T. Ahrens, 
M. Modo, Biomaterials 2012, 33, 2858. 
[20] Y. Amsalem, Y. Mardor, M.S. Feinberg, N. Landa, L. Miller, D. Daniels, A. Ocherashvilli, 
R. Holbova, O. Yosef, I.M. Barbash, J. Leor, Circulation 2007, 116. 
[21] J. Terrovitis, M. Stuber, A. Youssef, S. Preece, M. Leppo, E. Kizana, M. Schär, G. 
Gerstenblith, R.G. Weiss, E. Marbán, M.R. Abraham, Circulation 2008, 117. 
[22] J.W.M. Bulte, L. Kostura, A. Mackay, P.V. Karmarkar, I. Izbudak, E. Atalar, D. Fritzges, 
E.R. Rodriguez, R.G. Young, M. Marcelino, M.F. Pittenger, D.L. Kraitchman, Academic 
Radiology 2005, 12. 
[23] D.L. Kraitchman, A.W. Heldman, E. Atalar, L.C. Amado, B.J. Martin, M.F. Pittenger, 
J.M. Hare, J.W.M. Bulte, Circulation 2003, 107. 
[24] J.J. Graham, W.D. Foltz, A.K. Vaags, M.R. Ward, Y. Yang, K.A. Connelly, R. 
Vijayaraghavan, J.S. Detsky, M.R. Hough, D.J. Stewart, G.A. Wright, A.J. Dick, American 
Journal of Physiology-Heart and Circulatory Physiology 2010, 299. 
[25] C. Chapon, J. Jackson, E. Aboagye, A. Herlihy, W. Jones, K. Bhakoo, Mol. Imaging 
Biol. 2009, 11, 31. 
[26] D.J. Stuckey, C.A. Carr, E. Martin‐Rendon, D.J. Tyler, C. Willmott, P.J. Cassidy, S.J.M. 
Hale, J.E. Schneider, L. Tatton, S.E. Harding, G.K. Radda, S. Watt, K. Clarke, STEM CELLS 
2006, 24. 
[27] E.J. Ribot, J.M. Gaudet, Y. Chen, K.M. Gilbert, P.J. Foster, Int J Nanomedicine 2014, 
9, 1731. 
[28] J. Ruiz-Cabello, P. Walczak, D.A. Kedziorek, V.P. Chacko, A.H. Schmieder, S.A. 
Wickline, G.M. Lanza, J.W. Bulte, Magn Reson Med 2008, 60, 1506. 
[29] P. Boehm-Sturm, M. Aswendt, A. Minassian, S. Michalk, L. Mengler, J. Adamczak, L. 
Mezzanotte, C. Löwik, M. Hoehn, Biomaterials 2014, 35, 2218. 
[30] M.S. Fox, J.M. Gaudet, P.J. Foster, Magnetic Resonance Insights 2015, 8. 
[31] J. Yu, C. Zheng, X. Ren, J. Li, M. Liu, L. Zhang, L. Liang, W. Du, Z. Chao Han, Scand. 
J. Immunol. 2010, 72. 
[32] T.J. Kean, P. Lin, A.I. Caplan, J.E. Dennis, Stem Cells International 2013, 2013. 
[33] M. Wang, C. Liang, H. Hu, L. Zhou, B. Xu, X. Wang, Y. Han, Y. Nie, S. Jia, J. Liang, K. 
Wu,  2016, 6. 
[34] A. Nakamizo, F. Marini, T. Amano, A. Khan, M. Studeny, J. Gumin, J. Chen, S. 
Hentschel, G. Vecil, J. Dembinski, M. Andreeff, F.F. Lang, Cancer Res. 2005, 65. 
[35] M.R. Loebinger, P.G. Kyrtatos, M. Turmaine, A.N. Price, Q. Pankhurst, M.F. Lythgoe, 
S.M. Janes, Cancer Res. 2009, 69. 
[36] A.Y. Khakoo, S. Pati, S.A. Anderson, W. Reid, M.F. Elshal, Rovira, II, A.T. Nguyen, D. 
Malide, C.A. Combs, G. Hall, J. Zhang, M. Raffeld, T.B. Rogers, W. Stetler-Stevenson, J.A. 
Frank, M. Reitz, T. Finkel, J. Exp. Med. 2006, 203. 
[37] M. Studeny, F.C. Marini, R.E. Champlin, C. Zompetta, I.J. Fidler, M. Andreeff, Cancer 
Res. 2002, 62. 
[38] A.S. Arbab, G.T. Yocum, H. Kalish, E.K. Jordan, S.A. Anderson, A.Y. Khakoo, E.J. 
Read, J.A. Frank, Blood 2004, 104. 
[39] C. Kyriakou, N. Rabin, A. Pizzey, A. Nathwani, K. Yong, Haematologica 2008, 93. 
Chapter 3 In Vivo Tracking of MSCs Labelled with Copolymer 
 
[40] D. Furlani, M. Ugurlucan, L. Ong, K. Bieback, E. Pittermann, I. Westien, W. Wang, C. 
Yerebakan, W. Li, R. Gaebel, R.-k. Li, B. Vollmar, G. Steinhoff, N. Ma, Microvascular 
Research 2009, 77. 
[41] E.M. Horwitz, P.L. Gordon, W.K.K. Koo, J.C. Marx, M.D. Neel, R.Y. McNall, L. Muul, T. 
Hofmann, Proc. Natl. Acad. Sci. U. S. A. 2002, 99. 
[42] K. Le Blanc, I. Rasmusson, B. Sundberg, C. Gotherstrom, M. Hassan, M. Uzunel, O. 
Ringden, Lancet 2004, 363. 
[43] J. Gao, J.E. Dennis, R.F. Muzic, M. Lundberg, A.I. Caplan, Cells Tissues Organs 2001, 
169. 
[44] G. Weagle, P.E. Paterson, J. Kennedy, R. Pottier, Journal of Photochemistry and 
Photobiology B: Biology 1988, 2. 
Chapter 4 Ascertaining Uptake Mechanisms of Copolymer in MSCs 
Chapter Four 
4.1 Introduction 
To date, there are numerous publications on the development and application of novel NPs 
for various purposes including biomedical imaging; bio-sensing and targeted drug delivery.[1-
3] Nonetheless, clinical translation of many of these NPs is challenging, arguably due to the 
lack of knowledge on NP-cell interactions.[4, 5] For a successful clinical application of any 
novel NP, it is imperative to understand its interactions with cells of interest, and in this 
thesis, these are specifically MSCs. The uptake pathway adopted by a NP will affect its 
intracellular localisation, anticipated efficacy, toxicity and determines the eventual fate of the 
NP. Hence, it is vital to ascertain endocytic mechanisms utilised by our copolymer to enter 
PMSCs and to understand the general NP distribution in a cell for future clinical translation. 
In the studies described in this chapter, we comprehensively investigated the uptake 
mechanisms involved in the internalisation in MSCS of our fluorinated copolymer 
successfully employed as a 19F MR tracer. The copolymer discussed in Chapter Two and 
Three was synthesised using a novel perfluoropolyether methacrylate (PFPEMA) as the 
fluorinated monomer and oligo(ethylene glycol) methacrylate (OEGMA) as a hydrophilic 
component necessary to impart solubility in aqueous media.  
Generally, cell uptake of NPs may involve different established endocytic routes such as 
phagocytosis, macropinocytosis, clathrin dependent endocytosis and clathrin independent 
mechanisms that have been discussed in Chapter One of this thesis.[6] The mechanisms of 
internalisation of the copolymer can be studied by various methods, all with its own strengths 
and limitations. 
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Whilst there are many different chemical inhibitors described in literature, we focused on the 
utilisation of chemical inhibitors that are commonly used for the study of endocytic 
pathways.[7] The choice of different inhibitors is not dependent on the structure of polymers. 
Nonetheless, the route of uptake of nanoparticles is dependent on the structure of polymer.  
This approach is based on the assumption that these inhibitors exhibit specific effects on a 
particular endocytic route. The inhibitors employed for this study include chlorpromazine 
(CDE), EIPA (macropinocytosis), genistein and MβCD (CIE). Chlorpromazine hydrochloride 
is frequently used as an inhibitor of CDE by inducing a loss of clathrin and AP2 assembly 
from the surface of the cell. Fluorescent-labelled transferrin is selected as a positive control 
to confirm inhibition of CDE by treatment with CPZ.[8] MβCD is a cyclic oligomer 
glucopyranoside that blocks cholesterol dependent endocytic processes by removal of 
steroid from the plasma membrane.[9] Hence, it is employed to evaluate endocytosis that is 
reliant on the integrity of lipid rafts. Genistein, a tyrosine-kinase inhibitor has been reported 
to block utilisation of dynamin II and cause local disruption of the actin network which are 
fundamental events in caveolae mediated pathway.[7] Hence, MβCD and genistein were 
selected as inhibitors of CIE. Lactosylceramide (LacCer) is a glycosphingolipid that is 
localised in lipid rafts and is internalised by CIE, dynamin and caveolin-1 dependent 
pathways. [10, 11] It has been reported to be employed as a marker for CIE, caveolae mediated 
endocytosis. EIPA has been demonstrated to block macropinocytosis via inhibition of Na+/H+ 
exchange in the plasma membrane. High molecular weight dextrans are specifically taken 
up into macropinosomes and hence utilised as a marker for macropinocytosis.[12] 
Fluorescently tagged positive controls were optimised via flow cytometry and confocal 
imaging enabling the optimum concentration, incubation time and washing procedures to be 
established. Subsequently, cells were incubated with copolymer in the presence of inhibitors 
that were comprehensively assessed and optimised for specificity, cytotoxicity and efficacy 
in uptake  
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into MSCs. Optimisation of inhibitors/markers and uptake of copolymer were evaluated by 
flow cytometry and confocal imaging as detailed in this chapter Overall, it must be 
emphasised that the utilisation of inhibitors and markers must be optimised for each cell type 
and NP type, as an inhibitor might not display the same degree of high specificity, efficacy 
and cytotoxicity in some cell lines. Additionally, complementary studies were conducted with 
co-localisation of copolymer with specific organelles and endocytic markers to establish 
mechanism of uptake adopted by this copolymer. 
4.2 Experimental Section 
4.2.1 Materials 
Chlorpromazine, MβCD, genistein, EIPA, cell-counting kit (CCK-8), Dextran-FITC were 
purchased from Sigma-Aldrich. Dulbecco’s modified Eagle medium (DMEM) with high 
glucose, Opti-MEM™, phosphate-buffered saline (PBS), TrypLE™ Express, fetal bovine 
serum (FBS), antibiotic-antimycotic (AA), bovine serum albumin (BSA) complexed BODIPY 
FL C5 –LacCer, hTf-Alexa Fluor® 647, MitoTracker™ Deep Red FM, LysoTracker™ Red 
DND-99 were purchased from ThermoFisher Scientific. Tween-20 was obtained from Bio-
Rad and Odyssey blocking buffer from LI-COR Biosciences. Professor Rob Parton from the 
Institute for Molecular Bioscience, UQ, kindly donated Caveolin-1 antibody. 
4.2.2 Cell culture of human mesenchymal stem cells 
Third trimester placentas were acquired from healthy mothers with uncomplicated 
pregnancies at term during elective caesarean section (CS), as approved by The Human 
Research Ethics Committee of the Royal Brisbane and Women’s Hospital. MSCs were 
isolated from the maternal side of the placenta (decidua). Decidua-derived MSCs were  
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cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen), supplemented with 10% 
fetal bovine serum (FBS), 1% antibiotic-antimycotic (AA), at 37 °C in a humidified 
atmosphere, with 5% CO2. Cells were passaged at 90% confluency at a ratio of 1:2 or 1:3.[13] 
The PMSCs were characterized and fulfilled the minimal criteria established by the 
International Society of Cellular Therapy (ISCT).[14] 
 
4.2.3 Inhibition of endocytosis using pharmacological inhibitors (Optimisation & 
specificity studies) 
It is crucial to optimise several parameters in these experiments before understanding the 
mechanism of uptake of copolymer in MSCs. Four commonly used inhibitors were utilised 
and parameters optimised for its toxicity, inhibitory efficacy and specificity for distinctive 
endocytic mechanisms in MSCs. The use of pharmacological inhibitors must be optimised 
for each cell and NP type.  
4.2.3.1 Cytotoxicity analysis 
Trypan Blue exclusion tests (Invitrogen) were conducted immediately after incubation with 
varying concentrations of inhibitors to measure the effect of the inhibitors on cell viability. 
The cytotoxicity of inhibitors was evaluated using the CCK-8 assay kit. To quantify a 
potential impact of the inhibitors on the cells mitochondrial function, the CCK-8 assay 
compared cells incubated with drugs to control cells, as described previously.[15] The 
colourimetric CCK-8 assay measures the amount of formazan dye that is reduced by 
intracellular mitochondrial dehydrogenase. The number of living cells is proportional to the 
concentration of the formazan dye. 
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Briefly, MSCs were seeded at 10,000 cells/100 µl/well in a clear-bottom 96-well plate. After 
24 hours, they were incubated with a range of concentrations of inhibitors in OptiMem media 
for 2 hours at 37 °C. Subsequently, CCK-8 solution (10 μl per well) was added and incubated 
for three hours. Absorbance readings were taken on a Tecan plate reader at dual 
wavelengths of 450 nm and 650nm as reference. 
4.2.3.2 Control experiments 
Fluorescently labelled endocytic controls were used in inhibition studies. Transferrin from 
human serum (hTf), Alexa Fluor Conjugate 647 diluted in OptiMem to an optimised 
concentration of 25 µg/ml, was utilised to assess the inhibition of CME. BODIPY™ FL C5-
Lactosylceramide complexed to BSA (LacCer) (0.5 µmol/L) was used to measure inhibition 
of CIE. To assess macropinocytosis, 70 kDa dextran that has been conjugated with 
fluorescein isothiocyanate (FITC) was employed at a concentration of 2 mg/ml. The 
concentrations of controls, incubation time and cell culture conditions used specifically in 
PMSCs were optimised prior to inhibition and specificity studies. Uptake of fluorescently 
labelled controls were evaluated using flow cytometry and confocal microscopy. 
4.2.3.3 Efficacy of inhibitors & specificity studies 
Different endocytic inhibitors were evaluated for their optimal concentration, exposure time 
and cell damage caused. Inhibition of CDE was established with chlorpromazine 
hydrochloride and inhibition of CIE was performed using MβCD and genistein. EIPA was 
utilised to inhibit macropinocytosis.  
Cell numbers and other parameters for all experiments were kept constant. For inhibition 
and specificity studies, 100,000 MSCs/well were seeded on 12-well plates (for flow 
cytometry analysis) and 10,000 MSCs on sterile MatTek coverslip (1.5)-bottom dishes (for  
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confocal analysis).  24 hours later, cells were incubated with a range of concentrations of 
inhibitors in OptiMEM for 1-2 hours. The inhibitors were prepared that the final DMSO 
concentrations of the inhibitor solutions were less than 1%. Cells were then incubated with 
25 µg/ml hTf, 0.5 µmol/L LacCer, or 2 mg/ml Dextran for 30 mins in the presence of the 
inhibitors or without inhibitors (negative controls). hTf, LacCer and dextran uptake were 
quantitatively and qualitatively assessed using flow cytometry and CLSM respectively. 
4.2.3.4 Flow cytometry analysis 
It is critical to remove the fluorescently labelled markers that are not internalised but attached 
to the plasma membrane. For transferrin, an established acid wash routine was adopted for 
this purpose [16]. After incubation with hTf for 30 minutes, cells were washed twice with ice-
cold acid wash buffer (150 mM NaCl, 10 mM acetic acid, pH 4.1).[16]   
For LacCer, surface associated fluorescent lipid is extracted out of the plasma membrane 
by supplementing with defatted BSA. Only fluorescent lipid that have been attached to the 
plasma membrane will be removed by BSA addition. After incubation with LacCer, cells were 
washed twice with cold media. Subsequently, cells were washed six times for ten minutes 
with cold media supplemented with 5% defatted BSA. [11] 
Membrane-bound dextran were removed by extensive washing steps with ice-cold PBS. [17]  
After removal of non-internalised fluorescent markers, cells were detached with trypsin, 
centrifuged and resuspended in PBS and analysed with the BD Accuri™ C6 flow cytometer.  
 
 
For quantification, experiments were performed in duplicates, and 10,000 events were 
collected for each sample. Accuri Software was utilised for analysis. The uptake of 
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fluorescent markers was calculated as the mean fluorescence value of the duplicates.   
100% uptake (negative controls) was determined from cells that have not been treated with 
inhibitor and incubated with the specific markers, followed by the specified washing 
protocols. Background reading correction was done by subtracting the mean fluorescence 
value of cells incubated without both inhibitors and markers (blank) from each sample. 
 
4.2.3.5 Laser scanning microscopy of fixed and live cells 
The internalisation of fluorescent conjugated markers (hTf, LacCer and Dextran) was 
visualised and assessed with a confocal microscope (Zeiss 710 Confocal LSM).  After 
incubation with fluorescent markers, nuclei were stained with Hoescht dye. After which, cells 
were washed several times with PBS and incubated with OptiMem media for imaging.  
BODIPY FL-tagged LacCer was excited with the argon 488-nm laser line and emission light 
was collected from 500-530 nm filter. AlexaFluor 647 conjugated hTf was excited with the 
diode 639-nm laser line and emission light collected from 655-nm pass filter.  Dextran-FITC 
was excited with 490 nm laser line and emission light was collected from 520 nm filter. 
Representative 2D confocal images and 3D Z stack analysis were obtained to ascertain 
internalisation of fluorescent markers. Live cell imaging ran for a time period of 60 minutes 
and cells were kept in a constant environment at 37°C and 5% CO2. Image acquisition was 
performed Zen Blue Software. 
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4.2.4 poly(OEGMA-co-PFPEMA) uptake in MSCs incubated with pharmacological 
inhibitors. 
Copolymer uptake can be ascertained after careful optimisation of several factors including 
controls, inhibition effectiveness, specificity and cytotoxicity of pharmacological inhibitors 
utilised. Each step from exposure to inhibitors to copolymer uptake have been optimised for 
this cell type to ensure reproducibility of the data and quantitative information obtained. 
MSCs were seeded at 100,000 cells/well in a 12-well plate and were allowed to attach 
overnight (37°C and 5 % C02). After serum depletion for 1 hour, cells were treated with the 
optimised concentrations and conditions of the four inhibitors for 1 hour at 37°C. Energy 
dependence experiments were conducted by incubating the cells at 4°C for 30 mins prior to 
the addition of copolymer.  
Subsequently, cells were incubated with an optimised concentration of copolymer (10 
mg/ml) conjugated with dye, with inhibitors for a further 1 hour, either in the presence of 
inhibitors or at 4°C. Negative controls are cells incubated with copolymer but without 
inhibitors and normalised as 100 % copolymer uptake. Blank are cells incubated without 
drugs and copolymer and normalized as 0 % uptake. Cells were then washed with cold PBS 
several times to remove any non-internalised copolymer. Copolymer uptake were assessed 
using flow cytometry and confocal microscope imaging as described above.  
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4.2.5 Statistical analysis 
The quantification data from flow cytometry were analysed with Student t-test using 
GraphPad Prism 7. P values were calculated, by comparing mean fluorescence data 
acquired from inhibitor treated and non-treated samples. Compared means with P values 
less than 0.05 were deemed as treated samples being significantly different to the non-
treated samples. The P values were either presented as not significant ‘ns’ (P > 0.05), single 
asterisk ‘*’ (P ≤ 0.05), two asterisks ‘**’ (P ≤ 0.01), three asterisks ‘***’ (P ≤ 0.001) or four 
asterisks ‘****’ (P ≤ 0.0001). 
 
4.2.6 Co-localisation studies of poly(OEGMA-co-PFPEMA) with endocytic and 
organelle markers 
 
Apart from using chemical inhibitors, several endocytic markers were utilised to corroborate 
the endocytic pathways employed by the copolymer. Markers for specific organelles were 
used to further investigate the intracellular fate of the copolymer. Fluorescently tagged 
controls (hTf, LacCer and Dextran), which were used to optimize the chemical inhibitors, 
were employed as the endocytic markers. Commercially available MitoTracker and 
LysoTracker were chosen as the markers for organelles mitochondria and lysosomes 
respectively.  
For the endocytic markers (hTf, LacCer and Dextran) experiments, cells were exposed to 
10 mg/ml copolymer (with FITC or Cy 5.5 dye) for 4 hours and then stained with the specified 
endocytic markers as previously described.  
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4.2.6.1 Immunofluorescence (Copolymer Co-localisation with Caveolin-1) 
MSCs were seeded on coverslips at a density of 25,000 cells per sample. Adhered cells 
were exposed to 10mg/mL copolymer (with FITC dye) for 3 hours. Labelled cells were 
washed with TBS and fixed with 2% PFA in Odyssey Blocking Buffer (TBS) at room 
temperature. Fixed cells were permeabilized in 0.5% (v/v) Tween 20 in TBS. Cells were then 
blocked in the TBS for 1 hour followed by staining with caveolin-1 antibody (1:300). The cells 
were left to incubate for 2 hours at room temperature in a humidity chamber and washed 
thoroughly with TBS. Alexa Fluor® 555-conjugated secondary antibody (1:500) was added 
to the samples for 1-hour incubation at room temperature. A staining control was carried out 
by performing the same immunostaining procedures to cells not labelled with copolymer. A 
no primary antibody control was also performed to assess the possibilities of non-specific 
binding of the secondary antibody. The stained cells were washed with TBS, mounted on 
microscope slides using VECTASHIELD® Mounting Medium with DAPI and sealed with nail 
polish. Images acquired using a confocal microscope. 
4.2.6.2 Copolymer co-localisation with MitoTracker and LysoTracker 
For the organelle marker experiments, cells were again exposed to 10 mg/ml copolymer 
(with FITC dye) for 4 hours and 24 hours. The cells were then either stained with 100 nM of 
MitoTracker for 20 minutes or 75 nM LysoTracker for 30 minutes, both under appropriate 
growth conditions (37 °C, 5 % CO2) with washing steps in between.  
The intracellular localisation of the markers and copolymer were visualised and assessed 
with a confocal microscope as specified above. MitoTracker™ Deep Red FM was excited 
with the 633-nm laser line and LysoTracker™ Red DND-99 was excited with the 561-nm  
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laser line. Colocalisation of copolymer with endocytic and organelle markers were developed 
by determining the Pearson’s Correlation Coefficients of a region of interest (ROI) using the 
software ImageJ with JACoP plugin.  
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4.3 Results and discussion 
4.3.1 Optimisation of controls/markers 
 
 
 
A
B
C
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Figure 4.1. Evaluation by confocal microscopy of MSCs incubated with endocytic controls 
A) hTf (red), B) Dextran (green) and C) LacCer (green). The nuclei were stained with DAPI 
(blue). All experiments were performed at least three times and representative images are 
shown. Magnification 10x. 
Transferrin (Tf) is recognised as a well-established ligand that is exclusively take up via the 
clathrin coated pit pathway, CDE. Consequently, fluorescently labelled transferrin was 
selected as a positive control to confirm inhibition of CDE by treatment with CPZ. Similarly, 
the sphingolipid LacCer and high molecular weight dextran are internalised specifically by 
caveolae mediated, CIE and micropinocytosis, respectively. [18] These fluorescently tagged 
positive controls were optimised via flow cytometry and confocal imaging whereby the 
optimal concentration, incubation time and washing procedures were established (Figure 
4.1 & Table 4.1). It is vital to remove the fluorescently labelled markers that are not 
internalised but just attached to the plasma membrane. Markers that are not internalised will 
result in false positive fluorescent intensity. Hence, specific and established washing 
techniques have been adopted.[11, 16, 19] 
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Table 4.1. Optimised parameters for selected endocytic controls. 
 
 
 
 
 
 
 
 
 
 
 
Main Endocytic 
Pathway Affected 
Endocytic 
Control 
Optimal 
Concentration 
Incubation 
Condition 
Washing Protocol 
Clathrin-mediated 
endocytosis 
(CDE) 
hTf 25 μg/ml 30 minutes 
at 37 °C 
Multiple washes with 
ice-cold acid wash 
buffer  
(150 mM NaCl, 10 mM 
CH3COOH, pH 4.1) 
Lipid raft-
dependent 
endocytosis 
(Clathrin-
independent CIE) 
 
 
 
LacCer 
 
 
 
0.5 μM 
 
 
 
30 minutes 
at 4 °C 
 
 
 
Multiple incubation with 
defatted BSA 
Caveolae-
dependent 
endocytosis 
(Clathrin-
independent CIE) 
Macropinocytosis 
 
Dextran 2 mg/ml 30 minutes 
at 37 °C 
Extensive washes with 
ice-cold PBS 
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4.3.2 Optimisation of endocytic inhibitors 
4.3.2.1 Cytotoxicity of inhibitors 
 
 
Figure 4.2. In vitro cytotoxicity of inhibitors. In vitro viability of MSCs incubated for 2 
hours with endocytic inhibitors (a) chlorpromazine, (b) MβCD, (c) genistein, and (d) EIPA. 
Cell viability was assessed with a CCK-8 based assay. Values are given as mean ± SD of 
triplicates. 
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To identify an optimal protocol for the use of endocytic inhibitors in MSCs derived from 
human placenta, it is fundamental to evaluate specificity and in vitro cell toxicity. The viability 
of MSCs was investigated after exposure to four inhibitors selected for this study: 
chlorpromazine, genistein, MβCD and EIPA. Ranges of concentrations of each inhibitor 
were selected based on previous reports (Table 4.2), and toxicity was assessed with a CCK-
8 assay kit (Figure 4.2).  
Table 4.2. Range of concentrations of inhibitors utilised in uptake mechanism studies.  
Endocytic 
Pathway  
Inhibitor Comment Concentration 
Range 
Exposure 
Time 
Re
f 
Clathrin-
mediated 
endocytosis 
(CME) 
Chlorpromazi
ne 
(CPZ) 
- Reversible 
- Distinguish 
between 
clathrin- and 
caveolae-
mediated 
endocytosis 
5-10 μg/ml 30 min to  
2 hours 
[7, 
20-
24] 
Lipid raft-
dependent 
endocytosis 
(Clathrin-
independent 
CIE) 
Methyl-β-
cyclodextrin 
(MβCD) 
- Reversible 
- Interferes with 
macropinocytosi
s and clathrin-
mediated 
endocytosis 
1-10 mM 30 min to  
2 hours 
[7, 
21, 
23, 
25-
27] 
Caveolae-
dependent 
endocytosis 
(Clathrin-
independent 
CIE) 
Genistein 
(Gen) 
- Causes cell 
morphological 
changes 
200-400 μM 30 min to  
2 hours 
[7, 
20, 
21, 
28, 
29] 
Macropinocyt
osis 
Phagocytosis 
(N/A for 
MSCs) 
5-(N-Ethyl-N-
isopropyl) 
amiloride 
(EIPA) 
- Non-specific 
- Interferes with 
actin which 
affects other 
endocytic 
pathway 
25-150 μM 2 hours [19, 
21, 
23, 
30] 
* 
Endocytosis 4 °C - Non-specific - - [20, 
31] 
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All inhibitors were diluted in OptiMEM and incubated with cells for 2 hours.  80% cell viability 
was set as the lower limit for a suitable inhibitor concentration. The highest appropriate 
concentration of chlorpromazine was 10 µg/ml and at higher concentrations of 15 and 20 
µg/ml, cells had a viability of < 80%. MβCD did not affect viability of MSCs at any tested 
concentrations. MSCs treated with genistein at 500 µM had a cell viability of < 80%. Finally, 
EIPA at 250 µM and 350 µM had a decrease in cell viability, < 80%. It has been previously 
reported that the cytotoxicity of these inhibitors is dependent on cell type. [7] As these 
cytotoxic effects may confound data interpretation, it is crucial for any uptake mechanism 
studies adopting chemical inhibitors to assess the viability of inhibitors in each cell type to 
establish the upper concentration limit. 
4.3.2.2 Actin Cytoskeleton 
The main functions of the cytoskeleton include endocytosis and trafficking of endocytic 
vesicles. Hence, rearrangement of actin filaments may modify the function of plasma 
membrane proteins and influence uptake mechanisms, which do not directly involve actin, 
thus confounding the data. [32-34] Hence, a prerequisite for the utilisation of chemical 
inhibitors is that it should not affect the actin cytoskeleton in a destructive manner. Therefore, 
in addition to the cytotoxicity data obtained, we examined the effects of these inhibitors on 
the actin cytoskeleton. Actin filaments maintained their overall structure after 2 hours 
incubation with each of the inhibitors except for EIPA treated cells (Figure 4.3). Membrane 
ruffling was observed, whereby an actin rich membrane meshwork have formed (Figure 
4.3f). 
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Figure 4.3. Effect of different inhibitors on the actin cytoskeleton. MSCs were 
incubated with inhibitors and actin was stained red. a) Control b) CPZ, c) MβCD, d) 4°C, e) 
genistein and f) EIPA. The nuclei were stained with DAPI (blue). All experiments were 
performed at least three times and representative images are shown. 
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4.3.2.3 Specificity of inhibitors 
Table 4.3. Specificity of endocytosis inhibitors. 
 
Transferrin Lactosylceramide Dextran 
Chlorpromazine 
(CDE) 
** 
p = 0.0021 
ns 
p = 0.5653 
ns 
p = 0.0675 
MßCD 
(CIE) 
ns 
p = 0.1072 
* 
p = 0.0387 
ns 
p = 0.2120 
Genistein 
(CIE) 
ns 
p = 0.3124 
* 
p = 0.0439  
ns 
p = 0.5092 
EIPA 
(Macropinocytosis) 
** 
p = 0.0030 
** 
p = 0.0098 
** 
p = 0.0033 
 
The specificity of each inhibitor was evaluated quantitatively via flow cytometry based on its 
inhibitory effects on the uptake of the three established endocytic markers for CDE, CIE and 
macropinocytosis (Table 4.3).  All experiments were performed in serum free media to 
eliminate any possible interference from serum proteins. 
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The specificity of CPZ was established for inhibition of CDE by examining the inhibitory 
effects on the uptake of LacCer and Dextran. Correspondingly, specificity of genistein and 
MβCD for inhibition of CIE was evaluated by studying its inhibitory effect on the uptake of 
hTf and Dextran. As anticipated, CPZ treatment blocked uptake of hTf and had no significant 
inhibition on LacCer and Dextran uptake. Cells incubated with MβCD and genistein 
demonstrated inhibition of only LacCer uptake, with no significant inhibition of dextran and 
hTF uptake. Only EIPA had a significant inhibitory effect on the uptake of all three endocytic 
markers, which indicates its lack of specificity for dextran (macropinocytosis). 
An issue that if often raised concerning the use of chemical inhibitors is the specificity of 
these inhibitors since they are not specifically designed to block biological pathways. [23] 
Measurements of specificity of inhibitors in each cell type are very often missing in many 
published studies. Interestingly, Kuhn et al. demonstrated that murine macrophages 
(J774A.1 cells) treated with 100 µM CPZ had no inhibition of hTf uptake however human 
lung carcinoma (A549) treated cells had a significant inhibition of hTf. Additionally, they also 
reported that A549 cells treated with MβCD inhibited both classical markers of CDE and CIE 
[25]. Hence, MβCD treatment in this cell type did not exclusively block CIE marker as similarly 
reported elsewhere [35]. It is apparent from previously described data that inhibitors may 
have different effects depending on the cell type. This could be due to the genotypic or 
phenotypic variations between cell types and species. Therefore, it must be emphasised 
that the utilisation of inhibitors must be optimised for each type of cell and NP, as an inhibitor 
might not display the same degree of high specificity in some cell lines. Hence, establishing 
that an inhibitor solely affects one endocytic pathway without  
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significantly interfering with other uptake mechanisms is compulsory. While it is evident that 
chemical inhibitors should be used with caution, it should not impede their application to 
understand uptake mechanisms especially when used in combination with complementary 
approaches.  
Nonetheless, novel and more specific endocytosis inhibitors and biomarkers are required to 
better understand the endocytic pathways adopted by NPs.  
Undeniably, the combination of chemical inhibitors and biological approaches that can 
specifically inhibit pathways in endocytosis will provide crucial information regarding 
materials-cells interactions.  
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4.3.2.4 Efficacy of inhibitors in MSCs 
 
 
Figure 4.4. Efficacy of endocytosis inhibitors. Optimisation of the concentration of CPZ, 
MβCD, genistein and EIPA to inhibit fluorescently tagged hTf, LacCer and Dextran in MSCs 
respectively. Uptake of controls was measured using flow cytometry with 100 % uptake from 
cells treated with endocytic controls in the absence of inhibitors. Values are given as mean 
fluorescent intensity, ± SD of triplicates. 
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Figure 4.5. Efficacy of endocytosis inhibitors. Evaluation by confocal microscopy of 
MSCs incubated with markers and different concentrations of inhibitors A) CPZ (0, 5, 10 µg 
ml-1), hTF (red), B) MβCD (0, 3, 7.5 mM), LacCer (green) and C) Genistein (0, 200, 400 µM), 
LacCer (green) D) EIPA (0, 75, 150 µM), Dextran (green). The nuclei were stained with 
Hoescht stain (blue). All experiments were performed at least three times and representative 
images are shown.  
 
Two different methodologies were adopted to evaluate the inhibition of uptake of the 
endocytic markers. The efficacy of inhibitors at different concentrations was quantitatively 
evaluated by uptake of markers by flow cytometry (Figure 4.4), and qualitatively visualised 
via CLSM images (Figure 4.5) to establish the lowest concentration limit whereby the 
inhibitor is still effective. The lowest effective concentration was selected to reduce possible 
cell damage. Inhibition studies were performed within 2 hours as endocytic processes were 
very rapid and inhibitors might damage cells at longer incubation times. [36, 37] An appropriate 
inhibitor concentration was determined as having a minimum of 50% inhibition of the specific 
assigned markers while maintaining 80% cell viability (Figure 4.3 & 4.4).  Chlorpromazine 
treatment at 15 and 20 µg/ml effectively decreased the uptake of hTF by more than 85% 
(Figure 4.4a). Nonetheless, at these high concentrations, cell viability was less than 60% 
(Figure 4.2a). Consequently, CPZ at 10 µg/ml was selected as the optimal concentration 
based on the criteria imposed. MSCs treated with 3 mM of MβCD had a weak inhibition of 
LacCer uptake. However, at a higher concentration of 10 mM, MβCD effectively inhibited 
LacCer uptake by more than 90 % and did not have a significant effect on the cell viability 
(> 90%) (Figure 4.4b & 4.2b).  This inhibitory effect with 10 mM MβCD is in accordance with 
another study conducted with a different cell type (lung epithelial cells). However, in that 
study, a maximum of 30 minutes exposure was set  
Chapter 4 Ascertaining Uptake Mechanisms of Copolymer in MSCs 
 
since a longer exposure time was demonstrated to have a detrimental effect on the cells. [25] 
Genistein treatment exclusively at 400 µM blocked LacCer uptake by >45%. Inhibition was 
not dose dependent as at higher concentrations (500 and 600 µM), it blocked LacCer uptake 
by < 20% (Figure 4.4c). Subsequently, several parameters such as longer incubation time 
(3 hours) and higher genistein concentration (> 600 µM) were chosen to achieve a higher 
inhibition of LacCer.  Despite several attempts, inhibition of LacCer was not more than 50%. 
Vercauteren et al. studied the efficacy of genistein on inhibition of LacCer uptake in different 
cell types and similarly demonstrated LacCer uptake inhibition of less than 50%. [7] MSCs 
incubated with EIPA had a dose dependent inhibition of dextran uptake (Figure 4.4d). 
However, at concentrations higher than 150 µM, cell viability was less than 80% (Figure 
4.2d). Based on the efficacy of inhibition of specific markers and cytotoxicity data obtained, 
the optimised concentrations of inhibitors were determined (Table 4.4). Overall, treatment 
with inhibitors that have been effective in one cell type should not be applied to other cell 
lines without preliminary optimisation studies. 
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Table 4.4. Optimised inhibitor parameters.  
 
 
 
 
 
 
 
 
 
It should be noted that the effects of these inhibitors are reversible. MSCs were pre-
incubated with inhibitors for up to 90 minutes at 37 °C. Nonetheless, the removal of inhibitors 
and subsequent incubation with markers for 30 minutes did not result in inhibition of markers. 
Hence, markers must be added in the presence of the inhibitors. 
The flow cytometry data was corroborated by confocal microscopy (Figure 4.5).   Lower 
fluorescent intensities were observed when treated with inhibitors at optimal conditions. 
Slight morphological effects were observed after genistein treatment (Figure 4.5c). This 
could be due to the reported mechanism of genistein in which it will eventually lead to the 
local disruption of the actin network. [38] It should be noted that the CCK8 assay did not show 
significant cytotoxic effects at all concentrations of genistein used. Therefore, this  
 
Main Endocytic 
Pathway Affected 
Inhibitor Optimal 
Concentration 
Total 
Exposure 
Time 
Clathrin-mediated 
endocytosis 
(CME) 
Chlorpromazine 
(CPZ) 
10 μg/ml 
 
1.5-2 hours 
Lipid raft-
dependent 
endocytosis 
(Clathrin-
independent CIE) 
Methyl-β-
cyclodextrin 
(MβCD) 
7.5 mM 
 
1.5-2 hours 
Caveolae-
dependent 
endocytosis 
(Clathrin-
independent CIE) 
Genistein 
(Gen) 
400 μM 
 
1.5-2 hours 
Macropinocytosis 
 
5-(N-Ethyl-N-
isopropyl) amiloride 
(EIPA) 
150 μM 
 
1.5-2 hours 
Endocytosis 4 °C - 1 hour 
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slight alteration in cell morphology did not compromise cell survival. MSCs treated with CPZ, 
MβCD and EIPA at all concentrations had no noticeable differences morphology from 
untreated MSCs. 
As CLSM images only show a limited number of cells, care should be taken when evaluating 
inhibitory effects of inhibitors based on images only. Images shown are representative data.   
Hence, it should only be used in combination with quantitative flow data when studying 
uptake mechanism. 
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4.3.3 Evaluation of uptake of copolymer 
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Figure 4.6. Uptake of copolymer. A) Effect of inhibitors on the uptake of copolymer by 
MSCs. B) Treatment with a) No inhibitors (control) b) CPZ, c) EIPA, d) MβCD, e) genistein 
and f) 4°C. The nuclei were stained with Hoechst (blue). All experiments were performed at 
least three times and representative images are shown. 
 
To investigate the mechanisms of uptake by MSCs for poly(OEGMA-co-PFPEMA), cells 
were incubated with copolymer in the presence of inhibitors that were comprehensively 
assessed and optimised based on its specificity, cytotoxicity and efficacy in MSCs. Uptake 
of copolymer was evaluated by flow cytometry and confocal imaging as detailed previously 
(Figure 4.6).   
To ascertain whether copolymer entered cells via active or passive process, cells were 
incubated with copolymer at 4°C to block energy dependent endocytosis as metabolic 
processes, several proteins and enzymes are sensitive to lowered temperatures.[39] As 
anticipated, uptake of copolymer was significantly inhibited (< 20 % uptake) at low 
temperature. This indicates that copolymer are internalised via energy dependent receptor-
mediated pathways. 
Incubation of cells with 12 nm sized copolymer and pre-exposed to CPZ had negligible 
impact on the uptake of copolymer. These observations were validated by visual inspection 
of the confocal images (Figure 4.6b). CPZ is a widely used inhibitor for CDE and is known 
to disrupt the assembly of clathrin-coated pits at the plasma membrane. [40-42] Hence, these 
copolymer did not require association with clathrin to enter MSCs.  
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A study by Santos et al. reported that CPZ treatment resulted in a substantial inhibition of 
uptake of larger NPs size (200 nm) in comparison to smaller NPs (40 nm) in lung carcinoma 
cells. However, this group demonstrated similar uptake inhibition of both NPs in Hela cells 
[20].  In contrast, Rejman et al. studied uptake of NP sizes between 50 and 500 nm in 
melanoma cell lines and established that CPZ treatment affected the uptake of smaller NPs 
considerably (50 nm). Rejman’s study concluded that smaller NPs are preferentially taken 
up via CDE. Hence, results from these studies established that uptake via clathrin is cell, 
NP type and size dependent. 
Copolymer internalisation was strongly blocked by genistein treatment with a decrease in 
copolymer uptake by 96 % in comparison to normal control cells. Furthermore, uptake of 
copolymer was also significantly inhibited by 63% with MβCD treatment (Figure 4.6A). 
These observations were corroborated by the confocal images (Figure 4.6B; d and e). 
Genistein causes disruption of the actin network and inhibits utilisation of dynamin II, both 
recognised as requisite events in caveolae mediated uptake. Caveolae mediated 
endocytosis has also been reported to be dependent on cholesterol rich domains or lipid 
rafts.[43] Correspondingly, MβCD is employed as inhibitors of CIE, particularly in lipid raft 
dependent endocytosis via depletion of cholesterol in cells, which perturbs caveolae 
invagination. [35, 44] Overall, the data obtained indicates a strong contribution of lipid raft 
associated receptors in the endocytosis of copolymer.  
Clearly, the size of a typical caveolae between 60-80 nm could easily accommodate 12 nm 
copolymer. Nonetheless, several published studies have established that genistein had a 
huge impact in the uptake of larger NPs (200 nm). These publications suggested that 
caveolae invaginations are able to internalise larger particles more easily than clathrin- 
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coated pits despite a conventional size of 60 to 80 nm. However, these studies did not 
provide any clear explanation of the mechanism of action involved [20, 45]. 
 
Treatment of MSCs with EIPA had no impact on the uptake of copolymer. In fact, uptake of 
the copolymer was higher in comparison to control normal cells. A substantial involvement 
of macropinocytosis to the uptake of copolymer was considered less likely since MSCs are 
generally non-phagocytic cells. Considering the extent of suppression of internalised 
copolymer induced by genistein and MβCD, we concluded that uptake of copolymer 
occurred predominantly via CIE. To further strengthen this conclusion, we also examined 
co-localisation of copolymer with endocytic markers and organelles. 
4.3.4 Co-localisation of markers with copolymer 
To verify the mechanism of endocytosis used for uptake, MSCs were incubated with 
established markers (transferrin, LacCer, caveolin-1 and dextran) that are recognised to be 
internalised by a specific pathway. Co-localisation was visually assessed by the distribution 
patterns of the copolymer and endocytic markers. Co-localisation was then further 
investigated by taking representative cells and Pearson’s Correlation Coefficients (PCC) of 
the fluorescent intensities of the copolymer and the endocytic markers were calculated. PCC 
values close to 1 implied that these two fluorescent probes are closely related to each other 
as their fluorescent intensities demonstrated a linear relationship. 
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Figure 4.7. Evaluation of co-localisation of copolymer (red) and Dextran (green) by CLSM. 
r denote the PCC value of a specific cell. The nuclei were stained with DAPI (blue). All 
experiments were performed at least three times and representative images are shown. 
Magnification 40x. 
 
Chapter 4 Ascertaining Uptake Mechanisms of Copolymer in MSCs 
 
Figure 4.8. Evaluation of co-localisation of copolymer (green) and hTf (red) by CLSM. r is 
the PCC value of a specific cell. The nuclei were stained with DAPI (blue). All experiments 
were performed at least three times and representative images are shown. Magnification 
40x. 
 
Uptake of copolymer in MSCs was not co-localised with dextran and transferrin which are 
exclusively taken up by clathrin coated pits and macropinocytosis, respectively (Figure 4.7 
& 4.8). Nonetheless, copolymer appeared to be taken up by CIE in MSCs as there was 
substantial overlap with LacCer and Caveolin-1 (r-value close to 1, Table 4.5), a known 
marker for CIE, specifically caveolae mediated uptake. Caveolae mediated endocytosis is 
significantly regulated by dynamin, which was demonstrated to interact directly with  
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Caveolin-1.[46] Hence, significant co-localisation of copolymer with caveolin-1 and LacCer 
indicates that uptake may be regulated via caveolae mediated cholesterol dependent routes. 
Hence, copolymer was found to be taken up by CIE as supported by co-localisation with 
LacCer and caveolin-1 (Figure 4.9 & 4.10) and the substantial inhibition of copolymer 
uptake after treatment with genistein and MβCD (Figure 4.6). 
 
Figure 4.9. Evaluation of co-localisation of copolymer (red) and LacCer (green) by CLSM. r 
is the PCC value of a specific cell. The nuclei were stained with DAPI (blue). All experiments 
were performed at least three times and representative images are shown. Magnification 
40x. 
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Table 4.5. PCC values of endocytic markers with copolymer. 
Endocytic Marker PCC (r ± SD) 
hTf 0.310 ± 0.109 
Dextran 0.247 ± 0.053 
LacCer 0.862 ± 0.057 
Caveolin-1 0.804 ± 0.028 
 
 
 
Figure 4.10. Evaluation of co-localisation of copolymer (green) and Cav-1 (red) by CLSM. r 
is the PCC value of a specific cell. The nuclei were stained with DAPI (blue). All experiments 
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were performed at least three times and representative images are shown. Magnification 
40x. 
 
Figure 4.11. a) Caveolin-1 (red, controls) b) No primary control. No primary antibody added. 
The nuclei were stained with DAPI (blue). All experiments were performed at least three 
times and representative images are shown. Magnification 40x. 
Optimisation of caveolin-1 antibodies prior to labelling with copolymer was performed to 
confirm that the antibodies are functioning. The no primary control experiment is to check 
for non-specific binding of secondary antibodies. It is clear that the caveolin-1 antibodies are 
effective and there was an absence of non-specific binding of secondary antibodies (Figure 
4.11). 
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4.3.5 Co-localisation of copolymer with specific organelles 
CLSM was utilised to evaluate the co-localisation of fluorescently tagged copolymer with 
specific organelles in MSCs such as nucleus, mitochondria and lysosomes. CLSM allows 
the copolymer to be visualised within cell compartments at specific time points. 
 
Figure 4.12. Trafficking of copolymer within actin filaments in MSCs. a) No copolymer, 
b-f Incubated with copolymer (green) at different time points b) 30 mins, c) 4 hours, d) 24 
hours, e) 48 hours and f) 72 hours. The actin filaments were stained red.  The nuclei were 
stained with DAPI (blue). All experiments were performed at least three times and 
representative images are shown. 
MSCs were incubated with copolymer, and cells were fixed at different time points of 30 
minutes, 4, 24, 48 and 72 hours. This was to allow observation of copolymer distribution  
a b c
fed
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with actin filaments that were stained red and to examine the retention of copolymer within 
the MSCs. The copolymer was concentrated in the actin region at 30 minutes incubation as 
demonstrated in the overlay of yellow regions (Figure 4.12). This was anticipated as actin 
is involved in the trafficking of endocytic vesicles. After 4, 24 and 48 hours, copolymer began 
to accumulate in specific cellular compartments. Interestingly, at 72 hours’ time point, 
copolymer exited the specific compartments and was trafficked through the actin network 
again. However, the amount of copolymer observed in the actin region was less than at 30 
mins post incubation. Nonetheless, copolymer was still present within cells 72 hours post 
incubation as demonstrated by the z stack analysis (Figure 4.13). It was very clear that 
copolymer did not accumulate in the nucleus. 
 
 
Figure 4.13.  Z stack images. MSCs labelled with actin (red) and copolymer (green) for a) 
30 mins b) 72 hours. The nuclei were stained with DAPI (blue). All experiments were 
performed at least three times and representative images are shown 
a b
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To confirm intracellular distribution of copolymer, MSCs were incubated with both copolymer 
and Lyso Tracker, a specific marker for lysosomes. After 4 hours exposure to copolymer, 
there was no co-localisation observed (Figure 4.14a). However, 24 hours post incubation 
with copolymer, some distinct yellow regions were observed in the merged image, indicating 
that only a small fraction of internalised copolymer migrated to the lysosomes (Figure 
4.14b). This could indicate that a minor portion of the copolymer entered MSCs via other 
pathways hence trafficked to the lysosomes. The preceding data from the utilisation of 
inhibitors demonstrated that the uptake of copolymer is primarily by CIE, specifically 
caveolae or lipid raft mediated. Moreover, some pathogens adopt the caveolae mediated 
pathway to avoid lysosomal degradation as caveosomes lack proper signalling molecules 
required for interaction with other cellular compartments [47]. Therefore, the lack of migration 
of copolymer to lysosomes corroborates that uptake is mainly via CIE.  
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Figure 4.14. MSCs labelled with copolymer (green) for a) 4 hours incubation and 
LysoTracker (red), b) 24 hours incubation and LysoTracker (red)  c) 4 hours incubation and 
MitoTracker (red) and d) 24 hours incubation and Mitotracker (red). The nuclei were stained 
with DAPI (blue). All experiments were performed at least three times and representative 
images are shown. 
 
 
 
a b
c d
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Additionally, MSCs were labelled with both copolymer and MitoTracker, a specific marker 
for mitochondria. After 4 and 24 hours post incubation with copolymer (Figure 4.14c and 
d), distinct cellular distribution of copolymer and MitoTracker was observed in the merged 
images, demonstrating that the copolymer did not migrate to the mitochondria. Inability to 
enter mitochondria is due to the highly complex nature of this organelle, which is 
encompassed of four parts: the outer mitochondrial membrane (OMM), the intermembrane 
space (IMS), the inner mitochondrial membrane (IMM), and the matrix. [48].  In addition, the 
intricacy of cell signalling pathways involved makes targeted transport of foreign molecules 
to mitochondria challenging. 
 
4.4 Conclusions 
In this chapter, we provided detailed insights into the optimisation of markers and chemical 
inhibitors employed to comprehensively study the uptake pathways that regulate the 
internalisation of poly(OEGMA-co-PFPEMA) in PMSCs. Our results clearly demonstrate that 
the uptake of copolymer in PMSCs was by CIE, specifically caveolae mediated through 
cholesterol dependent routes based on the following findings: (1) genistein and MβCD 
treatment in cells strongly inhibited copolymer uptake, (2) treatment with CPZ and EIPA had 
no significant effect on copolymer uptake, (3) no co-localisation was found between 
copolymer with Dextran and hTf, (4) substantial co-localisation was observed between 
copolymer with both LacCer and caveolin-1. Despite these clear results, we cannot 
generalise that these copolymer will be taken up via CIE in all cell types. Therefore, it must 
be emphasised that the utilisation of inhibitors and markers must be optimised for each cell 
and NP type, as an inhibitor might not display the same degree of high specificity, efficacy 
and cytotoxicity in some cell lines.  
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Chapter Five Conclusions 
Chapter Five 
The incorporation of MRI cell tracking in clinical trials is currently in its early stage. 
Additionally, 19F MRI have not been completely exploited in the clinic largely because of the 
lack of appropriate and efficient tracers. Therefore, it is necessary to develop novel tracers 
to completely exploit MRI as a powerful imaging tool for the tracking of cellular therapeutics. 
MRI based cell tracking has great potential specifically in optimization of MSCs therapy to 
attain clinical success and it is anticipated to be routinely utilised in the near future. Overall, 
19F MRI provides a highly specific, unambiguous and quantitative approach of tracking 
labelled MSCs. 
 
Partially fluorinated polymers, poly(OEGMA-co-PFPE) and poly(OEGMA-co-TFEA),  were 
synthesized by RAFT polymerization and were presented as MR cell tracers. MSCs labelled 
with poly(OEGMA-co-TFEA) had a considerably lower fluorine content of observable fluorine 
nuclei in comparison to results previously reported for MSCs labelled with fluorinated 
nanoemulsions. Therefore, further studies focused on a unique polymer using a novel 
perfluoropolyether methacrylate (PFPEMA) as the fluorinated monomer and OEGMA as the 
hydrophilic component required to effect solubility in aqueous media.  
 
In Chapter 2, we have reported the successful and robust synthesis of a unique partially-
fluorinated polymer (poly(OEGMA-co-PFPE)) as a dual MR/fluorescence imaging agent. 
The copolymer, at a diameter of 12 nm has a high fluorine content of >20 wt. %, substantially 
higher than previously reported PFPs (< 5 wt. %) for MRI applications. Our results establish 
that PMSCs can be efficiently labelled with a content of observable fluorine nuclei that is  
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comparable or superior to results reported for MSCs and other therapeutically relevant cells 
labelled with PFPE nanoemulsions. In addition, cell uptake achieved with our unique 
copolymer, without addition of transfection agent, has negligible effects on the viability and 
mitochondrial function of MSCs 
Importantly, we were able to measure 19F MR images of labelled cell phantoms at 9.4 Tesla 
and display that the imaging performance is comparable or superior to previously published 
results.  
In Chapter 3, our results display that the partially fluorinated copolymer had no significant 
effect on typical MSC characteristics, which include expression of specific MSC markers 
and tri-lineage differentiation abilities of the MSCs. Leakage of copolymer from MSCs after 
internalisation was minimal and there is adequate retention to allow excellent in vivo 
imaging. Essentially, in vivo 19F MR images displayed that labelled cells could be readily 
detected up to seven days post injection within a short MRI acquisition scan period (12 
minutes).  In addition, ex vivo optical imaging showed that intravenous injection of labelled 
cells did not accumulate in any specific organs. 
We conclude that the copolymer reported here show outstanding potential to be employed 
as an imaging tracer for 19F MRI-based tracking and quantification of non-phagocytic and 
therapeutically-relevant cells such as MSCs.  
In Chapter 4, we reported a comprehensive evaluation on the optimisation of endocytic 
markers and chemical inhibitors utilised to ascertain uptake pathways that is involved in the 
internalisation of poly(OEGMA-co-PFPEMA) in MSCs. Our findings distinctly establish that 
the uptake of copolymer in MSCs was by CIE, specifically caveolae mediated through 
cholesterol dependent routes based on the following results: (1) genistein and MβCD  
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treatment in cells substantially inhibited uptake of copolymer, (2) treatment with CPZ and 
EIPA had no significant effect on copolymer uptake, (3) no co-localisation was found 
between copolymer with Dextran and hTf, (4) extensive co-localisation was observed 
between copolymer with both LacCer and caveolin-1. 
 
Nonetheless, assumption cannot be made that copolymer will be taken up via CIE in all cell 
types. Therefore, it must be highlighted that the utilisation of endocytic inhibitors and 
markers must be optimised for each cell and NP type, as an inhibitor might not exhibit the 
same degree of high specificity, efficacy and cytotoxicity in some cell lines.  
Outlook of 19F MRI  
Presently, clinical trials involving 19F MRI cell tracking with PFC tracers are still in its early 
phases. Therefore, this imaging technique is demonstrating promising clinical potential in 
the future. Overall, based on the results detailed in this study, the fluorinated copolymer and 
MRI methodologies are possibly safe for clinical application. Whilst the efficacy of tracking 
cells with 19F MRI is largely dependent on its sensitivity, the degree of detection sensitivity 
will be lower in a clinical environment due to the lower field strength, shorter acquisition time 
and larger radiofrequency coils. Nonetheless, 19F MRI cell tracking can be clinically 
applicable in the near future following advancements in MRI hardware and pulse sequence 
development. Therefore, 19F MRI based cell tracking has great potential especially in 
optimization of cell therapy to attain clinical success and it is anticipated to be routinely 
utilised in the near future. 
 
